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Trypanosomosis is a parasitic disease in man, domestic and wild animals and is of major
economic importance in many parts of the world, particularly in Sub-Saharan Africa.
Trypanosoma congolense, T vivax and T brucei brucei are the major pathogenic
trypanosomes infecting cattle in sub-Saharan Africa. The parasite itself is not directly
responsible for the disease, but rather causes illness through the release of pathogenic factors.
One of the major pathogenic factors released by trypanosomes is proteinases.
Trypanotolerant cattle produce antibodies against a trypanosomal proteinase, congopain, that
inhibit congopain activity. Congopain thus has vaccine potential. This study describes the
mapping of immunogenic epitopes of congopain to identify peptide regions of the protein that
induce enzyme inhibitory antibodies for inclusion in a trypanosome vaccine. This vaccine
approach targets the disease, rather than the parasite by focusing on a pathogenic factor. These
peptides also have potential for use in diagnostic assays. Peptides from the catalytic domain of
a trypanosomal cysteine proteinase, congopain, were selected using an epitope prediction
program. Peptides selected were from the two forms of congopain called CPl and CP2.
Antibodies against peptide-carrier conjugates were produced in chickens. The antibodies
recognised native congopain, recombinant CP2 and the recombinant catalytic domain (C2).
This suggests that the peptides selected have promise for use in vaccines.
The peptides were also used to determine whether they are natural immunogenic epitopes of
CP2 and thus have potential for use in diagnostic assays. Antibodies in the sera from T.
congolense infected cattle recognised all the peptides in an ELISA. Antibodies in the sera
from C2-immunised, non-infected cattle recognised most of the peptides in an ELISA. In
order to distinguish between T. congolense and T vivax infection, two different peptides from
the C-terminal extensions of CP2 and vivapain were used in ELISA tests with sera from
infected cattle. Although anti-peptide antibodies produced against the two C-terminal
extension peptides were specific for their respective peptides, thereby indicating the
discriminatory power of the peptides selected, there was cross-reactivity by the sera from T.
congolense and T. vivax infected cattle. Optimal antibody binding peptide sequences of these
two peptides need to be identified by testing modified sequences of these two peptides to
v
improve the sensitivity of this assay.
In addition to attempting to define the epitopes of congopain, preliminary studies to increase
the immunogenicity of congopain were also undertaken. Alpha 2-macroglobulin is a natural
host inhibitor of proteinases. Inhibition occurs by entrapment of an active proteinase within
the alpha 2-macroglobulin cage. In addition, it has been demonstrated that antigen complexed
with alpha 2-macroglobulin becomes more immunogenic, resulting in enhanced antigenic
presentation of an entrapped antigen. This study reports the interaction between congopain and
alpha 2-macroglobulin. The preliminary results of this study showing congopain-alpha 2-
macroglobulin interaction could be used to explore the possibility of increasing the
immunogenicity of congopain and congopain epitopes by complexing these to alpha 2-
macroglobulin. Congopain epitopes complexed with alpha 2-macroglobulin could be used to
form a peptide-based vaccine.
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Trypanosornosis" is a disease in man, domestic and wild animals that has a negative impact on
food production and economic growth in many parts of the world, particularly in sub-Saharan
Africa (Taylor, 1998). This disease is caused by trypanosomes, which are parasitic protozoa
that live and multiply in the blood and other body fluids of their hosts. The disease is
transmitted to man and animals by the bite of a tsetse fly (Glossina palpalis) infected with
trypanosomes (Grant, 2001). The hosts for trypanosomes are not only mammals (man, cattle,
horses, sheep, camels) but also fish, amphibians, reptiles and birds (Hall, 1977).
Trypanosomes cause the disease nagana and sleeping sickness in cattle and humans,
respectively.
None of the methods currently available for trypanosomosis control are completely successful.
Furthermore, there have been many difficulties and challenges in the development of a
vaccine against the trypanosome parasite, for example, one difficulty is the ability of the
parasite to cyclically change its surface coat and thus evade the host immune response
(Turner, 1997). However, it has been suggested for trypanosomosis, as well as other parasitic
infections that the parasite itself is not directly responsible for the disease, but rather causes
illness through the release of pathogenic factors which are toxic to the host (de Souza et al.,
1990; Mbawa et al., 1991a; b; Authie et al., 1993a; b; Troeberg et al., 1999). If the activity of
these parasitic components could be disturbed, the host's condition might improve.
Elimination of the parasite would therefore not be an absolute necessity. One way of inhibiting
such pathological factors could be through immunisation with parasite proteinases (Authie et
aI., 1993a; 1993b; Troeberg et aI., 1997). This study attempts to use this approach to tackle




Trypanosoma congolense, T. vivax and T. brucei brucei are the tsetse transmitted trypanosome
'Standardised nomenclature of animal parasitic diseases (Kassai et al., 1988)
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species of primary importance in causing trypanosomosis, also known as nagana in domestic
livestock (Mattioli et al., 1999). T. congolense is the dominant species in East Africa, while T.
vivax is dominant in West Africa , although both species occur all over Africa and cause
infection and a milder form of the disease where they are not dominant (Ukoli, 1984). T.
congolense has not been found in cerebro-spinal fluid but it has been localized in the
capillaries of the brain. Parasitaemia is usually low in the blood and may be missed if only
blood films are examined. The disease is characterised by chronic anaemia, weight loss,
infertility and increased susceptibility to other pathogens due to poor immune responses
(Taylor, 1998). Mixed infection of cattle with T. congolense, T. vivax and T. b. brucei is very
common and makes it very difficult to design diagnostic and therapeutic procedures (Mattioli
et al., 1999). Because of the immunosuppression in infected cattle, secondary bacterial
infections may occur and this complicates the disease, leading to a higher death rate.
Nagana is a major obstacle to increased livestock production, and to agricultural development
in most countries of sub-Saharan Africa. The presence of tsetse in tropical Africa has a large
impact on cattle breeding and there is a big difference in nutritional income between Africa
and the European Union due to nagana (Tables 1 and 2, Opperdoes, 1997). The estimated
direct losses in cattle alone are between US $6 000 million and US $12 000 million per year
(Taylor, 1998). In Africa alone, the total cost of the disease is estimated to be US $1.3 billion
per year (Lalmanach et al., 2002). The disease can result in the death of about 3 million cattle
per year (Hursey and Slingenbergh, 1995).
Different breeds of cattle have varying susceptibilities to trypanosome infection. For example,
Boran cattle are prone to trypanosomosis, while N'Dama cattle are known to be
'trypanotolerant' (Authie et al., 1993a). Trypanotolerance is defined as the genetically
determined ability to limit multiplication of the parasite and to resist the pathogenic effects of
infection (Murray and Dexter, 1988; Trail et al., 1989). The existence of an association
between immune recognition of a trypanosome antigen and resistance to trypanosomosis
might lead to new methods of immuno-prophylaxis in susceptible cattle . In addition, by
providing possible methods for selection of resistant cattle, it could contribute to genetic
improvement oftrypanotolerance in cattle (Authie et al., 1993a).
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Table 1. Differences in nutritional income between Africa and the European Union due to
nagana (Opperdoes, 1997).
Nutritional income
Proteins from cattle meat
Calories from cattle meat
European Union




<2000 cal / day
20%
6%





(mass of cattle / inhabitant)
136 kg
26 kg
1.2.2 Trypanosomosis in other livestock
Trypanosomosis in other livestock caused by T. evansi and T. equinum is called surra. Surra is
acutely fatal to horses and chronically fatal to camels (Gonzalez, 2001). T. evansi can also
affect cattle, pigs and a variety of other domesticated and wild animals (Cazzulo, 1997). T.
evansi and T. equinum are transmitted by biting flies such as Tabanus, Stomoxys and
Lyperosia and they are therefore far more widespread than trypanosomes which rely on tsetse
transmission. Their distribution range extends throughout North Africa, the Middle East, the
Indian sub-continent and also Central andSouth America (Purnell, 1985). T. equiperdum
."', . -=t~~.
affects horses causing a disease called dourine. The parasite is transmitted during coitus and
no insect vector is involved (Gonzalez, 2001). Other trypanosomes such as T. vivax, T.
congolense, T. b. brucei and T. simiae have also been reported to be pathogenic for sheep,
goats , dogs, pigs, antelope, camels and horses (Purnell, 1985; Gonzalez, 2001) .
1.2.3 Human trypanosomosis
African human trypanosomosis, also called sleeping sickness, is caused by two SUb-species of
T. brucei, viz. T. b. gambiense and T. b. rhodesiense, which are transmitted by the bite of two
species of tsetse fly, viz. Glossina palpalis (T. b. gambiense) and G. morsitans (T. b.
rhodesiense) (Welburn et al., 2001). Clinical signs and symptoms of sleeping sickness may be
suggestive but not conclusive (Kuzoe, 1993). Therefore, a demonstration of trypanosomes in
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the blood, lymph or cerebrospinal fluid is necessary to confirm diagnosis. The early stage of
the disease is characterised by fever, headache and joint pains followed in later stages by
neurological symptoms and endocrinal disorders (Welbum et al., 2001). T. b. gambiense and
T. b. rhodesiense are morphologically indistinguishable but the gambiense form is chronic and
slow in onset and its course may last from a few months to several years, while the
rhodesiense form is acute and rapid in onset and may last for only a few weeks or months
(Welbum et al., 2001).
South American trypanosomosis, also called Chagas' disease, is caused by T. cruzi which is
transmitted to man, wild and certain domestic animals by the bite of Rhodnius prolixus and
Triatoma infestans (Pumell, 1985). Transmission is effected by contamination of mucous
membranes or the skin with infected excreta. During the blood meal, or soon after, defaecation
occurs and metacyclic, infective trypomastigotes present in the hindgut and rectum of the
vector may be deposited onto the skin with the faeces and can penetrate the skin barrier
through the site of the bite, or the mucosae of the eye or lips or through other local abrasions
(Van Meirvenne and Le Ray, 1985). The disease can also be acquired with mother's milk and
by blood transfusion. Animals are infected by eating the vectors or licking their bites (Pumell,
1985). At the site of trypanosome penetration into a new host, the trypanosome invades
surrounding cells, especially macrophages, and multiplies locally. Spreading of infection is
ensured by migrating parasitised macrophages and by free trypomastigotes. The latter invade
blood and body fluids and penetrate muscle and reticulo-endothelial cells before further
multiplication (Van Meirvenne and Le Ray, 1985). The disease is characterised by fever,
enlarged glands, anaemia and disturbances of the nervous system (Pumell , 1985).
1.3 Classification and life-cycle of trypanosomes
Trypanosomatids are allocated to a number of genera based on morphological features and
host range (Momen, 2001; Figure 1). The major pathogenic species in the genus Trypanosoma
are T. congolense, T. vivax and T. b. brucei, that belong to the section salivaria, and T. cruzi
that belongs to the section stercoria (Mattioli et al., 1999). Salivarian trypanosomes, like most
parasites, may appear in different forms at different stages of their complex life cycles.
Completion of the life cycle depends upon the transmission between the host and the tsetse fly
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vector (Figure 2). The parasite undergoes two major transformations during its journey
through the two hosts , resulting in two different life cycle forms. Trypanosomes ingested by
the tsetse fly undergo a series of biochemical and structural changes in the fly's midgut. The
parasite residing in the salivary glands of the fly is in the procyc1ic form, due to its procyclin
(a glycosylated protein) coat. Here, it differentiates into the metatrypanosome form, the form
that can infect the host. When the fly bites a mammal, metacyclic trypanosomes are
introduced into the host's bloodstream where they rapidly differentiate into a form that can
proliferate (Turner , 1997). These rapidly proliferating forms divide by binary fission in the
bloodstream, lymphatic and cerebrospinal fluid (Markell et al., 1992). These rapidly dividing
trypomastigote forms are long and slender but they become short and stumpy in th,e later
stages after infection (Markell et al., 1992).
Trypanosomes can invade many sites in the host. One of these sites is the brain, where they
can cause tissue damage that leads to lethargy, confusion and, ultimately, death (Turner,
1997). Trypanosomes can be ingested once again by a tsetse fly when it bites the host, where it
will be taken into the gut of the fly along with the blood. Here it will transform back into the
procyclic form, undergo sexual reproduction and move into the salivary glands for the cycle to
be repeated.
1.4 Prevention and treatment methods for trypanosomosis
1.4.1 Prevention methods
Current methods of trypanosomosis control in Africa are based on chemoprophylaxis,
chemotherapy and the elimination of vectors using insecticides (Grant, 2001) . In Africa there
were widespread attempts at tsetse control by clearing the vegetation where the flies rested,
and shooting the wild animals on which the fli~_s fed. However, such ecologically unsound
methods are no longer accepted (Schofield and Maudlin , 2001). Large-scale use of
insecticides has been criticised for its effects on non-target organisms (Aksoy, 2001). One way
of solving this problem was the development of odour-baited traps and targets impregnated
with insecticides, whereby flies could be killed without severe threat of environmental
pollution (Schofield and Maudlin, 2001). However, absolute control cannot be achieved with
.these technologies and they require frequent maintenance. Clearly, new approaches that are
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environmentally acceptable, efficacious and affordable are needed for the control of tsetse
vector populations.
Aksoy et al. (200I) have introduced new prospects for the control of trypanosomosis. Their
approach is to focus on molecular genetic approaches to modulate tsetse vector competence.
Their technology aims to eliminate the ability of insects to transmit pathogens by introducing
and expressing foreign genes with anti-pathogenic properties that interfere with pathogen
viability, development or transmission. These genetically engineered insects can then be
driven into natural populations to replace their susceptible counterparts (Aksoy et aI., 200 I).
1.4.2 Treatment methods
There are currently only three trypanocides available for controlling tsetse-transmitted
trypanosomosis in domestic ruminants. These are isometamidium andhomidium, which have
both prophylactic and therapeutic effects, and diminazene, which has only _therapeutic
properties (Geerts et aI., 2001). Present chemotherapies are inadequate, toxic or both. The
trypanocides used to control tsetse transmitted trypanosomosis in domestic animals in Africa
have been in use for over 40 years and consequently resistance oftrypanosomes to these drugs
has emerged (Geerts et aI., 2001). Development of new drugs is not a priority for international
pharmaceutical companies because there is a limited market in Africa and the cost of
developing and licensing new drugs is high (Geerts et aI., 2001). It is therefore unlikely that
new chemotherapeutic agents will be available anytime soon.
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Figure 2. Life cycle of T. b. brucei showing morphological stages present in mammalian and tsetse fly hosts
(Troeberg, 1997).
1.5 Vaccine strategies
Vaccination is done to stimulate the host's normal immune response so that it can provide an
efficient immunity against an invading pathogen (Roitt, 1997). There are a number of crucial
9
conditions, which must be satisfied for a vaccine to work. The antigens chosen as part of the
vaccine must be able to produce a protective response that can be maintained over a long
period of time without the requirement of boosters, readily available, stable and cheap (Roitt,
1997). Furthermore, antigens should be safe and be able to produce a good, protective
response and not other non-protective mechanisms which might mask the response. The host
should be immunocompetent.
There are many challenges which are faced in developing successful parasite vaccines. Unlike
bacteria and viruses, parasitic organisms are very complex, having complex life cycles and the
effect of parasites on the host 's immune system is not fully understood. It is essential to
understand the protective mechanisms of parasites because it is necessary to know what
immune response is required of a vaccine. Furthermore, the development of new vaccines may
require high cost technology (Van Regenmortel, 1990c).
Vaccination against trypanosomosis has long been thought to be the most desirable control
method (Taylor, 1998). Experimental vaccines consisting of attenuated forms of the parasite
or parasite lysates or partially purified variable surface glycoprotein (Duxbury et aI., 1972;
Wellde et aI., 1975; Morrison et aI., 1982; Wells et aI., 1982; Bosombrio, 1990; Bosombrio et
aI., 1993; Onah and Wakelin, 1999; Paiva et aI., 1999), flagellar pocket antigen (Mkunza et
aI., 1995; Wrightsman, 1995; Miller et aI., 1996; Wrightsman and Manning, 2000) and naked
DNA (Pereira-Chioccola et aI., 1999) have been tested in laboratory animals with varying
degrees of success. Several of these studies showed that susceptible hosts may be partially
protected against death by vaccination before challenge but individual antigens capable of
ensuring survival against lethal challenge have not been identified (Wrightsman, 1995). The
development of a conventional vaccine capable of preventing trypanosome infection in
immunised animals seems to be very difficult (Lalmanach et aI., 2002). None of the vaccines
tested against trypanosomosis have yet met all the requirements for a successful vaccine. The
success of experimental vaccination becomes highly questionable when protection is
monitored with highly sensitive methods such as complement mediated lysis (CML) which
detects antibodies that lyse bloodstream trypomastigotes in the presence of complement
(Kierszenbaum, 1989). Lytic antibodies associated with active infection have been detected
with the CML method in spite of vaccination (Kierszenbaum, 1989).
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1.5.1 Vaccines based on variable surface glycoprotein (VSG)
Variable surface glycoprotein (VSG) is the most abundant, exposed and immunologically
dominant antigen of trypanosomes in the mammalian host (Donelson, 1996). Within the
mammalian host , a VSG coat covers the cell membrane of the bloodstream form trypanosome.
One approach used to protect against trypanosomosis was the immunisation of cattle with
purified VSG (Duxbury et al., 1972; Wellde et al., 1975; Morrison et al., 1982; Wells et al.,
1982, Lutje et al., 1995). Trypanosome-infected trypanotolerant Cape buffalo developed
antibodies that are specific for the VSG of the infecting trypanosomes and can lyse parasites,
indicating their capacity to fix complement (Black et al., 2001) . Antibody responses to surface
exposed epitopes of the VSG in T. congolense-infected N'Dama (trypanotolerant) and Boran
(susceptible) cattle were investigated (Williams et al., 1996) . It was found that
trypanosusceptible Boran cattle had low IgG1 responses to cryptic VSG epitopes but high IgM
responses to non-trypanosome antigens. In contrast, the N'Dama cattle had significantly
higher IgG1 responses to cryptic VSG epitopes and negligible responses to non-trypanosome
antigens (Williams et al., 1996).
These results seemed to show that anti-VSG antibody responses play a role in
trypanotolerance. However, VSG proteins cannot be used as vaccine targets due to their high
variability. The number of different kinds of VSGs displayed by trypanosomes is very great
and has been estimated to be up to 107 (Cross , 1990). When an animal is invaded by a
pathogen, the immune system of the host animal recognises some part of the pathogen as
foreign and makes antibodies to attack this foreign part (antigen) . The antibodies bind to the
antigen and either neutralise the effects of disease-producing microorganisms or help to
destroy them. Trypanosomes, however, avoid total destruction by the host's immune response
by repeatedly changing VSGs displayed on their surface coat membrane (Donelson, 1996).
Antigenic variation is the primary mechanism that prevents most domestic animals from
developing effective immunity against trypanosomosis. The control and function of the
bloodstream VSG expression sites in T. b. brucei is under investigation in the hope of
identifying factors which play a role in their control (Borst and Ulbert, 2001; Vanhamme
et al., 2001). Cattle immunised with purified VSG are protected against challenge with
homologous but not heterologous trypanosomes. Thus , the potential of trypanosomes to
express different VSG genes reduces the likelihood of an effective VSG based vaccine
(Taylor, 1998) .
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1.5.2 Killed or live, attenuated trypanosomes as vaccines
Killed or live, attenuated trypanosome parasites have been used as vaccines in many studies
(Basombrio, 1990; Basombrio et al., 1993; Gomez et al., 1996). In many instances the
immunity given by killed vaccines, even when given with adjuvant, is often inferior to that
resulting from infection with live organisms (Roitt, 1997). Attenuatiori is done to damage the
parasite in some way so that they may not develop fully, resulting in a live parasite with a
short life span but which survives long enough to stimulate the host's immune system (Roitt,
1997). The preventive effect of a vaccine consisting of cultured T. cruzi killed by freezing and
thawing in the presence of saponin was tested in mice and guinea pigs (Bosombrio, 1990). It
was found that after an exposure time of about four months, natural T. cruzi infection occurred
in 55% of the controls and 33% of the vaccinated group (Bosombrio, 1990). The results
showed that immunisation was only partially protective in animals. In another study, live
attenuated T. cruzi were used for vaccination (Bosombrio et al., 1993). The results showed
that vaccination failed to completely prevent natural infection (Bosombrio et al., 1993). These
two studies showed that for trypanosomes, the use of attenuated trypanosomes, compared to
the use of killed trypanosomes is not significantly better since in both studies only partial
protection was achieved. It has been proven that vaccination with live trypanosomes does not
cause any T-cell abnormalities (Paiva et al., 1999). However, this method is not sufficient
because it does not give complete immunity. Furthermore, trypanosomes appear in different
forms at their different life-cycle stages and it may not be possible to get enough infective
stages to make this type of vaccine effective.
1.5.3 Flagellar pocket antigens
The flagellar pocket of the trypanosome is an area where receptors are used for specific host
macromolecule uptake and this area is therefore thought to be invariant. For this reason, a
vaccine against flagellar pocket proteins may provide immunity. Experimental vaccines
consisting of flagellar pocket proteins have been tested and seem to show promise. Cattle were
vaccinated in Kenya with flagellar pocket antigens derived from T. b. rhodesiense and then
infected with T. congolense and T. vivax. It was found that the infection was reduced from
13% to 0.9% (Mkunza et al., 1995). Unlike most other studies, this experiment was carried out
in an environment of natural exposure, with a naturally infectious trypanosome species. Most
other studies have used a murine model, which is subject to disease based immunosupression
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(Mkunza et al., 1995). Pure paraflagellar rod proteins have been used alone, or in combination
with adjuvant, in many studies and most results seemed to show protection in immunised
animals (Wrightsman, 1995; Miller, 1996; Wrightsman and Manning, 2000).
1.5.4 Immunisation with naked DNA
Immunisation with naked DNA is an alternative strategy for the development of vaccines
against different infections, including those by protozoan parasites (Pereira-Chioccola, 1999).
Immunisation with a plasmid containing the trans-sialidase gene, a parasite antigen, resulted in
protective immunity against T cruzi infection in BALB/c mice. Immunisation using either
plasmid in a mouse strain, highly susceptible to infection, generated high levels of antibody
and decreased the mortality caused by acute infection (Pereira-Chioccola et al., 1999).
1.5.5 Congopain: anti-disease approach to immunological control of livestock
trypanosomosis
Most of the vaccine strategies mentioned above are aimed at developing vaccines against
trypanosomes. However, the ability of trypanosomes to escape host immune mechanisms
through antigenic variation makes it difficult to obtain a vaccine that would prevent
trypanosome infection. An alternative approach of vaccine research is to eliminate the
pathogenicity of the parasite , not the infection itself. Eradication of the infectious agent is not
always the most practical goal. For example, in malaria, the blood-borne form releases
molecules which stimulate production of tumour necrosis factor (TNF) and other cytokines
from monocytes and the secretion of these mediators is responsible for the disease symptoms.
Therefore, an antibody response targeted to the released antigens, with structurally conserved
epitopes, may be more effective than targeting the parasites with variable surface antigens
(Roitt, 1997). This has led to the development of vaccines which are composed of synthetic,
recombinant , or highly purified antigens which target the disease rather than targeting the
whole parasite. This form of vaccine is called a subunit vaccine.
Congopain is a major proteolytic enzyme from T. congolense, which displays pathogenic
effects in vivo and is released into the bloodstream of infected cattle (Authie et al., 1992).
Trypanotolerant cattle, originating from West Africa, have a genetically determined ability to
limit multiplication of the parasite and to resist the pathogenic effects of infection (Roelants,
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1986; Murray and Dexter, 1988; Trail et al., 1989). Studies have shown that congopain may
play a role in the different levels of tolerance (Authie et al., 1993a, 1993b, Authie et al., 2001,
Lalmanach et al., 2002). The important role played by congopain in pathogenicity was evident
in a study where recombinant congopain was used to immunise susceptible cattle (Authie et
al., 2001). Congopain-immunised cattle, together with a control group of non-immunised
cattle, were infected via tsetse fly bites with T. congolense. During the acute phase of the
disease, no major difference was observed in the state of health of the animals in the
congopain-immunised group compared to the control group. At the later stage of the disease,
however, immunised cattle maintained or gained weight, exhibited less severe anaemia,
developed prominent humoral immune responses to trypanosome antigens and their
haematocrit and leukocyte counts showed a tendency to recovery after two to three months of
infection (Authie et al., 2001). A more efficient immune response to congopain may thus
ameliorate the disease in trypanotolerant cattle (Authie, 1994).
1.6 Adjuvants and a,z-macroglobulin
New vaccines which require less immunogen, and which can be produced more economically,
are under development (Cianciolo et al., 2002). When a whole parasite or virus is used in a
vaccine formulation it will contain, in addition to the immunogens or epitopes that induce a
protective response, numerous additional epitopes that may have a suppressive effect on the
immune response. A more effective response may be induced by using the isolated protective
immunogen to produce what is known as a subunit vaccine. Congopain and its epitopes may
be used in the subunit vaccine concept. Subunit vaccines are usually of high purity and may
thus lack self-adjuvanting components which are found in attenuated or killed vaccines.
Consequently, subunit vaccines may have weaker immunogenicity (Vogel, 2003). Adjuvants
are used to ensure high quality and quantity, memory-enhanced antibody responses.
Formulation of vaccines with potent adjuvants can improve the immunogenicity of subunit
vaccmes.
A number of adjuvants have become available for use in experimental animals. However,
many are not suitable because of their high level of toxicity (Cianciolo et al., 2002). The
benefits of incorporating adjuvants into vaccine formulations must be weighed against the risk
of these antigens causing undesirable reactions (Vogel, 2003). The most commonly used
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adjuvant is Freund's complete adjuvant. This consists of a non-metabolisable mineral oil, a
surfacant (Arlacel A) and Mycobacterium tuberculosis or M. butyricum organisms or
components of the organism (Penney et al., 1998). It is used as a water-in-oil emulsion with
water-soluble immunogen. The antigen is released from the emulsion slowly over a period of
time, therefore effectively increasing the chances for interaction with macrophages. Freund's
complete adjuvant is effective but there are many disadvantages associated with its use.
Responses to it are antigen dependent and so it is not always the best choice. It should be used
when only small amounts of antigen are available and only for initial immunisations, because
chronic inflammatory responses may occur upon second exposure of the experimental animal
to Mycobacteria (Penney et al., 1998). Furthermore, this adjuvant is not safe for laboratory
personnel because of the presence of harmful mycobacteria (M. tuberculosis or M. butyricum)
which respond poorly to antibiotic treatment (Hanly, 1995).
Freund's incomplete adjuvant is composed of the same oil/surfactant mixture as Freund's
complete adjuvant but does not contain harmful mycobacteria. However, this adjuvant favours
humoral immunity without cell-mediated immunity and is therefore usually used in booster
injections (Hanly, 1995). It can also cause inflammatory responses but to a lesser extent than
Freund's complete adjuvant.
Other, effective adjuvants also have their limitations. Alternative adjuvants with their
shortcomings are summarised in Table 3. Reactions to adjuvants in experimental animals
include malaise, fever, adjuvant arthritis and anterior ureitis (Allison and Byars, 1991). A safe,
effective, more potent adjuvant than those currently available would help in the development
of new vaccines.
Alpha-2-macroglobulin (uzM) is a natural protein inhibitor of proteinases and has been
suggested to have another important functional role, i.e. of effectively enhancing delivery of
antigens to macrophages. The excellent adjuvanticity of uzM has been proven in a small
number of studies. Evidence for dramatically increased immunogenicity of hen egg lysozyme
(Chu and Pizzo, 1993; Chu et al., 1994), prostate-specific antigen (Otto et aI., 1998), uzM-
bound peptides (Binder et aI., 2001) and hepatitis B virus surface antigen (Cianciolo et al.,
2002), incorporated into uzM, have been reported.
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Table 3. Commonly used alternative adjuvants with their shortcomings (adapted from Hanly,
1995 and Penney et al., 1998).
Adjuvant
Montanide incomplete Seppic
(Seppic , Paris, France)
Ribi's (Ribi ImmunoChem










GMbH, Gaiberg , Germany)
Syntex (Syntex, Palo Alto, CA)
Composition
Different surfactants combined with
either non-metabolisable,
metabolisable, mineral oil or
mixtures
Oil, detoxified endotoxin and





Antigen entrapped in liposomes ,
ethylene-vinyl acetate copolymer
Poly (Dl.-Iactide-co-glycolide)
Immunostimulators and zinc proline
Oil, Tween 80 and pluronic
polyoxyethlene
Disadvantage
Chronic inflammatory response may
occur
Limited to certain antigens and
species
Bias antibody response to epitopes of
native protein rather than to epitopes
of denatured protein
Inflammatory reaction may occur





Antibodies raised may not react well
with nati ve protein
Preparation is complex
Frequent boostin g required
Activates complement by the
alternate pathway and is said to bias
the humoral immune response to
IgG2a in the mouse
A method which allows incorporation of a variety of subunit vaccine candidates into (l2M was
reported by Cianciolo et al. (2002). Complexes of antigens and (l2M could be used as effective
vaccines since antigens complexed with (l2M showed enhanced immunogenicity compared to
antigens delivered with other adjuvant systems (Liao et aI., 2002). As an adjuvant (l2 M is
entirely natural and there have been no risks reported with its use. Antigens incorporated into
(l2 M are sequestered and therefore protected from degradation until delivered to macrophages
(Liao et aI., 2002).
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U2M inhibits proteinases by a 'trapping' mechanism (Barrett et aI., 1979). Initially, U2M
cleaves proteinases and the cleavage triggers a conformational change in U2M that traps the
proteinase. Conformational changes of u2M-protein complexes expose receptor recognition
sites on U2M. This allows rapid delivery of u2M-protein complexes to cells which have U2M
receptors, such as macrophages (Chu and Pizzo, 1994). Non-proteolytic immunogens can also
be incorporated into U2M by the method introduced by Cianciolo et al. (2002). In this method,
U2M is incubated with ammonia and this leads to the cleavage of the bait region of U2M
without any proteolysis step. Consequently, U2M is converted to receptor-recognised U2M. The
non-proteolytic antigen is heated together with u2M-NH3 to 50°C and upon cooling to RT the
non-proteolytic immunogen is incorporated into 0'2M (Cianciolo et al., 2002).
It has been demonstrated that 0'2M interacts with the trypanosomal cysteine proteinase,
cruzipain (Ramos et al., 1997; 2002). It is possible that it also interacts with other
trypanosomal proteases, such as congopain. It was thus necessary to determine whether 0'2M
interacts with congopain before the possibility of enhancing the immunogenicity of congopain
and its epitopes by complexing with 0'2M could be explored. This result could then be
compared with those obtained with other adjuvants such as RWL (proprietary adjuvant from
Smith Kline Beecham), which has been used successfully in the immunisation of cattle with
congopain (Authie et al., 2001). The structure of 0'2M and its mode of interaction with
congopain and other proteases will be detailed in Chapter 5.
1.7 Proteases in parasites
The five major classes of proteases (aspartic, serine , cysteine, metallo and threonine) catalyse
the hydrolysis of polypeptide bonds. The protease enzymes control protein synthesis, turnover
and function and consequently regulate physiological processes such as digestion, fertilisation ,
growth, differentiation, cell signalling, immunological defence, wound healing and apoptosis
(Leung et al., 2000). These functions extend from the cellular level to the organ and organism
level, to produce a number of systems like haemostasis and inflammation, and complex
processes at all levels of physiology and pathophysiology.
Proteases of parasitic protozoa are also involved in different aspects of host-parasite
interactions. They facilitate the invasion of host tissues and allow nutrition as well as the
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survival of the parasite in its host. They also participate in the parasite 's evasion of the host's
immune response (Trap and Boireau, 2000; Paugam et aI., 2003).
The function of proteinases in parasitic protozoa is generally not well known. Members of all
five major classes of proteases have been identified in parasitic protozoa. For example, T.
cruzi, contains cysteine, serine, threonine, and metallo proteinases (Cazzulo, 2002). Several
proteinases of 25-55 kDa were identified from in vitro cultures of muscle larvae of Trichinella
spiralis; these were serine, cysteine and metalloproteinases active at pH 5-7 (Todorova, 2000).
Serine proteinases are present in African trypanosomes (Komblatt et aI., 1992; Troeberg et aI.,
1996; Morty et aI., 1999). A serine oligopeptidase has been purified from T. congolense
(Morty et aI., 1999), T. b. brucei (Troeberg et al., 1996) and T. cruzi (Ashall, 1990).
The class of trypanosomal protease most widely studied is the cysteine proteinases.
Homologous enzymes of trypanopain-Tc or congopain from T. b. brucei and T. cruzi are
called trypanopain-Tb and cruzipain respectively. These seem to be important proteinases in
pathogenesis because they readily digest host proteins (Coetzer, 1998).
Proteinases of many parasites are under investigation as potential contributors to pathogenesis
and as possible targets for novel anti-parasite drugs, with special attention focused on the
cysteine proteinases. Parasite proteinases studied in this context include those from protozoa;
Trypanosoma (Lonsdale-Eccles and Grab, 2002); Leishmania (Rafati et aI., 2001; 2002);
Plasmodium (Raphael et aI., 2000; Rosenthal et aI., 2002); Trichinella spiralis (Todorova
2000); four helminths species; Schistosoma, Fasciola , Taenia and Heamanchus (Trap and
Boireau, 2000); Entamoeba histoIytica (Que and Reed, 2000) and the nematodes (Zang and
Maizels, 2001). In all these organisms, cysteine proteinases have been found to be the major
proteinases and located in the lysosomes. Cysteine proteinases of protozoan parasites are




The cysteine proteinases of various pathogens have received attention as potential targets for
chemotherapeutic intervention. Cysteine proteinases of malaria parasites offer potential new
chemotherapeutic targets. Cysteine protease inhibitors block parasite haemoglobin hydrolysis
indicating that cysteine proteinases play a major role in haemoglobin degradation, a necessary
function for development of erythrocyte trophozoites (Rosenthal et aI., 2002). Cysteine
proteinases are a key virulence factor of E. histolytica and play a role in intestinal invasion by
degrading the extracellular matrix and circumventing the host's immune response (Que and
Reed, 2000).
For trypanosomes, cysteine proteinase inhibitors have been shown to kill T. cruzi (Cazzulo et
aI., 2001), T. congolense (Mbawa et aI., 1992; McKerrow et aI., 1999) and T.b. brucei
(Troeberg et aI., 1999). Current knowledge of the parasite enzyme has arisen largely from
analysis of enzyme activities, many of which have been found to show variation between life-
cycle stages, or to occur in unusual locations such as the blood brain barrier. Parasites contain
many cysteine proteinases. Although they perform many different roles, there may be some
overlap between the actions of the individual enzymes (Robertson et aI., 1996).
The essential amino acid residues in the active site of cysteine proteinases are cysteine,
histidine and asparagine in positions 25 and 159 and 175 respectively, based on the numbering
of papain. These three amino acid residues form a catalytic triad involved in the catalytic
function of the enzyme (Turk et aI., 1998). Cysteine proteinases are most reactive at slightly
acidic pH values but some are also active at basic pH values (Dehnnann et aI., 1995). The
active site cysteine residue acts as a nucleophile that attacks the carbonyl carbon of the
susceptible peptide bond of the substrate. The active site histidine residue forms a thiolate
imidazolium ion pair with active site cysteine residue. During hydrolysis a covalent acyl-
enzyme intermediate is formed (Storer and Menard, 1996).
Congopain, trypanopain-Tb and cruzipain are thought to have active sites similar to that of
papain. These proteinases belong to the papain superfamily. Papain has a large active site
which extends over about 2sA and can be divided into seven "subsites" each accommodating
one amino acid residue of the peptide substrate. The substrates are lined up in the active site in
such a way that the scissile bond always occupies the same place (close to the catalytic site).
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The amino acid residues that occupy adjacent subsites are those towards the NH2-end, (called
Pjto P4), occupying subsites SI to S4, and those towards the COOH-end (called PI' to P3')
occupying subsites SI' to S3' (Figure 3) (Schechter and Berger, 1967). The substrate is
visualised as fitting into the pocket , binding to several subsites of specific geometry (Figure
3).
The protease activity in T congolense, T'b. brucei and T vivax changes from one life cycle
stage to another (Mbawa et al., 1991a). The highest level of protease activity is in the
bloodstream forms of the parasite and, therefore, proteases are thought to play an important




Figure 3. Schematic representation of the enzyme-substrate complex for cysteine proteinases (Schechter
and Berger, 1967). (S) represents the subsite of the cysteine proteinases active site and (P) represents the
corresponding substrate amino acid residue. The scissile bond is indicated by an arrow.
1.7.2 Congopain
T. congolense has at least two families of closely related cysteine proteinases, named CPl
(Fish et al., 1995, EMBL accession number Z25813) and CP2 (Jaye et al., EMBL accession
number L25130). The deduced amino acid sequences of the two cysteine proteinases are 90%
identical (Figure 4) but they differ in their N-terminal sequences and in their catalytic domains
(Boulange et al., 2001). Congopain is a 33 kDa cysteine proteinase purified from T.
congolense bloodstream form lysates (Authie et al., 1992) and has been shown by N-terminal
sequencing to belong to the CP2 type of enzymes (Lalmanach et al., 2002). This enzyme is
equivalent to the trypanopain-Tc , identified by Lonsdale-Eccles and Grab (1987) and Mbawa
et al. (1991a), which has an apparent molecular weight of 32 kDa when analysed by
SDSIPAGE and 66 kDa when analysed by molecular exclusion chromatography (MBC). No
CP l-type of enzyme has yet been isolated from T. congolense. Among T. congolense cysteine
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proteinases, only congopain (CP2) has been studied in detail.
Congopain shares a high sequence identity with the cathepsin L-like enzyme from T. cruzi,
cruzipain (McKerrow et aI., 1995). The alignment of trypanosome cysteine proteases from T.
congolense, T. vivax, T. b. brucei and T. cruzi with mouse cathepsin L and plant papain is
shown in Figure 4. Like mammalian cysteine proteinases, congopain is synthesised as a
zymogen that is converted to the mature form by proteolytic release of the pro-region. This
maturation can also be effected by autolysis in vitro under acidic conditions (Boulange et aI.,
2001). The transcript of congopain can be divided into four parts, viz. a pre-region, a pro-
region, a catalytic domain and a 130 amino acid residue C-terminal extension that is joined to
the catalytic domain by a proline-rich hinge region (Lalmanach et aI., 2002). The hinge region
forms a flexible region readily accessible to proteolytic cleavage.
The C-terminal extension is a feature that distinguishes cysteine proteases of trypanosomatids
from other cysteine proteases of the papain superfamily. The function of the C-terminal
extension is as yet unknown (Stoka et aI., 2000). It has been suggested that it may have a role
in immune evasion, as the extension is highly immunogenic and could potentially divert the
host's immune response (Lalmanach et aI., 2002).
Previous studies showed that the C-terminal extension is not required for protein folding,
enzyme trafficking or catalysis (Stoka et aI., 2000). Unlike many mammalian lysosomal
cysteine proteases, congopain and cruzipain are stable at both acidic and alkaline pH
(Lalmanach et aI., 2002). Initially, it was proposed that the C-terminal extension may play a
role in the stability of trypanosomal cysteine proteinases. However, Stoka et al. (2000) showed
that truncated cruzipain, devoid of the C-terminal domain, has the same stability as the full
length enzyme. This proved that the different stabilities of congopain and cruzipain, compared
to related mammalian proteases, may be due to differences in the number, nature and
distribution of charged residues within the catalytic domain and not due to the presence of the
C-terminal domain. These authors reached this conclusion from studies on cruzipain stability
using different, same-molarity buffer systems with appropriate pKa values over the pH range
of 2.25 to 12, without taking account of the change in ionic strength. For a constant molarity
phosphate buffer, ionic strength increases sigmoidally between pH 5.5 to 8.5, with the most
dramatic change at the pKa (pH 7.21). Stoka et al. (2000) used phosphate over the range of5.7
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to 7.5. It was shown by Dehnnann et al. (1995) that failing to take account of the effect of
ionic strength, overstates the effect of increasing pH on the activity and stability of e.g.
cysteine proteinases. Hence it is erroneously generally accepted that mammalian cysteine
proteinases are not significantly active and stable at neutral pH. It would be interesting to
repeat the experiments of Stoka et al. (2000) using acetate-MES-Tris buffers of constant ionic
strength (Ellis and Morrison, 1982) over the pH range tested.
A 3D model of congopain has been proposed, based on the sequence homology (68%
identical) between cruzipain and CP2 (Lecaille et al., 2001). The model has a structure similar
to that of most papain-like cysteine proteinases (Figure 5). It folds into two domains the L-
domain and the R-domain. The catalytic triad (Cys 25, His 159 and Asn 175; papain
numbering) are located in the cleft between the R-domain and the L-domain (Lecaille et al.,
2001).
Dithiothreitol and 2-mercaptoethanol are the most effective agents for the activation of
isolated congopain, while glutathione and cysteine are only moderately effective (Mbawa et
al., 1992). This means that the activity of isolated congopain is enhanced by the presence of
reducing agents. Congopain has an optimal activity at pH 6.0 with a broad peak of activity
extending well into the alkaline range (pH from 4.0 to 8.5) (Boulange et al., 2001). This is
similar to the characteristics of cysteine proteases of protozoan parasites in general (North et
al., 1990b).
Congopain is a Z-Phe-Arg-NHMec-hydrolysing enzyme that has a noticeable preference for
aromatic residues at P2. Lalmanach et al. (1993) observed that the hinge region between the
catalytic domain and the C-tenninal extension has cystatin-like motifs. Furthermore, cystatin-
derived peptides have been identified as congopain (and other papain-like proteases) sensitive.
Based on these findings, the amino acid sequence LVG, which constitutes the N-tenninal
portion of the inhibitory site of cystatin C, and QVG, which constitutes the central portion of
cystatin C, have been used to form internally quenched fluorogenic substrates of the series
Abz-peptide-EDDnp (Abz, O-amino-benzoyl; EDDnp, ethylenediamine 2-4-dinitrophenoyl).
Abz-His-Pro-Gly-Pro-Gln-EDDnp is hydrolysed by trypanosomal cysteine proteinases below
pH 6.8. Furthermore, it competitively inhibits cruzipain and congopain above pH 6.8 and
mammalian cathepsins Band L at all pH values (Serveau et al., 1999).
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It is more likely that CP2, rather than CP1, plays pathogenic roles in the host. The catalytic
domains of CP1 (referred to as Cl) and of CP2 (referred to as C2) were expressed and
characterised (Boulange et aI., 2001). C2 appears to be stable over a wide pH range, while Cl
is rapidly inactivated at neutral and alkaline pH and strictly requires acidic pH for its activity.
Therefore, CP1 is unlikely to be active at physiological pH to interact with host proteins .
Kinetic studies confirmed the relatedness between C2 and native congopain isolated from T.
congolense bloodstream forms, but did not relate Cl to any of the described trypanosomal
cysteine proteinases (Boulange et aI., 2001). The results obtained by Authie et al. (2001)
indicated that both CP1 and CP2 may contribute to the mechanism of anaemia, while mainly
CP2 appears to be involved in trypanosome induced immunosuppression. A predominant role
of CP2 over CP1 in pathology would be consistent with the capacity of CP2, but not of CP1,
to degrade protein substrates at physiological pH. It has been hypothesised, therefore, that
these closely related but distinct enzymes perform different roles in vivo in the parasite and in
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Figure 4. Alignment of the T. congolense cysteine proteinases, CP2 and CPI, with related cysteine proteinases. The deduced amino acid sequences of
CP2 (Jaye et al., EMBL accession number L25130) and CP I (Fish et al., 1995) are aligned with the deduced amino acid sequences of the cysteine proteinases
from T. cruzi (Eakin et al., 1992) and T. brucei (Mottram et al., 1989), human cathepsin L (Ritonja et al., 1988), papain (Cohen et al., 1986) and the C-terminal
extension of a cysteine proteinase from T. vivax (Prof. Theo Baltz, University of Bordeaux, France, personal communication). The numbe ring system for
mature papain (Drenth et al., 1971) is shown.
24
Figure 5. The homology-based model of the catalytic domain of congopain (Lecaille et aI., 2001). The X-ray
crystallographic structure of cruzain is represented in pink and that of cathepsin L in yellow. The catalytic triad
(Cys 25, His 159 and Asn 175; papain numbering) is located between the L-domain (helical) and the R-domain
(anti-parallel sheets).
Several important roles are played by congopain (CP2) in the survival of the parasites, as
evidenced by the finding that potent congopain inhibitors, Z-Leu-Leu-Met-CHN2, Z-Leu-Met-
CHN2 and Z-Leu-Lys-CHN2 were trypanocidal (Mbawa et al., 1992). Furthermore,
trypanotolerant cattle have anti-congopain antibodies, whereas susceptible cattle do not
(Authie et al., 1993b). The lysosomal location of congopain makes it likely that the enzyme is
involved in digestion of exogenous protein taken up into the cell by pinocytosis as a source of
nutrition for the parasite (Mbawa et al., 1991b). Congopain may also protect the parasite
against attack by the host immune system because it is involved in the intralysosomal
processing or turnover of the VSG proteins (Mbawa et al., 1991a).
Congopain (CP2) catalyses the limited proteolysis of a variety of protein substrates such as
fibrinogen and serum albumin in vitro and this could present a mechanism by which the
enzyme contributes to disease pathology in the host bloodstream (Mbawa et al., 1992). Thus
inhibition of CP2 by specific chemical inhibitors or specific antibody produced by
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trypanotolerant cattle during infection, or artificially elicited by immunisation, may result in
higher resistance to trypanosomosis.
1.8 Anti-trypanosomal therapy based on congopain
1.8.1 Chemotherapy
Many parasites are sensitive to cysteine proteinase inhibitors (Ashall et aI., 1990; Wasilewski
et aI., 1996; Irvine et aI., 1997). Peptidyl chloromethyl ketones, dimethyl formamides and
diazomethyl ketones are effective irreversible inhibitors of congopain (Mbawa et aI., 1992).
Congopain has a preference for an aromatic residue such as Phe at Pz and for Pro at Pz'
(Lalmanach et aI., 2002). Peptidyl diazomethanes which have non-polar residues in Pz and P3
were found to be potent inhibitors for the enzyme. They were about lOO-fold more effective
inhibitors than the classical cysteine protease inhibitor, E-64 (Mbawa et aI., 1992a). However,
reversible inhibitors are preferred for use in vivo because an irreversible inhibitor may
eventually inhibit proteinases it reacts with only slowly, whereas a reversible inhibitor will not
interfere with the activity of an untargeted proteinase when that inhibitor is at a concentration
above the K, for the reaction (Salvesen and Nagase, 1989).
Congopain is inhibited by cystatins and kininogens with K, values in the pM range, similar to
the inhibition constants obtained for native cruzipain (Lalmanach et aI., 2002). However,
complexes between congopain and their natural inhibitors have been shown to have enzymatic
activity (Lalmanach et aI., 2002). This implies that even in the presence of natural inhibitors,
congopain may retain its activity, and this may explain its role in pathogenicity.
Isolated propeptides may still bind and inhibit their mature enzyme even when released from
the proenzyme (Fox et aI., 1992; Mach et aI., 1994). The ability of prodomains of
trypanosomal cysteine proteinases to inhibit their active form was studied using a set of 23
overlapping l5-mer peptides covering the whole pro-sequence of congopain (Lalmanach et aI.,
1998). Three consecutive peptides with a common 5-mer sequence YHNGA were found to be
competitive inhibitors of congopain (Lalmanach et aI., 1998). These results agreed with the
findings of Tao et al. (1994). Pro-peptides of mammalian and plant cysteine proteinases were
found to take part in the proper folding, intracellular trafficking or secretion of the mature
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proteinases, and in the control of proteolytic activity by blocking the active site (Tao et al.,
1994). The YHNGA-containing peptides specifically inhibited cysteine proteinases from other
trypanosomal species but not mammalian lysosomal cathepsins. The K, values of these pro-
region derived peptides are too high to make these peptides efficient inhibitors. Nevertheless,
these YHNGA containing peptides represent a promising new feature that may contribute to
the design of proteinase-directed anti-parasitic drugs of therapeutic interest (Lalmanach et al.,
1998).
1.8.2 Antibody therapy
Another approach for interfering with the activity of proteases is the use, in passive immunity,
of anti-catalytic antibodies produced in experimental animals. Congopain was identified as a
major antigen recognised in cattle and human infections (Authie et al., 1993a). Immune
recognition of parasite factors involved in pathogenesis may be one of the processes by which
trypanotolerant animals control the disease. Antibodies against congopain are not likely to be
internalised by trypanosomes, therefore they are not likely to affect the survival of the parasite
itself. Anti-congopain antibodies may, however, be useful in ameliorating the disease since
congopain is likely to be the main pathogenic factor of T. congolense (Lalmanach et al., 2001).
An IgG-antibody response may be important either in inhibiting some of the enzyme activity,
or in removal of circulating proteases via immune complexes. Thus, animals which are not
able to induce an antibody response may be exposed to more of the potential harmful effects
of the protease (Authie et al., 1993b). For this reason, congopain was used for immunisation in
cattle, and it was found that congopain is antigenic in both trypanotolerant and susceptible
cattle. Antibody response to congopain appeared to be associated with higher resistance to
disease (Authie et al., 1992, Authie et al., 1993a). However, the switch from IgM to IgG was
delayed in susceptible cattle during infection (Authie et al., 1993a).
An immunisation trial was conducted where trypanosusceptible cattle were immunised with a
recombinant catalytic domain of CP2, called C2 (Authie et al., 2001). Cattle immunised with
C2 developed features typical of trypanotolerant cattle, such as development of antibodies
against other trypanosome antigens such as VSG. Antibodies against C2 had an inhibitory
effect on congopain, although the inhibition was not as effective as that of antibodies from T.
congolense infected N'Dama (trypanotolerant) cattle (Authie et al., 2001). These results show
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that it may be possible to increase resistance to trypanosomosis in susceptible cattle through
immunisation against pathogenic factors of the parasite.
Both anti-whole congopain antibodies (Authie et al., 1993b) and anti-C2 antibodies (Authie et
al., 2001) had an inhibitory effect on congopain activity. This suggests that the essential
epitopes for inducing inhibitory antibodies are likely to be located in the catalytic domain of
the enzyme. It may thus be possible to produce antibodies against a particular peptide selected
from the catalytic domain that will inhibit congopain activity. The production of anti-peptide
antibodies is preferred because anti-peptide antibodies have specificity more similar to that of
monoclonal antibodies than to anti-protein polyclonal antibodies (Lemer, 1984). Furthermore,
anti-peptide antibodies may recognise the target sequence in many different conformations and
all have different binding sites because they bind overlapping regions of the peptide, thus
allowing the enzyme to be recognised in both its native and denatured forms (Muller, 1990b).
A peptide consisting of a sequence of 10 or more amino acids is likely to produce specific
antibodies because there is a good chance that that peptide would be unique to that protein
(Briand et al., 1985).
The peptides critical for the induction of effective immunity against congopain (congopain
epitopes) have not been identified. To raise effective anti-congopain peptide antibodies,
immunogenic epitopes in congopain need to be identified. Such epitopes can not only be used
in raising anti-peptide antibodies that could be used for passive immunotherapy, but they
could also be used in the development of a synthetic peptide-based vaccine (subunit vaccine)
composed of purified components and devoid of substances that could carry the risk of the
disease. These peptides could possibly also be used for diagnostic assays.
1.9 Objectives of the study.
Previous studies showed that the production of anti-congopain antibodies have some
correlation with trypanotolerance (Authie et al., 1993a,b; Authie 1994; Authie et al., 2001).
This implies that there are epitopes in congopain responsible for inducing antibodies that
inhibit enzymatic activity. This type of epitope was previously identified in our laboratory for
trypanopain-Tb and the resulting anti-peptide antibodies were shown to bind to the whole
parent enzyme and to inhibit enzyme activity (Troeberg at al., 1997). Such epitopes could
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replace whole recombinant congopain, currently under evaluation by collaborators of this
laboratory, as a subunit vaccine. The major objective of this study was thus to map epitopes of
congopain that could form the basis of a subunit vaccine. To evaluate the immunogenicity of
the peptides selected from congopain, anti-peptide antibodies were raised against the peptides
conjugated to a carrier protein. The resulting anti-peptide antibodies were examined for their
ability to recognise whole congopain in ELISA and western blot assays and to inhibit enzyme
activity (Chapter 3).
Epitopes of major pathogenic factors, such as those of congopain, may also have a use in
diagnostics. As techniques commonly applied in the detection of trypanosome infections have
poor sensitivity, they often fail to detect a high proportion of chronic and often aparasitemic
infections (Masake et al., 2002). A diagnostic method for trypanosomosis which is sensitive,
specific, simple and inexpensive is thus required. The peptides identified in Chapter 3 were ·
tested for their ability to be recognised by sera from T. congolense infected cattle, C2
immunised, uninfected cattle and rabbits immunised with native congopain or with C2.
Attempts were also made to identify peptides that would discriminate between T. congolense
and T. vivax infections. These studies are described in Chapter 4.
One of the main determinants of protection elicited by a vaccine is the adjuvant vehicle
(Cianciolo et al., 2002). The availability of a new, entirely natural adjuvant might assist in the
efforts to exploit the use of a trypanosomal subunit vaccine. The general protease inhibitor,
alpha-2-macroglobulin (a2M) has potential as such an adjuvant. In this regard this study also
aimed to first ascertain whether there is interaction between congopain and a2M. a2M was
isolated from bovine plasma and the interaction between congopain and a2M was
demonstrated by inhibition assays, described in Chapter 5. The preliminary results of this
study showing congopain-n-M interaction paves a way for the possibility of using a2M as an
alternative natural adjuvant that could enhance the immunogenicity of congopain as well as
congopain peptides. These peptides could be complexed with a2M by the chemistry described
by Cianciolo et al. (2002) which involves incubation of a2M with ammonia, changing a2M to a
receptor recognised "fast" form in which the thiol ester of a2M has been cleaved without any





The various experimental methods described in this Chapter are the common biochemical
techniques used throughout this study. These are mainly general protein methods,
chromatographic techniques and immunochemical techniques. More specific experiments are
described in their appropriate sections.
2.2 Materials
The following list includes specialised products that were used in this study. All general
chemicals were of analytical reagent standard. Sephacryl S-300, imidodiacetic acid-epoxy-
activated Sepharose 4B, Coomassie brilliant blue, sodium dodecyl sulfate (SDS), L-
cysteine.HCI, ovalbumin, m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), N-
Benzoyl-Pro-Phe-Arg-p-nitroanilide hydrochloride (Bz-Pro-Phe-Arg-pNA), Carbobenzoxy-
Phe-Arg-7-amino-4-methylcoumarin (Z-Phe-Arg-NHMec), dialysis tubing (12 kDa cut-off),
rabbit albumin, azocasein and Freund's complete and incomplete adjuvants were from Sigma
(St Louis, USA). 2,2'-Azinobis [3-ethyl-2, 3-dihydrobenzthiazole-6-sulphonate] (ABTS),
bovine serum albumin (BSA), 5-bromo-4-chloro-3-indolylphosphate (BCIP), nitroblue
tetrazolium (NBT), a2-macroglobulin (a2M) and dithiothreitol (DTT) were from Roche
diagnostics (Mannheim, Germany). Protein M, standards, Sephadex G-IOO and Sephadex G-
25 were from PharmaciaUCB Biotechnology (Lund, Sweden). Dry dimethyl formamide
(DMF), dimethyl sulphoxide (DMSO) and glutaraldehyde solution were from Fluka (Buchs,
Switzerland). Serva blue G-dye was from Serva (Heidelberg, West Germany). Gelatin was
from Difco (Michigan, USA). Whatman No. 1 filter paper was from Whatman International
Ltd (Maidstone, England). Tween 20 and Brij 35 were from Merck (Darmstadt, Germany).
Nunc-Immuno Maxisorp F96 plates and FluorNunc® 96 well plates were from AEC
Amersham (SA). Disposable polystyrene columns were from Biorad (Hercules, California).
SulfoLink™ and Aminol.ink coupling gels were from Pierce (Rockford, USA). Distilled
H20 and deionised water was produced by Milli-Q Plus ultra pure water system (Millipore,
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Marlboro, USA). Purified recombinant CP2 and C2 expressed in Pichia pastoris were
provided by Edith Authie [International Livestock Research Institute (ILRI), Nairobi, Kenya].
2.3. Bradford dye binding assay
This is a rapid and sensitive method for the quantification of protein (Bradford, 1976).
Coomassie brilliant blue G-250 exists in two different colour forms, red and blue. This dye
binds to most basic amino acid side chains, primarily to arginine, and to a lesser extent to
histidine and lysine and also to tyrosine, tryptophan and phenyalanine. Upon binding of the
dye to protein, the red cationic form, which absorbs maximally at 470 nm, is converted to the
blue anionic form, which absorbs maximally at 595 nm (Compton and Jones, 1985).
A micro assay, which quantifies small amounts of protein, described by Read and Northcote
(1981) was used in this study. This is a modification of the method of Bradford (1976) and
uses Serva Blue G dye to minimise variation in the response to different standard proteins.
However, the sensitivity is decreased (Read and Northcote, 1981).
2.3.1 Reagents
Dye reagent. Serva blue G dye (SO mg) was dissolved in 88% phosphoric acid (SO ml) and
99.5% ethanol (23.5 ml). The solution was made up to 500 ml with distilled H20 , stirred for
30 min on a magnetic stirrer, filtered through Whatman No. 1 filter paper and stored in an
amber coloured bottle at room temperature. It is stable for several weeks but during this time
the dye may precipitate and so the stored reagent was inspected for precipitate, filtered if
necessary and recalibrated before use.
Standard protein solution (l mg/ml ovalbumin). Ovalbumin (10 mg) was dissolved in distilled
H20 (10 ml). This stock solution was diluted to 100 ug/rnl before use for the micro-assay.
2.3.2 Procedure
Protein standard (0-50 ul of the 100 ug/rnl solution, i.e. 1-5 ug) or sample was diluted to 50 Jll
with distilled H20 in 1.5 ml polyethylene microfuge tubes. Dye reagent (950 ul) was added,
and mixed in by inversion. The absorbance at 595 nm was determined in 1 ml plastic micro-
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cuvettes, against reagent blank, between 2 min and 1 h after mixing. Mean absorbance values
of four replicates were used to construct a standard curve. The concentration of the sample of
unknown concentration was calculated from an equation generated by linear regression of the
standard curve values.
2.4 Concentration of protein samples
2.4.1. Dialysis against PEG
Dilute samples, usually obtained after protein purification steps, were concentrated before
molecular exclusion chromatography using dialysis against polyethylene glycol (PEG)
M, 20000. The dialysis tubing pore size prevents the protein from escaping (Bollag et al.,
1996). Water from the dilute sample moves along a concentration gradient out of the dialysis
bag to dissolve dry polymer, thereby concentrating the sample without affecting its activity.
2.4.1.1 Procedure
The dialysis bag was soaked in distilled H20 for 10 min before use. The dilute protein sample
was placed in the dialysis bag, which was surrounded by solid PEG 20 000. The dialysis bag
was covered with solid PEG and stored at 4°C. The bag was rinsed with distilled H20 after
concentration, and the sample was squeezed out.
2.4.2 SDSIKCIprecipitation
Dilute samples were sometimes concentrated, before reducing SDS-PAGE, by precipitation
with sodium dodecylsulfate (SDS) and KCl. A negatively charged complex of protein and
anionic detergent, SDS, is formed. This complex is precipitated out of water solution by
reacting with potassium which precipitates KDS (Hames, 1981). The concentrated protein
sample has a high salt concentration and this method is therefore only suitable for reducing
SDS-PAGE.
2.4.2.1 Reagents
5% (w/v) SDS. SDS (0.5 g) was dissolved in 10 ml of distilled H20 .
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3 M KCl. KCl (2.24 g) was dissolved in 10 ml of distilled H20.
2.4.2.2 Procedure
5% SDS (l0 111) was added to the sample (100 111) in a polyethylene microfuge tube. The
solution was mixed by inverting the tube. 3 M KCl (10 111) was added. The mixture was again
inverted and centrifuged (12 000 x g, 2 min, RT), the supematant discarded and the precipitate
dissolved in stacking gel buffer (l0 111) and reducing treatment buffer (10 111) (Solution G,
Section 2.5.1) added.
2.5 SDS-PAGE
The disc electrophoresis method for analysing proteins consists of two gels, a small pore
running gel (with higher pH) overlain by a large-pore stacking gel (with lower pH). The
protein sample is layered on top of the stacking gel. The gels contain Tris buffer with a
counter ion of high mobility (e. g. Cl), called the leading ion (Ornstein, 1964). The electrode
compartments on the other hand contain Tris buffer with a counter ion of relatively low, but
pH-dependent mobility (e. g. glycinate"), called the trailing ion. Upon application of the
electrical potential, a sharp interface is formed between the leading and the trailing ion as they
migrate downwards, and the proteins of intermediate mobility are swept up and concentrated
into a stack of thin bands between the leading and trailing ions. When the stack of proteins
reach the running gel, a change in pH causes an increase in the mobility of the trailing ion and
this passes the protein bands. Proteins are left behind to separate in a uniform voltage gradient
(Omstein, 1964).
Sodium dodecyl suifate-polyacrylamide gel electrophoresis (SDS-PAGE) is a low cost,
reproducible, and rapid method for comparing and characterising proteins. In this technique
proteins are reacted with the anionic detergent, sodium dodecyl sulfate (SDS), to form
negatively charged complexes (Makowski and Ramsby, 1997). SDS dissociates non-
covalently bound polypeptide chains and unfolds these proteins to form rod-like complexes.
SDS binds to most proteins at a constant ratio of 1.4 gram SDS per gram of protein (Reynolds
and Tanford, 1970). The negative charge of SDS is sufficient to mask the charge on the
protein. As a result, all proteins acquire the same charge/mass ratio and an anodic migration
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(Makowski and Ramsby, 1997). The separation of proteins is thus only due to differences in
size, controlled by the 'sieving effect' of the gel. The molecular weight of a protein is
estimated by comparing the relationship between size and mobility of a protein band with that
of standard proteins of known size (Makowski and Ramsby, 1997).
SDS-PAGE can be conducted under non-reducing or reducing conditions. In reducing SDS-
PAGE, protein samples are combined with a treatment buffer which contains 2-
mercaptoethanol. Mercaptoethanol reduces disulfide bonds. In the case of proteins in which
disulfide bonds remain intact, the amount of SDS bound per unit mass of protein is less than
normal because the protein is constrained and cannot unfold sufficiently to form the
characteristic rod-like structure (Makowski and Ramsby, 1997). Glycerol increases the density
of the sample and therefore aids in loading of the sample. A drop of saturated bromophenol
blue, which migrates with the buffer front, is added to each sample before loading to allow
monitoring of electrophoresis progress. The SDS-PAGE method described by Laemmli (1970)
was employed in this study.
2.5.1 Reagents
Solution A: Monomer solution [30% (w/v) acrylamide, 2.7% (w/v) bis-acrylamidel.
Acrylamide (73 g) and bis-acrylamide (2 g) were dissolved together and made up to 250 ml
with distilled H20 . The solution was filtered through Whatman No. 1 filter paper and stored in
an amber coloured bottle at 4°C.
Solution B: Separating gel buffer (1.5 M Tris-HCl buffer, pH 8.8). Tris (45.37 g) was
dissolved in approximately 200 ml of distilled H20 , titrated to pH 8.8 using HCI and made up
to 250 ml. The solution was filtered through Whatrnan No. 1 filter paper and stored at 4°C.
Solution C: Stacking gel buffer (0.5 M Tris-HCI buffer, pH 6.8). Tris (3 g) was dissolved in
approximately 40 ml of distilled H20 , titrated to pH 6.8 using HCI and made up to 50 ml. The
solution was filtered through Whatrnan No. 1 filter paper and stored at 4°C. The pH of this
solution was checked before use, because of its poor buffering capacity at 2.1 pH units below
its pKa at 4°C (Pharmacia products catalogue).
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Solution D: 10% (w/v) Sodium dodecyl suIfate (SDS). SDS (10 g) was dissolved in 100 ml of
H20 with gentle heating if necessary.
Solution E: Initiator [10% (w/v) ammonium persulfate]. Ammonium persulfate (0.2 g) was
made up to 2 m!' This solution is stable for a week at 4°C.
Solution F: Tank buffer [0.25 M Tris, 0.192 M glycine, 0.1% (w/v) SDS, pH 8.3]. Tris (15 g)
and glycine (72 g) were dissolved and made up to 5 I with distilled H20. Prior to use, 2.5 ml of
SDS stock (solution E) was added to 250 ml for use in the Bio-Rad Mini-Protean®II appartus.
Solution G: Reducing treatment buffer [0.125 M Tris-HCI buffer, 4% (w/v) SDS, 20% (v/v)
glycerol, 10% (v/v) 2-mercaptoethanol, pH 6.8]. Buffer C (2.5 ml), 10% SDS (4 ml) (solution
D), glycerol (2 ml) and 2-mercaptoethanol (1 ml) were made up to 10 ml with distilled H20
and stored in aliquots at -20 °C.
Solution H: Non-reducing treatment buffer [0.125 M Tris-HCI buffer, 4% (w/v) SDS, 20%
(v/v) glycerol, pH 6.8]. Buffer C (2.5 ml), 10% SDS (4 ml) (solution D) and glycerol (2 ml)
were made up to 10 ml with distilled H20 and stored at 4°C.
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Table 4. Preparation of running and stacking gels of different acrylamide concentrations.
Reagent Volume (ml)
Running gel (%) Stacking gel (%)
15.0 12.5 5.0 4.0
A 7.5 6.25 2.5 0.94
8 3.75 3.75 3.75 0
C 0 0 0 1.75
D 0.15 0.15 0.15 0.07
E 0.75 0.75 0.75 0.35
Distilled H2O 3.5 4.75 8.5 4.3
TEMED 0.075 0.075 0.075 0.015
2.5.2 Procedure
The gel sandwich was assembled according to the manufacturer's instructions. The gel plates
and spacers were cleaned with 70% ethano l. The gel plates and spacers were carefully placed
against a flat surface before tightening the clamp to avoid misalignment which might result in
a leak. The running gel solution was introduced into the gel sandwich, using a pipette, to a
depth of 3 cm from the top of the front plate. The running gel solution was over-layered with
distilled H20 to allow for even polymerisation. When the gel polymerised (about 45-60 min.),
a distinct interface appeared between the running gel and the water layer. The water was
poured off. The stacking gel solution was poured into the gel sandwich on top of the
separating gel until the solution reached the top of the front plate. A comb was inserted to
form sample application wells. Once the gel had set (about 30 min.) the comb was removed
and the wells were rinsed with distilled H20 to remove unpolymerised acrylamide.
The gels were attached to the electrode assembly before inserting into the electrophoresis tank.
The electrophoresis buffer (solution F) was added to the inner and outer reservoirs, ensuring
that both top and bottom of the gels are immersed in buffer. For reducing SDS-PAGE, samples
were combined with an equal volume of reducing treatment buffer (sol ution G) and incubated
in a boiling waterbath for 2 min . The samples were cooled on ice before loading. For non-
reducing SDS-PAGE, samples were combined with half their volume of non-reducing
treatment buffer (solution H) before loading. Gels were run at 18 mA per gel until the
bromophenol blue tracker was 0.5 cm from the bottom of the running gel. The gels were
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removed from the glass plate sandwich and stained (Section 2.6) or subjected to electro
blotting (Section 2.7).
2.6 Protein staining procedures
2.6.1 Coomassie blue staining
This method of staining is simple and rapid. It can detect up to 0.1 ug of protein in a single
band. This method is based on the principle that dyes tend to be attracted to positively charged
groups (Lys, Arg) in proteins. Consequently, basic proteins tend to stain more strongly than
acidic proteins (Scopes, 1982). This method can, however, be used when high sensitivity is not
required because of its simplicity.
2.6.1.1 Reagents
Stain stock solution [1% (w/v) Coomassie blue R-250]. Coomassie blue R-250 (1 g) was
dissolved in distilled I-hO (100 ml) by magnetic stirring for 1 h. The solution was filtered
through Whatman No. 1 filter paper . The solution was stored at RT.
Staining solution [0.125% (w/v) Coomassie blue R-250, 50% (v/v) methanol, 10% (v/v) acetic
acid]. Stain stock (62.5 ml) was mixed with methanol (250 ml) and acetic acid (50 ml) and
made up to 500 ml with distilled H20 . The solution was stored at RT.
Destaining solution I [50% (v/v) methanol, 10% (v/v) acetic acid]. Methanol (500 ml) and
acetic acid (100 ml) were made up to 1 litre with distilled H20 . The solution was stored at RT.
Destaining solution II [7% (v/v) methanol, 5% (v/v) acetic acid]. Methanol (50 ml) and acetic
acid (70 ml) were made up to 1 litre with distilled H20 . The solution was stored at RT.
2.6.1.2 Procedure
Gels were removed from the electrophoresis unit using gloves and transferred to a small
container containing staining solution (50 ml, 4 h). The staining solution was poured out.
Following rinsing with a few changes of distilled water, gels were placed into destain I (100
ml, overnight). Gels were soaked in destain II until the background had cleared fully and
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stored hydrated in polythene zip-seal bags until photographed.
2.6.2 Silver staining
The method of silver staining was first introduced by Switzer et al. (1979). It provides
detection sensitivity between 20-200 times higher than methods using Coomassie brilliant blue
R-250, being able to detect about 0.1 ng protein/band (Switzer et al., 1979). In silver staining,
ionic silver is reduced to its metallic form by formaldehyde made alkaline with either sodium
carbonate or NaOH. Thiosulfate chemically dissolves salts by complexation. The improved
method of silver staining of proteins introduced by Blum et al. (1987) utilizes thiosulfate and
reduces non-specific background staining without loss of sensitivity and contrast.
2.6.2.1 Reagents
All reagents were stored at RT.
Fixative [50% (v/v) methanol, 12% (v/v) acetic acid, 0.05% (v/v) formaldehyde]. Methanol
(100 ml), acetic acid (24 ml) and 37% formaldehyde (0.1 ml) were mixed and made up to 200
ml with deionised H20.
Wash solution [50% (v/v) ethanol]. Ethanol (100 ml) was made up to 200 ml with deionised
H20.
Pre-treatment solution [0.02% (w/v) Na2,fu0ll Na2S203.5H20 (40 mg) was dissolved in 200
ml of deionised H20.
Impregnation solution [0.2% (w/v) AgN03, 0.075% (v/v) formaldehyde]. AgN03 (400 mg)
and 37% formaldehyde (0.15 ml) were dissolved in 200 ml of deionised H20.
Developer [6% (w/v) Na2C03, 0.05% (v/v) formaldehyde, 0.0004% (w/v) Na2,fu03.5H2Ql.
Na2C03 (12 g), 37% formaldehyde (0.1 ml) and pre-treatment solution (4 ml) were combined
and made up to 200 ml with deionised H20.
Stop solution [50% (w/v) methanol, 12% (v/v) acetic acid]. Methanol (50 ml) and acetic acid
(12 ml) were diluted to 100 ml with deionised H20.
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2.6.2.2 Procedure
The developing procedure was carried out on a Belly Dancer®agitator (Stovall Life Sciences,
Greensboro, USA) and in scrupulously clean glass containers to minimize background
staining. Gels were soaked in fixing solution (100 ml, 1 h or overnight) and washed in
washing solution (3 x 20 min) to remove acetic acid. Gels were soaked in pre-treatment
solution (1 min). Gels were washed in deionised H20 (3 x 20 s) followed by soaking in
impregnation solution (20 min). After washing in deionised H20 (3 x 20 s), the developer was
added. When the bands became visible, the developing solution was immediately replaced
with deionised H20 and the gels were washed until the bands were fully developed.
Development was stopped by soaking the gels in stopping solution (10 min). Gels were stored
hydrated in polythene zip-seal bags, until photographed .
2.7 Western and dot blotting
Western blotting is an electrophoretic technique that allows testing of recognition of individual
protein bands separated on a SDS-PAGE gel with an antibody raised against a specific antigen
(Towbin et aI., 1979). This method is usually used to verify the identity of a protein band. In
western blots, proteins are transferred electrophoretically from the SDS-PAGE gel to a sheet
of nitrocellulose, which binds proteins well. The unoccupied sites on the nitrocellulose sheet
are blocked with a non-antigenic protein, for example, non-fat milk to prevent non-specific
immunoglobulin binding to the nitrocellulose. The nitrocellulose is treated with the primary
antibody raised against the target protein and next with an enzyme linked secondary antibody
that binds to the primary antibody. The marker enzymes most commonly used for detection of
the antigen-antibody interaction are alkaline phosphatase and horseradish peroxidase
(Copeland, 1994). Enzyme activity is visualized by incubating the nitrocellulose with an
appropriate chromogenic substrate that is converted to a coloured, insoluble product (Kemeny
and Chantler, 1988).
A dot blot assay is very similar to western blotting. The only difference is that, in dot blots,
antigen is applied directly to the nitrocellulose in the form of a small dot without being
transferred electrophoretically. This method was particularly useful when determining the
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optimum secondary antibody dilution to use in a western blot or an ELISA by observing the
relative intensity of the dots that resulted from label development.
2.7.1 Reagents
Blotting buffer [0.05 M Tris, 0.19 M glycine, 5% (v/v) methanol, 10% (w/v) SDS]. Tris (27.23
g) and glycine (64.8 g) were dissolved in approximately 3.5 litre of distilled H20, and
methanol (900 ml) was added. The volume was made up to 4.5 litres and stored at 4°C. Just
before use, 10% (w/v) SDS (4.5 ml solution D, Section 2.5.1) was added to 450 ml of blotting
buffer.
0.1% (w/v) Ponceau S. Ponceau S (0.1 g) was dissolved in 1% (v/v) glacial acetic acid. The
solution was stored at RT.
Tris buffered saline (TBS) (0.02 M Tris-HCI buffer, 0.2 M NaCl, pH 7.4). Tris (2.42 g) and
NaCl (11.69 g) were dissolved in approximately 950 ml of distilled H20, titrated to pH 7.4
with HCl, and made up to 1 litre. This buffer was stored at 4°C.
5% Low fat milk (w/v) in TBS. Low fat milk powder (5 g) was dissolved in 100 ml ofTBS.
0.5% (w/v) BSA-TBS. BSA (0.5 g) was dissolved in TBS (100 ml).
1 M MgCh. MgCh (9.5 g) was dissolved in 100 ml ofdistilled H20.
\
0.05 M Tris-HCl buffer, pH 9.5. Tris (3.0 g) was dissolved in approximately 450 ml of
distilled H20, titrated to pH 9.5 with HCl, made up to 500 ml and stored at 4°C.
5-Bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium (BCIPINTB) alkaline
phosphatase substrate. NTB (30 mg) was dissolved in 70% (v/v) dry dimethyl formamide
(DMF) (1 ml) and BCIP (15 mg) was dissolved in 70% (v/v) DMF (1 ml). The two solutions
were combined and 1 M MgCh (500 ul) was added. The mixture was made up to 100 ml with
0.05 M Tris-HCl buffer, pH 9.5.
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4-chloro-l -naphthol substrate solution [0.06% (w/v) 4-chloro-l-naphthol, 0.0015% (v/v)
!:hiliJ 4-chloro-1-naphthol (0.03 g) was dissolved in methanol (10 ml). Two ml of this
solution was mixed with 30% H202(4 Ill) and diluted to 10 ml with TBS.
2.7.2 Procedure
Western blotting After separation of proteins by SDS-PAGE (Section 2.5), usually on
duplicate gels, one gel was stained directly and the other one used for immunoblotting. The
Bio-Rad Mini Trans-Blot transfer cell was used. Gloves were worn when handling
nitrocellulose. Nitrocellulose was cut to a suitable size and floated on top of the blotting buffer
before immersion to prevent entrapment of air-bubbles. Three pieces of wetted blotting paper
(NW 218 B, Macherey-Nagel, Germany) were placed on a well-soaked fibre pad on the black
panel of the transfer cassette which in turn was submerged in blotting buffer. Blotting buffer
was used for soaking. The gel was carefully placed on the wet filter paper. The immersed
nitrocellulose was placed on top of the gel, and bubbles removed by rolling a small test tube
over the nitrocellulose. Three more pieces of wetted blotting paper were placed over the
nitrocellulose. The sandwich was covered with the second well-soaked fibre pad and the
transfer cassette was closed.
Blotting buffer was added to a buffer chamber until half full and the stirrer bar was inserted.
The cooling unit was inserted. The transfer cassette was slid into the electrode insert in the
buffer tank, keeping the black panel of the cassette on the same side as the black panel of the
electrode assembly to ensure that the nitrocellulose is connected to the anode. The buffer tank
was filled with blotting buffer. The electrodes were attached and the · entire Trans-Blot
apparatus was placed on a magnetic stirrer and stirred throughout the process to allow even
distribution of cooling. Electrotransfer of the proteins from the gel to the nitrocellulose was
done at 30 V for 16 h with unlimiting current.
Following blotting, molecular weight markers were visualized by transient staining of the
nitrocellulose sheet with 0.1% (w/v) Ponceau S, and with background stain removed with
distilled H20. The positions of molecular weight markers were marked on the nitrocellulose in
pencil and the blot was completely destained by the addition of a few drops of 0.5 M NaOH to
the distilled H20.
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Dot blotting. The protein samples were applied to a nitrocellulose sheet in the form of small
dots. The visualisation steps for both western blotting and blot dotting are the same.
Development of blots. The nitrocellulose was air dried for about 1.5 h. Unoccupied
nitrocellulose binding sites were blocked with 5% (w/v) low fat milk powder in TBS for
1 h. The nitrocellulose was washed in TBS (3 x 5 min) and incubated for 2 h with primary
antibody in 0.5% BSA-TBS. Following washing in TBS (3 x 5 min), the nitrocellulose was
incubated in rabbit anti-chicken IgG-HRPO linked secondary antibody (Jackson
Immunoresearch laboratories inc, Pennsylvania, USA), rabbit anti-chicken IgG-alkaline
phosphatase conjugate (Sigma, St Louis, USA) or goat anti-rabbit IgG-alkaline phosphatase
conjugate (Sigma, St Louis, USA) in 0.5% BSA-TBS for 1 h, and again washed in TBS (3 x 5
min). When HRPO-linked secondary antibody was used, the nitrocellulose sheet was
immersed in 4-chloro-1-naphthol substrate solution and when alkaline phosphatase linked
secondary antibody was used, the nitrocellulose sheet was immersed in BCIPINBT alkaline
phosphatase substrate and reacted in the dark until bands (for western blotting) or dots (for dot
blotting) were clearly evident. The reaction was stopped by washing the blots in distilled H20 .
The blots were kept between filter paper discs to preserve the bands for photography.
2.8 Immunisation of chickens
Immunisation of experimental animals for antibody production is done by injecting the
immunogen mixed with an adjuvant. A good immune response depends on three variables:
antigen, adjuvant and the immunised animal (Schwarzkopf et al., 2001). Antibody production
is promoted by adjuvants by increasing both humoral and cellular immune responses and by
inducing immunological memory (Schwarzkopf et al., 2001). Adjuvants stimulate an immune
response by forming an immunogen depot at the immunisation site, from where the
immunogen is released slowly over a long period of time. Adjuvants activate macrophages by
inducing the release of co-stimulators in macrophages (Sharon, 1998). Adjuvant stimulation is
independent of the kind of antigen used and is therefore non-specific.
The choice of adjuvant depends on the type of immune response desired, the animal species to
be immunised, the route of administration of the immunogen and the tolerance of an animal
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for any side effects caused by an adjuvant (Allison and Byars, 1994). Classes of adjuvant
include aluminium salts, bacterial derivatives [Mycoplasma tuberculosis in Freund 's complete
adjuvant (FCA)], surface-active agent (saponins), vehicles (syntax adjuvant formulation) , slow
release agents [Freund's incomplete adjuvant (FIA)] and liposomes (Allison and Byars, 1994).
Undesirable side effects of adjuvants often limit their use. FCA can induce injection site
granulomas and results in the animal becoming tuberculin sensitive. This is avoided by
injecting animals once only with FCA, followed by FIA in subsequent injections. Alpha-2-
macroglobulin (U2M) is a promising new adjuvant. It is safe, effective and more potent than
any other currently available adjuvants (Cianciolo et al., 2002). Incorporation of antigens into
U2M can be used to convert a poorly immunogenic immunogen into one that is strongly
immunogenic (Cianciolo et al., 2002). The mode of operation of this adjuvant will be
explained further in Chapter 5.
The choice of animal for immunisation is important and can determine the success of the
immunisation. It would have been impract ical in the present study to use cattle to test the
immunogenicity of the congopain peptides. Usually, rabbits are preferred because they are
relatively cheap, easy to care for, able to withstand intensive immunisation and they are fairly
easy to bleed. Chickens are easier to handle than rabbits and have some additional benefits.
Chickens do not require bleeding. The hen transfers her serum IgG to the egg yolk and gives
immunity to her offspring and, because of this, chicken antibodies can be readily isolated from
the egg yolks (Polson et al., 1980). The use of eggs instead of bleeding animals, represents a
more humane, non-invasive treatment of experimental animals. The antibodies are called IgY,
because Y represents their location in the egg yolk. There is a high amount of IgY in egg yolk
compared to IgG obtained from rabbit serum (Erhard and Schade, 2001). One egg yolk yields
between 60 and 100 mg of IgY whereas the same amount of IgG is obtained from 5-8 ml
rabbit serum (10-16 ml blood). While chickens lay between 5-7 eggs per week, only 50 ml
blood can safely be taken from a rabbit per month. A further benefit in using chickens is found
in the evolutionary distance between the avian immune system and the mammalian or parasite




The methods used for the preparation of immunogens (conjugation of peptides to a carrier
protein) will be given in Chapter 3, because the background information on the selection of
peptides and details of the peptides selected are given in Chapter 3.
Peptide-carrier conjugates were mixed with an equal volume of adjuvant. A stable water-in-oil
emulsion was prepared by trituration using a syringe. The peptide-carrier conjugates contained
200 ug of peptide per inoculation and were mixed with FCA for the first immunisation and
with FIA at weeks 2, 4 and 6. Chickens were injected on either side of the chest into the breast
muscle. Eggs were collected before the first immunisation (non-immune control IgY) and
daily thereafter until 16 weeks post immunisation.
2.9 Isolation of antibodies from chicken egg yolks
The yolk in a hen's eggs consists of dry matter and water in nearly equal proportions. The dry
matter is made up of proteins, fats, carbohydrates and inorganic matter. The protein in the yolk
can be divided into four fractions: lipovitellin, vitellin, phosvitin and livetin. The livetin
fraction consists of alpha-livetin (the equivalent of plasma albumins), beta-livetin (the
equivalent of u2-glycoprotein) and gamma-livetin (the equivalent of serum gamma-globulins
together with transferrin). IgY constitutes the gamma-livetin fraction (Staak et aI., 2001) .
A number of methods have been described for the extraction of IgY (Jensenius et aI., 1981).
Various procedures for isolating IgY from the yolk of immunised eggs may be used, based on
the following criteria: yield and purity of IgY isolated and antibody activity. The use of
polyethylene glycol (PEG, M, 6000) for IgY isolation was introduced by PoIson et al. (1980).
This method can be regarded as a standard technique because it is the most widely accepted
method (Staak et al., 2001). PEG is a hydrophilic polymer and it is thought to precipitate
proteins by excluding the protein from the solvent (Dennison, 1999). Protein is brought to its
solubility limit with an increase in protein concentration. The PEG method is suitable for the
isolation of large proteins since they can easily be brought to their solubility limit. The




0.1 M Na-phosphate buffer, 0.02% (w/v) NaN 3, pH 7.6. NaH2P04.2H20 (15.7 g) and NaN 3
(0.2 g) were dissolved in 950 ml of distilled H20, titrated to pH 7.6 using NaOH, and made up
to 11.
2.9.2 Procedure
IgY was isolated from eggs from weeks 0-16 post immunisation. Two chickens were used for
antibody production against each peptide. Eggs from chickens immunised with the same
peptide were kept separate to compare the responses of the two chickens. Egg yolks were
separated from egg white and washed under running water. The yolk sac was punctured and
the yolk volume determined in a measuring cylinder. The yolk was mixed with 2 volumes of
0.1 M phosphate buffer, pH 7.6. PEG (3.5%) was added and dissolved by stirring. The mixture
was centrifuged (4 420 x g, 30 min, RT), forming two phases. The watery phase containing the
IgY and other chicken serum proteins were filtered through absorbent cotton wool. The solid
phase containing lipoproteins and fatty substances was discarded. The chicken serum proteins
that remained were separated from IgY by increasing the PEG concentration to 12% (w/v) [i.e.
8.5% (w/v) was added to the supematant], the solution was mixed until the PEG was dissolved
and centrifuged (12 000 x g, 10 min, RT) . The supematant was discarded and the pellet ofIgY
was dissolved 0.1 M phosphate buffer pH 7.6, in a volume equal to the volume of the original
egg yolk. IgY was purified further by precipitation once more with 12% (w/v) PEG . The
solution was stirred thoroughly and centrifuged (12 000 x g, 10 min, RT) . The supematant was
discarded and the final IgY pellet was dissolved in a volume of 0.1 M phosphate buffer, pH
7.6 equivalent to 1/6 of the original yolk from which IgY was derived. The antibodies were
stored at 4°C.
2.9.3 Determination of IgY concentration
Antibody solution (20 Ill) was added to phosphate buffer (980 Ill) making a 1 in 50 antibody
dilution. The absorbance at 280 nm was determined and the concentration of IgY was
calculated using the equation: A = e x I Xc
where A = absorbance
c = extinction coefficient
i } ..
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1= the length of the light path (cm)
c = concentration of the absorbing solution.
The dilution factor was taken into account for the calculation of the concentration of the
undiluted sample. The extinction coefficient ofIgY, E~;cf~:1 =1.25 (Coetzer, 1985).
2.10 Enzyme-linked immunosorbent assay (ELISA)
The immunoreactivity (Section 3.4.3) and the specificity (Section 3.4.5) of the isolated
antibodies were tested using ELISA. The assay allows detection of a partially denatured
antigen with great accuracy and sensitivity (Kerr and Thorpe, 1994). Antigens are adsorbed
directly onto the wells of microtitre plates. The unoccupied sites are blocked with a non-cross
reacting protein to prevent non-specific binding of reagents used in subsequent steps. The
antibodies to be quantitated are added. These are detected by the addition of an anti-species
enzyme linked detection ("secondary") antibody which, upon addition of a substrate, produces
a coloured product which can be quantified photometrically (Figure 6).
When antibodies are raised against peptide-carrier conjugates,antibodies are produced against
the peptide, the carrier protein and the carrier residues modified by the conjugation reaction
(Briand et aI., 1985). In order to detect the presence of antibodies produced specifically against
the peptide, an unconjugated peptide should therefore be used to coat the wells of the
microtitre plates. The subpopulation of anti-peptide antibodies that is able to cross-react with
the whole CP2 enzyme was measured by coating the microtitre plates with either the whole
CP2 enzyme or the catalytic domain C2 (Section 3.4.5).
2.10.1 Reagents
PBS, pH 7.2. NaCl (8 g), KCl (0.2 g) Na2HP04.2H20 (1.15 g) and KH2P04 (0.2 g) were
dissolved in 1 1of distilled H20. The pH of this buffer does not require adjustment to pH 7.2.
50 mM Carbonate coating buffer, pH 6.0. NaHC03 (0.21 g) was dissolved in 45 ml of distilled
H20, titrated to pH 6.0 with HCl and made up to 50 ml.
0.5% (w/v) Bovine serum albumin (BSA) - PBS. BSA (0.5 g) was dissolved in 100 ml PBS.
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Figure 6. An illustration of a non-competitive indirect ELISA (Lauritzen et at, 1994).
0.1% (v/v) PBS-Tween. Tween 20 (1 ml) was made up to 1 1in PBS.
0.15 M Citrate phosphate buffer, pH 5.0. A 0.15 M solution of citric acid. H20 (21.0 g/l) was
titrated with a 0.15 M solution ofNa2HP04.2H20 (35.6 g/l) to pH 5.0.
Substrate solution [0.05% (w/v) ABTS and 0.0015% (v/v)H2!D in citrate phosphate buffer].
ABTS (7.5 mg) and H202 (7.5 ul) were dissolved in citrate phosphate buffer, pH 5.0 (15 ml).
Stopping buffer [citrate-phosphate buffer; 0.1% (w/v) NaN3}. NaN3 (0.1 g) was dissolved in
citrate phosphate buffer, pH 5.0 (100 ml).
2.10.2 Procedure
The peptides (5 ug/ml in PBS) or, CP2 or C2 (1 ug/ml, in 50 mM carbonate buffer, pH 6.0)
were coated (150 ul, 16 h at 4°C or 3 h at 37°C). Non-specific binding of antibody was
prevented by blocking the wells with 0.5% BSA-PBS (200 ul, 1 h at 3?OC) and the plates
washed three times with 0.1% (v/v) PBS-Tween, a non-ionic detergent which blocks
hydrophobic interactions. Appropriate dilutions of IgY were prepared in duplicate in 0.5%
BSA-PBS and incubated in the coated wells of the plate (100 ul, 2 h at 37°C). The plates were
washed three times with 0.1% (v/v) PBS-Tween. The rabbit anti-chicken IgG-HRPO-linked
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secondary antibody (Jackson ImmunoResearch laboratories inc, Pennsylvania, USA) at a
dilution of 1/30 000 in 0.5% BSA-PBS, was added to each well and incubated (120 ul, 1 h at
37°C) and the plates washed three times with 0.1% (v/v) PBS-Tween. Substrate solution (150
ul) was added and the colour was allowed to develop in the dark against the background of the
negative controls to check non-specific binding (usually 10-20 min). The enzyme reaction was
stopped by the addition of 0.1% (w/v) NaN3 in citrate-phosphate buffer (50 ul per well) and
the absorbance determined at 405 nm in a Molecular Devices Versamax microplate reader.
2.11 Immuno-affinity purification of anti-peptide antibodies
Affinity chromatography is a method of purification based on biological recognition between
ligand and receptor molecules and is mainly used for the purification of biologically active
molecules (Kruger and Hammond, 1988). Affinity chromatography takes advantage of the
reversible binding interactions that occur on a protein's surface. The specific interaction
between antibodies and their antigens may be exploited in the irnmuno-affinity purification of
antibodies specific for a peptide from other contaminating antibodies such as those against a
carrier protein.
Specific antigens or antibodies are covalently coupled to an insoluble matrix such as cellulose,
agarose beads or glass beads (Tharakan, 1994). In this study, peptides were used as affinity
ligands and were covalently coupled to agarose beads. The careful selection of the matrix is
crucial to the successful operation of any affinity process (Tharakan, 1994). The physical and
chemical stability of bonds linking the support should be considered to ensure minimal
leakage of an immobilised protein or peptide. In this study, the peptides had to have the same
orientation on the affinity matrix as they had on the carrier protein during immunisation.
Peptides with N- or C-terminal cysteine residues were therefore coupled to Pierce's
SulfoLineM through their free cysteine residues. The peptide which did not have an internal
lysine group was coupled to Pierce's AminoLink™ through its free amino group.
2.11.1 Preparation of peptide-Sulfolink™ affinity matrices
To couple a peptide to a SulfoLink™ gel, the peptide with a cysteine residue at the N- or C-
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terminal end is first reduced to make sulfhydryls , which react efficiently with an alkylating
agent, available. Peptides with sulfhydryls bind specifically to a SulfoLineM gel because the
gel has an immobilised iodoacetyl which reacts with the sulfhydryls (Pierce SulfoLink™ data
sheet).
2.11.1.1 Reagents
0.1 M Na-phosphate buffer, 0.005 M EDTA, pH 6.0. NaH2P04.2H20 (1.56 g) and EDTA
(0.186 g) were dissolved in 90 ml of distilled H20, titrated to pH 6.0 with NaOH and made up
to 100 ml.
0.05 M Tris-HCl buffer, 0.005 M EDTA, pH 8.5. Tris (3.03 g) and EDTA (0.939 g) were
dissolved in 450 ml of distilled H20, titrated to pH 8.5 with HCl and made up to 500 ml.
0.01 M Dithiothreitol eDIT). DIT (7.71 mg) was dissolved in 5 m! of Tris -HCl buffer, pH
8.5.
0.05 M Na-phosphate buffer, pH 7.0. NaH2P0 4.2H20 (3.9 g) was dissolved in 450 ml of
distilled H20, titrated to pH 7.0 with NaOH and made up to 50 ml.
0.01 M Ellman's reagent. 5,5 -dithiobis-2-nitrobenzoic acid (DTNB) (0.004 g) was dissolved
in 10 J..ll of methanol and diluted to 1 ml with 0.05 M phosphate buffer, pH 7.0.
0.05 M cysteine. Cysteine (0.0176 g) was dissolved in 2 ml of Tris-HCl buffer, pH 8.5.
1 M NaCl , 0.05% NaN3. NaCl (58.44 g) and NaN3 (0.5 g) were dissolved in 1 litre of distilled
H20.
0.1 M Na-phosphate buffer, 0.02% NaN 3, pH 6.5. NaH2P0 4.2H20 (7.8 g) and NaN3 (0.1 g)




CP 1 (10 mg) and CP2 (7.5 mg) peptides were individually dissolved in the minimum amount
of DMSO (approximately 100 Ill) and made up to 1 ml with Tris-HC1 buffer, pH 8.5. The
peptides were reduced by adding 10 mM DTT (1 m1) slowly to the dissolved peptide with
stirring. The mixture was incubated for 1.5 h at 37°C. The reduced peptide was separated from
excess DTT on a Sephadex G-10 column (130 mm x 10 mm, flow rate 0.13 mllmin), pre-
equilibrated with 50 mM Tris-HCI buffer, pH 8.5. Fractions (500 Ill) were collected and the
elution profile was determined by the addition of 0.01 M Ellman's reagent (10 Ill) to an equal
sample volume from each fraction. A yellow colour was indicative of the elution of the
reduced peptide peak, which was separated from the unreacted DTT peak, which gave an
intensely yellow colour.
The Sulfol.ink' I" gel was supplied as a 50% slurry, 4 ml of which was packed into a Biorad
disposable polystyrene column. The liquid was drained from the gel until the wet cake
remained. The gel was washed with 6 column volumes (12 ml) of Tris-HCI buffer, pH 8.5.
The reduced peptide was added to the gel. The gel was mixed at RT by gentle end-over-end
rotation for 15 min and incubated at RT for 30 min without mixing. The buffer was drained.
The column was washed with 3 column volumes (6 ml) of Tris-HCI buffer, pH 8.5. The non-
specific binding sites were blocked by applying 2 ml of cysteine to the column. The gel was
mixed at RT by gentle end-over-end rotation for 15 min and incubated at RT for 30 min
without mixing. The column was washed with 16 column volumes (32 ml) ofNaCI, 2 column
volumes (6 ml) ofNa-phosphate buffer, pH 6.5, and stored at 4°C until use.
2.11.2 Preparation of a peptide-Amlnol.Jnkf affinity matrix
The AminoLineM coupling gel has many advantages. It uses a coupling chemistry that is
active over a wide pH range. More than 85% of coupling with AminoLink™ support is
obtained throughout the pH range of 4-1O. It can couple proteins of different molecular masses
and isoelectric points with high efficiency. The Aminol.ink'I" gel has no additional charge on
the matrix, thus reducing non-specific binding of proteins and allowing greater purification of
proteins (PIERCE, Immuno Pure instruction manual). The AminoLink™ coupling gel consists
of a 4% cross-linked beaded agarose matrix, activated to form aldehyde functional groups,
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suitable for coupling peptides and proteins using reductive amination. The aldehyde groups on
the matrix react with the primary amine group of the peptide to form a labile Schiff base.
Reduction of the Schiff base intermediate with sodium cyanoborohydride (NaCNBH4) results
in the formation of a stable secondary amine bond between the matrix and the peptide or
protein. NaCNBH4 is the preferred reducing agent because of its specificity toward the Schiff
base structure and because it is more gentle, especially when antibodies are immobilised
(Hermanson, 1996). The unreacted aldehyde groups on the coupling gel are quenched with
Tris-HCl. The Schiff base intermediate formed between the Tris primary amine and coupling
gel is reduced with a further addition of NaCNB~ to form a stable Schiff base. The
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Figure 7. Reductive amination mechanism for coupling of a peptide to an Aminol.Ink" matrix. The
mechanism was adapted from Ginsburg (1967) and Hennanson (1996). Pierce's Aminol.ink'Yagarose containing
aldehyde functional groups react with primary amine to form labile Schiff bases which are reduced to form amine
linkages.
2.11.2.1 Reagents
0.1 M Na-phosphate buffer, 0.05% NaN 3, pH 7.0. NaH2P0 4.2H20 (7.8 g) was dissolved in
450 ml of distilled H20 , titrated to pH 7.0 with NaOH, NaN3 (0.25 g) added and made up to
500 ml.
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1 M Tris-HCl buffer pH 7.4. Tris (60.75 g) was dissolved in 450 ml of distilled H20, titrated
to pH 7.4 with HCI and made up to 500 ml.
1 M Na-cyanoborohydride. NaCNBH3 (0.0623 g) was dissolved in 1 ml of distilled H20. This
solution was prepared 1 h before use.
1 M NaCl. NaCI (29.22 g) was dissolved in 500 ml of distilled H20.
0.05% NaN3. NaN3 (0.25 g) was dissolved in 500 ml of distilled H20.
2.11.2.2 Procedure
Peptide #3 [Section 3.4.1 (10 mg)] was coupled to the AminoLineM coupling gel (2 ml)
according to the method in the PIERCE, Immuno Pure instruction manual. To prepare a
peptide solution, peptide (10 mg) was dissolved in Na-phosphate buffer, pH 7.0 (2 ml).
AminoLink™ gel (4 ml), supplied as a 50% slurry, was packed into a Biorad disposable
polystyrene column. The liquid was drained from the gel until only the wet gel cake remained.
The gel was washed with Na-phosphate buffer, pH 7.0 (2 ml). The peptide solution was added
to the column, followed by addition of NaCNBH3 solution (200 Ill) in a fume hood. The
column was mixed by gentle end-over-end rotation (2 h, RT). The reduction amination
reaction proceeded at RT for an additional 4 h. The gel was washed with Tris-HCl buffer, pH
7.4 (2 ml). NaCNBHJ solution (200 Ill) was added to the column in a fume hood. The column
was mixed by gentle end-over-end rotation (30 min, RT). The gel was drained and washed
with 10 column volumes (20 ml) of NaCI solution followed by washing with 10 column
volumes (20 ml) of Nabl, solution. NaNJ solution (2 ml) was added to the column which was
stored at 4QC until use.
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2.11.3 Affinity purification of anti-peptide antibodies on SulfoLink-™ or AminoLink-™
peptide matrices
2.11.3.1 Reagents
0.1 M Na-phosphate.buffer, 0.02% NaN 3, pH 6.5. As per Section 2.11 .1.1
0.1 M Na-phosphate buffer, 0.05% NaN 3, pH 7.0. As per Section 2.11.2.1
0.1 M Glycine-HCl, pH 2.8. Glycine (3.7535 g) was dissolved in 450 ml of distilled H20,
titrated to pH 2.8 with HCI and made up to 500 m!'
1 M Na-phosphate buffer, pH 8.5. NaH2P04.2H20 (78.005 g) was dissolved in 450 ml of
distilled H20, titrated to pH 8.5 with NaOH and made up to 500 m!'
2.11.3.2 Procedure
For the affinity purification of antibodies, the appropriate column was first brought to RT. The
column was equilibrated with 10 column volumes (20 ml) of 0.1 M Na-phosphate buffer, pH
6.5 (Sulfcl.ink matrix) or pH 7.0 (Aminol.ink" matrix) at a flow rate of 0.13 ml min-I .
Chicken antibodies (IgY) (maximum volume of 60 ml) were circulated through the column
overnight. The column was washed with 10 column volumes (20 ml) of 0.1 M Na-phosphate
buffer, pH 6.5 (SulfoLink™ matrix) or pH 7.0 (AminoLink™ matrix). Anti-peptide antibodies
(900 p.l fractions) were eluted using glycine-HCl buffer, pH 2.8. Samples were collected into
tubes containing 100 ul of 1 M Na-phosphate buffer, pH 8.5, to increase the pH of eluted
samples to pH 7.2. The elution of anti-peptide antibodies was monitored by reading
absorbance values at 280 nm . The fractions containing anti-peptide antibodies were pooled.
The column was regenerated with 0.1 M Na-phosphate buffer, pH 6.5 (Sulfol.ink! matrix) or
pH 7.0 (Aminolink matrix) ;
2.12 Inhibition of catalytic activity of CP2 using antibodies
Fluorogenic substrates contain fluorescent leaving groups conjugated to a short peptide which
has selectivity and specificity for the protease under study (Knight, 1995). In this study, Z-
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phenylalanyl-arginyl-aminomethyl coumarin (Z-Phe-Arg-AMC) was used. Z-Phe-Arg-AMC
seemed appropriate to use because congopain is similar to cathepsin L (Mbawa et al., 1992)
and it was used successfully in the CP2 inhibition assay (Authie et al., 2001) . Furthermore, 7-
amino-4-methyl coumarin is a sensitive , safe and convenient leaving group to use in enzyme
assays (Barrett and Kirschke, 1981). Both the substrate and the product are intensely
fluorescent, but with different excitation and emission wavelengths (Knight, 1995). 7-amino-4
methylcoumarin has a Aex of 345 nm and Aemof 445 nm. The release of 7-amino-4-
methylcoumarin can be measured against low background fluorescence of unhydrolysed
substrate at a Aex of 370 nm and Aem of 460 nm.
2.12.1 Reagents
Assay buffer [400 mM Na-phosphate buffer, 4 mM Na2EDTA, 2 mM DTT, pH 7.0l.
NaH2P0 4.2H20 (3.12 g) and Na2EDTA (0.075 g) were dissolved in 40 ml of distilled H20 and
titrated to pH 7.0 with NaOH, NaN3 (0.01 g) added and made up to 50 ml. DTT (3 mg) was
added to 10 ml of buffer just before use.
Stock substrate solution [1 mM Z-Phe-Arg-AMC]. Z-Phe-Arg-AMC (1 mg) was dissolved in
DMSO (1.5 ml) and stored at 4°C.
Working substrate solution [20 !lM Z-Phe-Arg-AMCl. Stock substrate solution (100 lll) was
diluted to 5 ml with distilled H20. This was also kept at 4°C.
0.1% (w/v) Brij 35 diluent. Brij 35 (0.1 g) was dissolved in 100 ml of distilled H20.
Stoppingreagent [100 mM monochloroacetate, 30 mM sodium acetate, 70 mM acetic acid, pH
4.3]. Monochloroacetate (4.275 g), sodium acetate (2.04 g) and glacial acetic acid (2 ml) were
dissolved in 475 ml of distilled H20, titrated to pH 4.3 with NaOH and made up to 500 ml
with distilled H20.
Antibody diluting buffer [100 mM Na-acetate, 1 mM Na2EDTA, 0.02% (w/v) NaN3, 0.1%
(v/v) Tween-20, pH 8.0. Glacial acetic acid (2.85 ml) and Na2EDTA. 2H20 (0.185 g) were
dissolved in 450 ml of distilled H20 and Tween-20 (500 ul) was added. The solution was
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titrated to pH 8.0 with NaOH, NaN3 (0.1 g) added and made up to 500 ml with distilled H20.
2.12.2 Procedure
Serial two fold dilutions of anti-peptide antibodies (from 500 ug/ml, in antibody diluting
buffer, 25 III per well) were mixed with CP2 or C2 [20 ng in 0.1% (w/v) Brij 35, 15 min.
37°C]. The assay buffer was added (25 Ill, 1 min, 37°C) followed by substrate (25 Ill, 10 min,
37°C). The reaction was terminated by the addition of stop reagent (100 Ill). Fluorescent
product was determined (excitation 370 nm and emission 460 nm) in a Cambridge Technology
7620 Microplate Fluorometer. The inhibition or activation of an enzyme by antibody was
expressed as a percentage of the activity detected after incubation with the same concentration
of non-immune antibody.
2.13 Azocasein assay for determination of CP2 proteolytic activity
Azocasein is formed by coupling of diazotised sulfanilic acid or sulphanilamide to tyrosyl and
histidyl side chains with in alkali (Barrett and Kirschke, 1981). Azocasein is a suitable
substrate for determining proteolytic activity in crude samples (Barrett and Kirschke, 1981).
When azocasein is proteolytically degraded, peptides which are soluble in dilute
trichloroacetic acid are released. The soluble peptides are intensely yellow as a result of the
presence of the azo-groups. The yellow colour can be quantified at 366 nm. Azocasein is
mixed with urea because this is known to selectively depress the activity of other proteases
and enhances that of cathepsin L (Barrett and Kirschke, 1981). CP2 is a cathepsin L-like
enzyme (Lalmanach et aI., 2002) and azocasein/urea is therefore a suitable substrate. In this
study, the azocasein assay was used to determine the proteolytic activity of free CP2 in
comparison with the proteolytic activity of CP2-uzM complexes (Section 5.3.1.2). The assay
was based on the method of Ramos et al. (2002).
2.13.1 Reagents
Assay buffer [0.1 M Na-acetate, 0.001 M Na2EDTA, 0.02% (w/v) NaN3, 1 ug/ml pepstatin,
0.04 M cysteine, pH 6.0]. Glacial acetic acid (2.86 ml) and Na2EDTA.2HzO (0.185 g) were
dissolved in 450 ml of distilled H20 , titrated to pH 6.0 with NaOH, NaN3(0.1 g) and pepstatin
(500 ug) were added and the solution made up to 500 ml. Just before the assay, cysteine.HCl
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(0.04 g) was added to 5 ml of the buffer.
6% (w/v) Azocasein. Azocasein (3 g) was dissolved in 50 ml of distilled H20 with gentle
magnetic stirring at RT for- approximately 1 h.
Azocasein/3 M urea solution. Urea (54 g) was dissolved in 6% azocasein solution (50 ml) by
stirring on a magnetic heater stirrer at less than 30°e. The volume was made up to 150 ml with
the assay buffer without cysteine.
5% (w/v) TCA. TCA (25 g) was dissolved in 500 ml of distilled H20.
2.13.2 Procedure
Enzyme (l 00 ul) was mixed with assay buffer (l00 ul). The mixture was activated for 5 min at
37°C. Azocasien/urea solution (200 ul) was added. A sample (200 ul) of the mixture was
immediately withdrawn and mixed with 5% TCA (1 ml) in a polyethylene microfuge tube.
This served as the blank: for the reaction. The remainder of the mixture was incubated for
2 h at 37°C. The samples (200 ul) were mixed with 5% TCA (1 ml). All samples were
centrifuged (12 000 x g, 5 min, RT). Absorbance values were read at 366 nm using glass
micro cuvettes with blacked-out sides. Proteolytic activity was determined by measuring the
hydrolysis of substrate at 366 nm compared to the blank.
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Chapter 3
Production and characterisation of anti-CPl and CP2 peptide
antibodies.
3.1 Introduction
Anti-peptide antibodies may be considered to be site directed probes for proteins (Hancock et
al., 1998). They may recognise the corresponding peptide in the whole protein molecule,
provided that some conformations, observed in the peptide , are similar to those that occur in
the corresponding constrained regions of the parent protein (Troeberg et al., 1997). Anti-
peptide antibodies in the antiserum that cross-react with the complete protein are regarded as
antibodies of predefined specificity, since they react with a single antigenic region of the
protein (Muller, 1990b). Unlike conventional anti-protein polyclonal antibodies, anti-peptide
polyclonal antibodies share with monoclonal antibodies the property of binding to a discrete
region of the protein antigen (Muller, 1990b). Monoclonal antibodies are commonly used
because of their high specificity, but they have a disadvantage of being very expensive and
their production is time consuming compared to anti-peptide antibodies . An immune response
is usually generated against the peptide but the main problem with anti-peptide antibodies is
that they may not recognise the whole protein molecule. It is therefore very important to
carefully select a peptide in order to increase the chances of success and to minimize the cost.
In this study, anti-peptide antibodies were used to study their effect on CP2 activity.
Antibodi es against both CPl and CP2 have previously been raised in cattle (Authie et al.,
2001). However, it may be more advantageous to have antibodies against peptides
corresponding to specific regions of these proteases. Such antibodies would potentially
possess the desired specificities since they are "site directed" (Bulinski and Gundersen, 1986).
Antibodies against a sequence of 10-20 residues are more likely to be specific for the protein
of interest because it is very probable that a sequence of this length will be unique to a
particular protein (Coetzer et al., 1991).
Peptides from both CP1 and CP2 were selected for immunisation (Sections 3.2 and 3.4.1). The
CPl and CP2 peptides selected were conjugated to rabbit albumin via M-maleidobenzoyl-N-
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hydroxysuccinimide ester (MBS) or glutaraldehyde (Section 3.3.2 or 3.3.3) pnor to
inoculation into chickens. Antibody production against the respective peptides was monitored
by ELISA (Section 3.4.3) prior to affinity purification (Section 3.4.4). Recognition of whole
CP2 by the anti-peptide antibodies was determined by ELISA and western blotting (Sections
3.4.5 and 3.4.6). Finally, the effect of anti-peptide antibodies on CP2 activity was investigated
(Section 3.4.7).
3.2 Prediction of immunogenic peptides in proteins
The position of an epitope in an intact protein may be detected by limited enzymatic digestion
of the antigen, followed by immunoblotting of the protein fragments (Westwood and Hay,
2001). Once the fragment is identified, it is sequenced and the epitope is characterised. This
method requires high purity of the protein and the data is not always precise. Alternatively,
peptides of different lengths are produced for sequencing using cyanogen bromide that cleaves
peptides at the carbonyl group of methionine residues, hydroxy-amine that cleaves asparagine-
glycine bonds, or 2-nitro-5-thiocyanobenzoate that cleaves on the amine side of cysteine
residues. The advantage of using chemicals over enzymes for protein cleavage is that
chemicals are not prone to steric hindrance and can easily reach the target sites deep within the
tertiary structure (Westwood and Hay, 2001).
There are several methods used in identifying immunogenic peptides, including predictive
algorithms that look for certain features in the primary structure of a protein. These features
are mainly hydrophilicity, segmental mobility and surface probability. The predicted peptides
are then synthesised and screened. The amino acid sequence of the protein of interest should
be known when using this method. The major disadvantage of this method is that the
predictions are not always accurate (Sumar, 2001). Predict 7, a program for protein structure
prediction, uses seven different algorithms simultaneously. The algorithms used include:
secondary structure analysis, hydrophilicity, side chain flexibility, surface probability,
antigenicity and the location of putative N-glycosylation sites (Carmenes et al., 1989).
Another epitope mapping method IS called multiple pm peptide scanning ('Pepscan')
technology. In this method, solid phase synthesis of peptides on polystyrene pins, in
conjunction with ELISA, assist in the identification of epitopes of an antigen. One of the main
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differences between this method and the above method is that peptides are synthesised and do
not result from cleaving of a protein sequence. Linear peptides (for example, 12-mers with an
overlap of four residues) spanning the whole protein sequence are synthesised on pins which
are attached to a plastic support. The polystyrene pins are arranged in blocks of 8 x 12 (96
pins), which are immersed into the wells of a microtitre plate. The pins are then incubated with
sera or antibodies of interest and with species-specific secondary antibody conjugated with an
enzyme. The substrate is added and the colour is developed and measured in an ELISA reader
(Sumar, 2001). The ELISA results show whether serum antibodies bind to the peptide or not
and therefore help in the identification of peptides which are epitopes.
The three dimensional structure of the protein can also be inspected to map surface regions
which are easily accessible to antibodies and are therefore more likely to be epitopes. In this
study, a very quick and yet fairly accurate method was required. In view of the high cost of the
other methods, the Predict 7 program remained attractive to use.
3.2.1 Structural parameters analysed by the Predict 7 program
Predict 7, is a program which analyses protein sequences (Carmenes et al., 1989)~ The main
features analysed by this program are: hydrophilicity, segmental mobility and surface
probability.
3.2.1.1 Hydrophilicity
Hydrophobic amino acids tend to be buried within the native structure of globular proteins,
while hydrophilic side-chains are on the exterior where they can interact with water. Most
hydrophilic segments of a protein tend to correspond to continuous epitopes (Hopp and
Woods, 1981). Local maxima in hydrophilicity plots were found to correspond to segments
that were exposed at the surface of the molecule and at the same time were part of epitopes
(Van Regenrnortel, 1990a). However, for predicting the positions of continuous epitopes, it is
preferable to consider only the highest peaks appearing in hydrophilicity plots (Van
Regenmortel, 1990a). Some hydrophilic amino acid sequences may be buried in water pockets
forming inter or intra molecular bonds. Hydrophilicity is required, but not sufficient for
selecting peptides. There is a correlation between secondary structure of a protein and
hydrophilicity. Methods that predict the position of loops or turns, at the same time predict
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regions of highest hydrophilicity
3.2.1.2 Segmental mobility
X-ray and NMR studies indicated that amino acid residues at the surface of a protein molecule
have higher mobility (Westwood and Hay, 2001). The more flexible a stretch of amino acids,
the more likely it is to be immunogenic (Gullick, 1994). Regions of highest mobility
correspond with highly accessible segments at the surface of the molecule. In several proteins,
a correlation between the peaks in the mobility plot and the position of epitopes was found
(Gullick et al., 1986). The induced fit model proposes that antigen and antibody interaction
largely depends on side-chain movements of the antigen and some movements of the
backbone conformation. This model highlights the importance of the observed link between
antigenicity and local mobility of the peptide main chain (Van Regenmortel, 1989).
3.2.1.3 Surface probability
Antibodies bind to the surfaces of proteins, and therefore it is expected that epitopes will
usually consist of residues exposed at the surface of a protein (Van Regenmortel, 1990a).
Regions of proteins exposed on the surface, were found to correlate with the position of
continuous epitopes and correlated well with side-chain flexibility, but there was less
correlation with hydrophilicity (Thomton et al., 1986). Any accessible part of a molecule may
be considered to be potentially antigenic but some accessible parts are naturally more
immunogenic than others (Westwood and Hay, 2001).
3.2.2 Selection of peptides using the 3-dimensional structure of a protein
When this study was started, the three dimensional structure of CP2 was not known. It was
published later after the selection of peptides (Lecaille et aI., 2001). CP2 shares a high
sequence homology with papain, whose three dimensional structure is known (Drenth et al.,
1971). The three-dimensional structure of papain was therefore used to ascertain the position
of the peptides selected using Predict 7 parameters. The papain structure was an appropriate
structure to use, because, as expected, the subsequently published three dimensional model of
CP2 exhibits a framework common to most papain-like cysteine proteinases (Lecaille et al.,
2001).
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The peptides were selected based on the results obtained from the epitope prediction plots and
also on their location in the three dimensional structure of papain. In addition to this, they
were selected for the following reasons: firstly, it is likely that antibodies against the active
site would inhibit enzyme activity compared to antibodies against other regions of the enzyme.
Anti-peptide antibodies which targeted the active site of trypanopain-Tb (Troeberg et al.,
1997) and the active site of cathepsin L (Coetzer et al., 1991) inhibited enzyme activity. For
this reason, peptides covering the active site of CP1 and CP2 were selected. Secondly, the
peptides in the N-and C-termini of the proteins are usually good antibody targets, because they
may more closely resemble the peptide immunogen than internal, more conformationally
constrained sequences (Hancock et al., 1998). Thirdly, peptides in the C-terminal extensions
of CP2 and vivapain are likely to be good immunogens because the C-terminal extension is
thought to form an important part of antigenicity in the trypanosomal cysteine proteinases
(Lalmanach et al., 2002). This was shown by high reactivity of infected sera with the
recombinant C-terminal domain of CP2 (Lalmanach et al., 2002).
3.3 Considerations for coupling of peptides to carrier proteins
Short peptides can be poor immunogens, therefore it is essential to covalently conjugate them
to carrier proteins to enhance the production of anti-peptide antibodies. Coupling of the
peptide to a carrier protein can increase its immunogenicity by 100 fold (Mariani et al., 1987).
The carrier-peptide complex has both T-cell epitopes on the carrier protein and B-cell epitopes
on the peptide for interaction between T- and B- lymphocytes, an interaction which is
necessary for antibody production (Roitt, 1997). The orientation of the peptide after
conjugation to a carrier protein (i.e. whether the peptide-carrier link is at the peptide's N- or C-
terminus) should be such that the most immunogenic residues are exposed to the experimental
animal's immune system.
Choosing the appropriate conjugation procedure is important since the antigenic activity of a
peptide may be affected by different coupling methods (Briand et al., 1985). Most coupling
methods are based on the use of symmetrical or asymmetrical bifunctional reagents which
become incorporated into the final conjugate. Alternatively, they activate certain reactive sites
of the carrier protein molecule for subsequent linkage with the peptide (Muller, 1990a).
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There is a wide range of coupling reagents available. Glutaraldehyde and MBS were used in
this study. The coupling reaction should preferably not affect the configuration of amino acids
which form the epitope (Muller, 1990a). Glutaraldehyde reacts mainly with N-terminal a-
amine and lysine s-amine groups. Glutaraldehyde is appropriate to use for conjugation of
peptides which are more immunogenic towards their C-termini and which do not have an
internal lysine residue. However, the majority of the peptides selected in this study had
internal lysine residues whose s-arnines would cross-react with glutaraldehyde. This
necessitated conjugation using MBS. For peptides which did not have a terminal cysteine, an
additional cysteine was added at either the N- or C- terminus of the sequence, as appropriate,
during peptide synthesis.
Rabbit albumin is a readily available protein with a molecular weight of 68 kDa which makes
it big enough to be used as a carrier protein. Chickens were the animals of choice for
immunisation in this study and their immune system is likely to recognise rabbit albumin as
foreign. Rabbit albumin was therefore chosen as a carrier protein to be conjugated to peptides .
Apart from peptide # 3 (Section 3.5.1), which was conjugated via glutaraldehyde, all peptides
were conjugated via MBS.
3.3.1 Synthesis of peptides
Some modifications to the original sequences were made for the synthesis of peptides. For
some of the peptides (peptides A, B, C, D and E, Section 3.4.1, Table 6) an additional Cys-
residue was added either at the C-terminus or the N-terminus of the peptide for MBS
conjugation . Since one of the peptides contained an internal Cys-residue, this residue was
synthesised as 2-aminobutyric acid that is similar to the conformation of an internal Cys-
residue in a disulfide bond without presenting an additional Cys-residue for unwanted
conjugation (Muller, 1990a). All the peptides were synthesised as C-terminal amides so that
they could mimic the peptide conformation in the native protein, since amidation renders the
C-terminal residue uncharged as it would be in a peptide bond in a native protein (Multiple
peptide systems technical bulletin).
3.3.2 Conjugation of peptides to rabbit albumin using MBS
MBS reacts in two steps, firstly by acylation of the amino groups of a carrier via the active N-
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hydroxy succinimide ester and, secondly, by formation of a thioether bond through addition of
a thiol group (from cysteine in the peptide) to the double bond of the maleimide (Figure 8),
(Kitawa and Aikawa, 1976).
This coupling procedure is divided into three steps. Firstly, the peptide, which may be
dimerised because of the cysteine residue at the N- or C-terminus, is reduced by incubation
with the reducing agent dithiothreitol (DTT) and reduced peptide is separated from unreacted
DTI using Sephadex G10 molecular exclusion chromatography (MEC). In the second step,
the carrier protein is activated by MBS and activated carrier is separated from unreacted MBS
using Sephadex G25 MEC. In the final step the reduced peptide and activated carrier protein
are incubated together. Peptides A, B, C, D, E, F (Table 6) and 1, 2, 4, 5 (Table 7) were
conjugated to the carrier via MBS. For the sake of brevity, the procedure followed has been
described for only one peptide (peptide 1) as an example, and summarised for the remainder of
the peptides in Table 5. A final molar ratio of carrier protein to MBS of 1:40 was used, and a
molar ratio of peptide to carrier protein of 40:1 was used.
+
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Figure 8. The mechanism for coupling of peptides to carrier proteins using the MBS conjugation method
(Muller, 1990a). PI represents the carrier protein and P2 represents the peptide.
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Purity" mg umoles mg umoles
(%)
91 4 2.53 4.32 0.06
75 4 3.06 5.22 0.08
73 4 3.12 5.32 0.08
88 4 3.25 5.55 0.08
90 4 3.56 6.07 0.09
73 4 1.84 3.14 0.05
87 4 1.68 2.86 0.04
95 4 1.66 2.83 0.04
>77 4 2.03 3.46 0.05
>80 4 2.22 3.79 0.06
>90 4 2.47 4.21 0.06
"Determined by RP-HPLC (see text)
3.3.2.1 Reagents
Peptides. Peptides A, B, C, D, E and F (CP1) were custom synthesised by Sigma Genosys,
Cambridge, UK. Peptides 1 and 2 (CP2) were custom synthesised by Mimotopes, Clayton
Victoria, Australia. Peptides 3, 4 (CP2) and 5 (vivapain) were custom synthesised by Auspep,
Parkville, Australia. The purity of all peptides were 70% or greater as determined by reverse
phase-high performance liquid chromatography (RP-HPLC) (Table 5). The molecular weight
of each peptide was confirmed by mass spectral analysis by the suppliers. The selected
peptides were modified, during synthesis, as described in Section 3.3.1.
0.01 M Ellman's reagent. As per Section 2.11.1.1
Reducing buffer [0.1 M Tris-HCI buffer, 0.001 M Na2EDTA, 0.02% (w/v) NaN3, pH 8.0]. Tris
(1.21 g), Na2EDTA (0.037 g) and NaN3 (0.02 g) were dissolved in 90 ml of distilled H20,
titrated to pH 8.0 with HCI and made up to 100 ml with distilled H20 .
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0.01 M DTT in reducing buffer. DTT (1.5 mg) was dissolved in 1 ml of reducing buffer just
before use.
Phosphate buffe red saline (PBS) pH 7.2. As per Section 2.10.1
MEC buffer [0.1 M Na-phosphate buffer, 0.02% (w/v) NaN3, pH 7.0]. NaH2P04• H20 (27.598
g) and NaN3 (0.4 g) were dissolved in 950 ml of distill ed H20, titrated to pH 7.0 with NaOH
and made up to 2 1with distilled H20.
0.016 M MBS. MBS (5 mg) was dissolved in DMF (1 ml)
3.3.2.2 Procedure
Rabbit albumin (2.86 mg, 0.0419 umoles, M, 68 200) was dissolved in PBS (1.79 ml). MBS
(105.6 III 1.68 umoles M, 2382.7 , giving a 1:40 molar ratio of carrier: MBS) was slowly
stirred into the carrier solution. Carrier protein was acylated at RT for 30 min. Unreacted MBS
was removed by MEC on a Sephadex G25 column (12 mm x 170 mm, flow rate 0.19 ml/min).
Fractions (1 ml) were collected. The elution profile was monitored by reading absorbance
values at 280 nm. Fractions constituting the first peak, which contained activated carrier, were
pooled. The second peak , which contained unreacted MBS, eluted soon after the first peak.
Peptide #1 (4 mg, 1.68 umoles, M, 2382.7) was dissolved in DMSO (300 Ill) and PBS
(700 Ill). 10 mM DTT in reducing buffer (1 ml) was added to the dissolved peptide with
stirring and reduction was effected by incubation at 37 QC for 1.5 h. Reduced peptide was
separated from excess DTT by MEC on a Sephadex G10 column (130 mm x 10 mm, flow rate
0.13 ml/min) pre-equilibrated with MEC buffer. Fractions (500 Ill) were collected and the
elution profile was determined by taking 10 III of each fraction and mixing it with an equal
volume of the Ellman's reagent. A yellow colour was an indication of the presence of the
eluted peptide. Thereafter, fractions with excess DTT, indicated by an intensely yellow colour,
were eluted. The reduced peptide was mixed with the activated carrier, giving a 40: 1 molar
ratio of peptide to activated carrier, and incubated for 3 h at RT.
To confirm the formation of a peptide-carrier conjugate, conjugates were analysed by non-
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reducing SDS-PAGE gel (Section 2.5).
3.3.3 Conjugation of a peptide to rabbit albumin using glutaraldehyde
Peptide #3 (Section 3.4.1, Table 7) was conjugated via its free N-terminal a-amino group to
rabbit albumin according to Briand et al. (1985).
3.3.3.1 Reagents
PBS, pH 7.2. As per Section 2.10.1
3.3.3.2 Procedure
Peptide (4 mg, 2.03 umoles , M, 1969) was added to a 1 mg/ml solution of rabbit albumin
protein (3.464 mg, 0.051 umoles , M, 68200, to give a molar ratio of peptide to carrier of 40:1)
in PBS (3.46 ml). Glutaraldehyde (25% (v/v); 138.4 ul) was added slowly with stirring to the
protein mixture, to give a final concentration of 1% (v/v) glutaraldehyde. The reaction was
allowed to proceed for 1 h. The reaction was stopped by incubation for 1 h at 4°C after the
addition ofNaBH4 (10 mg/ml). The mixture was dialysed against PBS (16 h, 3 changes) and
stored at 4 "C.
3.4 Results
3.4.1 Selection of peptides
The epitope prediction plots for the complete CPl and CP2 sequences and that for the C-
terminal extension of vivapain were plotted (see Appendix). These plots were used for peptide
selection. The prediction plots for peptides selected show local peaks of hydrophilicity,
flexibility, surface probability and antigenicity. The prediction plots for peptides selected from
the pro-region of congopain are shown in Figure 9, the CPl catalytic domain in Figure 10 and
the CP2 catalytic domain in Figure 11. The epitope prediction plots for the peptides in the C-
terminal extensions of CP2 and vivapain are shown in Figure 12.
The CPl peptides selected are shown in Table 6. The first three peptides (peptides A, Band C)
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are [Tom the pro-region of CP 1. Antibodies against the peptides in the pro-region of CP cannot
recognise the active, mature enzyme because the pro-region is cleaved upon maturation of the
enzyme (Boulange et al., 2001). Pro-peptides and antibodies against them can, however, be
used to study inhibitory properties of the pro-region of trypanosomal cysteine proteinases and
also to study the processing of the protease. For the purposes of this study, antibodies against
peptides in the pro-region of congopain were raised to test the immunogenicity of the peptides
chosen but these antibodies were not characterised further. The epitope prediction plots
(Figure 9) show that peptides A and C are more immunogenic towards their N-termini and
peptide B towards its C-terminus . Peptides A and C were therefore conjugated to the carrier
protein via their C-termini and peptide B via its N-terminus.
An N-terminal peptide (D), a catalytic domain peptide (E) and an active site His-containing
peptide (F) were selected from the catalytic domain of CP1 (Table 6). The epitope prediction
plots (Figure 10) show that peptides D, E and F are more immunogenic towards their C-
termini and were therefore conjugated to the carrier protein via their N-termini. An N-terminal
peptide (#1), a catalytic domain peptide (#2) and an active site His-containing peptide (#3)
selected from the catalytic domain of CP2 and peptides in the C-terminal extensions of CP2
(peptide 4) and vivapain (peptide 5) are shown in Table 7. The epitope prediction plots (Figure
11 and 12) show that peptides #1 and #5 are more immunogenic towards their N-termini and
peptides #3 and #4 towards their C-termini. Peptides #1 and # 5 were therefore conjugated to
the carrier protein via their C-termini and peptides #3 and #4 via their N-termini. The epitope
prediction plot of peptide #2 (Figure 11) shows that this peptide is immunogenic at either end
but this peptide was conjugated to the carrier protein via its N-terminus.
67
-r- ---- - - - - ------ - --, 0.08
0.06







-l---- ,-----,,----------,-- ----r----t -0.04
60
Amino acid residue number
C
2.0 0.15
1.5 0.10 '" e-s:: s"'0 .. .-s:: .- --.. 1.0 >,-€.. := J!l 0.05 .~ $~>, oD •__ .. s::
0.5 .- >, '-o .D :l
s:: _ s::
. - 0 CJ . - ::l:= ... e- 0.00 01) :=-a c, s .- .D
e 8 :.0 0.0 t: . ~< '-''" 't! ... -0.5 -0.05 ...:>.='~
::c '"
-1.0 -0.10
110 112 114 116 118 120 122
Amino acid residue number
Figure 9. Epitope prediction plots for peptides selected from the pro-region of CPt. The CP1 amino acid
sequence was deduced by Fish et aI., 1995. Prediction plots of peptide A (panel A), residues 46-58; peptide B
(panel B), residues 67-76 and peptide C (panel C), residues 111-120. The parameters plotted are: hydrophilicity
(0), surface probability (.6), flexibility (0) and antigenicity ( X) . The computer program, Predict 7 (Carmens et
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Figure 10. Epitope prediction plots for peptides selected from the catalytic domain of CPl. The CPl amino
acid sequence was deduced by Fish et aI., 1995. Prediction plots of peptide D (panel A), resid ues 128-137; peptide
E (panel B), residues 239-247 and peptide F (panel C), resid ues 279-299. The parameters plotted are:
hydrophilicity (<», surface probability (6.), flexibility (D) and antigenicity ( X). The computer program, Predict 7
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Figure 11. Epitope prediction plots for peptides selected from the catalytic domain of CP2. The CP2 amino
acid sequence was deduced by Jaye et aI., EMBL acces sion number L25 l30. Prediction plots ofpeptide #1 (panel
A), resi dues 126-147; peptide #2 (panel B), residues 226-247 and pep tide #3 (panel C), residues 281-298 . The
parameters plotted are: hydrophilicity (0), surface prob ability ( .6.), flexibility (D) and antigenicity ( X). The
computer program, Predict 7 (Carmens et aI., 1989), was used to generate the data.
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Figure 12. Epitope prediction plots for peptides selected from the C-terminal extensions of CP2 and
vivapain. The CP2 amino acid sequence was deduced by Jaye et aI., EMBL access ion number L25130 and that of
vivapain by Prof. Theo Baltz, University of Bordeaux, France, personal communication. Predicti on plots of CP2,
residues 430-445 (peptide #4, panel A) and residues 20-36 (peptide #5, panel B). The parameters plotted are:
hydrophilicity (0), surface probabi lity ( f::,.), flexibility (0) and antigenicity ( X). The computer program, Predict 7
(Carmens et at, 1989), was used to generate the data.
The catalytic domains of CPl and CP2 have significant sequence homology (Figure 4).
Consequently the amino acid sequence of peptide D is similar to its CP2 counterpart peptide
#1. The same applies to peptide E and peptide #2 as well as peptide F and peptide #3. The
alignment of the sequences of these peptides is shown in Figure 13. Because of the homology
of CP1 peptides to CP2 peptides, antibodies against CP1 peptides are likely to cross-react with
CP2 peptides and with native CP2.
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Table 6. CPl peptides chosen for anti-peptide antibody production
Residue #a Peptide sequence Region in CP 1 Peptide #
46-58 (14) Q-K-Y-S-R-S-Y-K-D-A-T-E-E-Cb Pro-region A
67-76 (11) C-Q-N-M-E-R-A-K-E-E-A Pro -region B
111-120(11) A-L-K-R-P-R-K-V-V-N-C Pro-region C
128- 137 (11) C-P-A-V-D-W-R-K-K-G-A catalytic domain D
239-247 (10) C-G-H-I-N-L-P-K-D-E catalytic domain E
280-299 (20) C-I-S-K-G-L-D-H-D-V-L-L-V-G- catalytic domain F
Y-D-D-T-S-K
"Number of amino acid residues in peptide, including additional Cys residue is given in brackets. bCys_
residue shown in bold represents additional Cys-residues added during synthesis for MBS conjugation.
Table 7. CP2 peptides and the vivapain peptide chosen for anti-peptide antibody production
Residue #a Peptide sequence
























"Number of amino acid residues in peptide given in brackets. bThe interna l Cys-residue was synthesised as a
2-aminobutyric acid that mimics the conformation of an internal disulfide bonded Cys residue .
The peptides selected appear to be on the surface of the 3-dimensional structure of papain,
which has an analogous structure to that of congopain (Lecaille et aI., 2001) (Figure 14 and
Figure 15). The peptides selected seem accessible and could thus be good immunogens.
Furthermore, peptide F and peptide 3 include the active site histidine residue, and antibodies
against these peptides could be inhibitors of the enzyme. Analogous peptides that include the
active site His-residue from cathepsin L (Coetzer et aI., 199 1) and trypanopain-Tb (Troeberg
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Figure 13. Alignment ofthe peptide sequences selected from the catalytic domains of CPl and CP2. Peptides
D, E, and F are from the catalytic domain of CP1 and peptides #1, #2 and #3 are from the catalytic domain of
CP2. Underlined residues denote differences between CPl and CP2 peptide sequences. ·Cys residues in bold were
additional residues added at the N-terminus for conjugation using the MBS-method.
Figure 14. Papain structure (Drenth et al., 1971) showing the positions of peptides selected from the
catalytic d~main of CPl. Peptide D, CPI residues 128-137 Ce); peptide E, CPl residues 239-247 Ce) and peptide
D, CPI residues 280-299 Ce). The arrow indicates the active site histidine residue.
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Figure 15. Papain structure (Drenth et al., 1971) showing the positions of peptides selected from the
catalytic domain of CP2. Peptide #1, CP2 residues 126-147 Ce); peptide #2, CP2 residues 226-247 Ce) and
peptide #3, CP2 residues 279-298 (e). The arrow indicates the active site histidine residue.
3.4.2 Evaluation of a conjugate by SDS-PAGE analysis
In order to confirm that peptide-carrier conjugates were formed, samples of carrier protein
taken before and after conjugation were analysed on a non-reducing SDS-PAGE gel (Figure
16). Rabbit albumin alone gave a band at approximately 66 kDa (lane d) and MBS-activated
rabbit albumin (lane c) gave a broad band of slightly greater and smaller size compared to lane
d. The final conjugate (lane b) gave a band of slightly greater size compared to those of both





Figure 16. Non-reducing SDS-PAGE comparing protein sizes before and after peptide-carrier conjugation.
Samples (10 ug) were electrophoresed on a 12.5% non-reducing SDS-PAGE gel (Section 2.5.2) . Molecular mass
markers (phosphorylase b, 94 kDa; BSA, 67 kDa; ovalbumin , 43 kDa; carbonic anhydrase, 30 kDa; soya-bean
trypsin inhibitor, 20 kDa in lanes a and e); peptide-rabbit albumin conjugate (lane b); rabbit albumin-MBS (lane c)
and rabbit albumin (lane d). The bands were visualised by Coomassie blue R-250 protein stain as described in
Section 2.6.2.2.
3.4.3 Monitoring of antibody production by ELlSA.
There was very little difference in the responses of the two chickens immunised with the same
peptide, therefore results for only one chicken are shown. The ELISA results shown in Figures
17, 18 and 19 indicate that antibodies were raised in chickens against all the peptides when
compared to non-immune antibody preparations. All the antibodies recognised the peptides
very well except for peptide E (Figure 18 C) and peptide #3 (Figure 19 B) which gave low
responses. Antibody production peaked between weeks 7 and 12 (Table 8). Most antibodies
were produced between weeks 6 and 12. Although it may be speculated that the low titre of
the anti-peptide E antibodies could be due to the small size (10 residues) of the peptide,
peptide D (11 residues) produced antibodies of high titre. Their epitope prediction plots
(panels A and B, Figure 10) did not suggest potential differences in immunogenicity. A
portion of the immunogen was lost during preparation of the peptide #3 conjugate, so chickens
received less immunogen. However, affinity purification of both anti-peptide E and anti-
peptide #3 antibodies resulted in good targeting of the corresponding peptides in ELISA
(Section 3.4.4).
Both peptides corresponding to sequences in the C-terminal extensions of congopain and
vivapain gave fairly good immune responses (Figure 19 C and D). For the peptide in the C-
terminal extension of CP2 antibody production was already high by week 6 post immunisation
and for the peptide in the C-terminal extension of vivapain the highest antibody production
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was at week 9 post immunisation. Table 8 gives a summary of the timing of peak antibody
production against each peptide.
Table 8. Timing of peak of anti-CP peptide antibody and anti -vivapain C-terminal extension
peptide antibody production.
Peptide # Region in protease Peptide length Peak week
CP2 catalytic domain 22 12
2 CP2 catalytic domain 22 7
3 CP2 catalytic domain 18 7
4 CP2 C-terminal extension 16 7
5 Vivapain C-terminal extension 17 9
A CPI pro -region 14 7
B CP 1 pro-region 11 12
C CP 1 pro -region 11 9
D CP 1 catalytic domain 11 8
E CPl catalytic domain 10 10
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Figure 17. Recognition of peptides corresponding to sequences in the pro-region of CP1 in an ELISA by the
anti-peptide antibodies raised in chickens at various weeks post immunisation. Plates were coated with
peptides A (panel A), B (panel B) and C (panel C) (5 ug/ml in PBS, pH 7.2,4 °C, 16 hours). See Table 6 for
sequence details of peptides . Production of anti-peptide antibodies was determined at week zero (x), week 3 (.),
week 6 (A), week 9 (D), week 12 (0) and week 15 (.) post immunisation. All the anti-peptide antibodies were
titrated between 100 ug/ml and 12.5 ug/ml. Binding was visualised by incubation with rabbit anti-chicken HRPO- .
linked detection antibody (Jackson ImmunoResearch Laboratories inc, Pennsylvania, USA) and ABTSIH20 2
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Figure 18. Recognition of N-terminal peptides and catalytic domain peptides selected from CP1 and CP2 in an ELISA by the anti-peptide antibodies
raised in chickens at various weeks post immunisation. Plates were coated with pcptides 0 (panel A), #1 (panel B), E (panel C) and #2 (panel D) (5 ug/ml in
PBS, pH 7.2,4 °C, 16 hours). See Tables 6 and 7 for sequence details ofpep tides. Production of anti-peptide antibodies was determined at week zero (x), week 3
(. ), week 6 (A ), week 9 (D), week 12 (0) and week 15 (.) post immunisation . All the anti-p eptide antibodies were titrated between 100 ug/ml and 12.5
ug/ml, Binding was visualised by incubation with rabbit anti-chicken HRPO-linked detection antibody (Jackson ImmunoResearch Laboratories inc, Pennsylvani a,
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Figure 19. Recognition of active site-associated peptides from CP1 and CP2 and peptides from the C-terminal extension of CP2 and vivapain in an
ELISA by the anti-peptide antibodies raised in chickens at various weeks post immunisation. Plates were coated with peptides F (panel A), #3 (panel B), #4 (panel
C) and #5 (panel D) (5 ug/rnl in PBS, pH 7.2, 4 °C, 16 hours). See Tables 6 and 7 for sequence details of peptides. Production of anti-peptide antibodies was determined at week
zero (x), week 3 (.), week (j ( .... ) , week 9 (D), week 12 (0) and week IS (.) post immunisation. All the anti-peptide antibodies were titrated between 100 ug/rnl and 12.5 ug/m l,
Binding was visualised by incubation with rab bit anti-chicken HRPO-linked detection antibody (Jackson ImmunoResearch Laboratories inc, Pennsylvania, USA)
and ABTS/H202 substrate as described in Section 2.10.2. Each point is the mean absorbance at 405 nm of duplicate samples.
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3.4.4 Affinity purification of anti-peptide antibodies
A representative elution profile for the affinity purification of anti-peptide antibodies is shown
in Figure 20.
5040302010










Figure 20. Elution profile for affinity purification of anti-peptide antibodies. The peptide affinity column was
equilibrated in 0.1 M Na-phosphate buffer, 0.05% NaN j , pH 7.0 (2 ml bed volume, 0.13 ml/min). After elution of
unbound protein, bound protein was eluted by applic ation of 0.1 M glycine-HCI, pH 2.8 (as described in Section
2.11.3 .2), applied at the point indicated by the arrow (J,). Antibody fractions pooled (-).
To determine whether there is increased reactivity of the affinity purified antibodies with their
respective peptides, ELISAs with immobilised peptide were done as described in Section
2.10.2. In the ELISAs the ' reactivity of the affinity purified antibodies, non-affinity purified
antibodies, and the antibody fraction that did not bind to the peptide affinity column was
compared. For each peptide , IgY samples were combined as follows: antibodies produced 2-6,
7-10, 11-12, 13-14 and 15-16 weeks after the first immunisation.
The affinity purified antibodies showed increased reactivity with the peptides compared to the
non-affinity purified antibodies and the antibody fraction that did not bind to the peptide
affinity column (Figures 21-23). Non-affinity purified antibodies recognised the peptides
better than the antibody fraction that did not bind to the peptide affinity column. However, the
reactivity of affinity purified antibodies targeting the N-tenninal peptide (#1) and the catalytic
domain peptide (#2) was only slightly higher than the reactivity of non-affinity purified
antibodies and the antibody fractions that did not bind to the peptide affinity column (Figures
22A and 22B). This may be due to poor efficiency of the peptide affinity matrices where these
two peptides were immobilised. On the other hand the reactivity of affinity purified antibodies
targeting the active site-associated peptide (#3) and the vivapain C-tenninal extension peptide
(#5) were significantly higher than the non-affinity purified preparations (Figures 22C and
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23B). In these cases the peptide matrices seemed to bind all the specific antibodies. In assays
where these affinity purified antibodies were used, the development of the substrate colour
was very quick and the whole reaction had to be stopped while the colour was still developing
in wells containing non-affinity purified antibodies and the antibody fractions that did not bind
to the peptide affinity column. This accounts for the low absorbance readings where non-
affinity purified antibodies and the antibody fractions that did not bind to the peptide affinity
column were used (Figure 22C and Figure 23B). The recognition of the active site His-
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Figure 21. ELISA of affinity purified antibodies produced against peptides located in the catalytic domain
of CP1. Plates were coated with N-terminal peptide D (panel A), catalytic domain peptide E (panel B) and active
site-associated peptide F (panel C) (5 ug/ml in PBS , pH 7.2, 4 °C, 16 hours). The recognition of the peptides by
non-immune IgY (x), antibody fraction that did not bind to the peptide affinity matrix (.), non-affinity purified
antibodies (A) and affinity purified antibodies (.) was determined. Antibodies were titrated betw een 100 ug/rnl
and 12.5 ug/ml . Binding was visualised by incubation with rabbit anti-chicken HRPO-linked detection antibody
(Jackson ImmunoResearch Laboratori es inc, Pennsylvania , USA) and ABTS/H202 substrate as described in
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Figure 22. ELISA of affinity purified antibodies produced against peptides located in the catalytic domain
of CP2. Plates were coated with N-tenninal peptide # 1 (panel A), catalytic domain peptide #2 (panel B) and
active site-associated peptide #3 (panel C) (5 ug/rnl in PBS, pH 7.2, 4 QC, 16 hours). The recogn ition of the
peptides by non-immune IgY (x), antibody fraction that did not bind to the peptide affinity matrix (.), non-
affinity purified antibodies (....) and affinity purified antibodies ( . ) was determ ined. Antibodies were all titrated
between 100 ug/ml and 12.5 ug/ml. Binding was visualised by incubation with rabb it anti-chicken HRPO-linked
detection antibody (Jackson ImmunoResearch Laboratories inc , Pennsylvania, USA) and ABTSIH 20 z substrate as
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Figure 23. ELISA of affinity purified anti-C-terminal extension peptide antibodies. Plates were coated with
congopain peptide #4 (panel A) and vivapain peptide #5 (panel B) (5 ug/rnl in PBS, pH 7.2, 4°C, 16 hours) . The
recognition of the peptides by non-immune IgY (x), antibody fraction that did not bind to the peptide affinity
matrix (.), non-affinity purified antibodies (~) and affinity purified antibodies ( .) was determined. Antibodies
were all titrated between I00 ug/ml and 12.5 ug/ml. Binding was visualised by incubation with rabbit anti-
chicken HRPO-linked detection antibody (Jackson ImmunoResearch Laboratories inc, Pennsylvania, USA) and
ABTSIH20 2 substrate as described in Section 2.10.2. Each point is the mean absorbance at 405 nm of duplicate
samples .
3.4.5 Recognition of C2 and CP2 coated on ELISA plates by anti-peptide antibodies.
Anti-peptide antibodies were able to recognise CP2 in an ELISA. On comparing the
recognition of CP2 by anti-CP2 peptide and anti-CP 1 peptide antibodies, enhanced recognition
was observed with the former. The reactivity of anti-CP2 peptide antibodies with CP2 in
diminishing order of reactivity was: anti-active site peptide (#3) > anti-C-terminal extension
peptide (#4) > anti-catalytic domain peptide (#2) > anti-N-terminal peptide (#1) (Figure 24A).
The reactivity of anti-CPl peptide antibodies with CP2 in diminishing order of reactivity was:
anti-active site peptide (F) > anti-N-terminal peptide (D) > anti-catalytic domain peptide (E)
(Figure 25A). Antibodies against both peptide #3 and peptide C recognised CP2 best and both
peptides include the active site histidine residue.
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Anti-peptide antibodies apparently reacted more strongly with C2 than CP2. The reactivity of
anti-CP2 peptide antibodies with C2 in diminishing order of reactivity was: anti-N-tenninal
peptide (#1) > anti-catalytic domain peptide (#2) > anti-active site peptide (#3) >ant i-C-
terminal extension peptide (#4) (Figure 24B). The reactivity of anti-CPI peptide antibodies
with C2 in diminishing order of reactivity was: anti-active site peptide (F) > anti-N-tenninal
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Figure 24. Recognition of CP2 and C2 by affinity purified anti-CP2 peptide antibodies in an ELISA. Plates
were coated with CP2 (Panel A) or C2 (Panel B) (1 ug/ml for 16 hours at 4 0 C in 50 mM carbo nate coating buffer,
pH 6.0) . Affinity purified antibodies against: N-terminal peptide #1(.), catalytic domain peptide #2 (.....), active
site-associated peptide #3 ( . ), C-terminal extension #4 (0 ) and non -immune IgY (x) were titrated between 250
ug/ml and 0.49 ug/ml, Binding was visualised by incubation with rabbit anti-chicken HRPO-linked detection
antibody (Jackson ImmunoResearch Laboratories inc, Pennsylvania, USA) and ABTS/H202 substrate as described
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Figure 25. Recognition of CP2 and C2 by affinity purified anti-CPI peptide antibodies in an ELISA. CP2
(Panel A) and C2 (Panel B) was coated at I ug/rnl for 16 hours at 4 0 C in 50 mM carbonate coating buffer, pH 6.0 .
Affinity purified antibodies against N-tenninal peptide D (.), catalytic domain peptide E (A), active site-
associated peptide F (.) and non-immune IgY (x) were titrated between 250 ug/ml and 0.49 ug/ml . Binding was
visualised by incubation with rabb it anti-ch icken HRPO-linked detection antibody (Jackson ImmunoResearch
Laboratories inc , Pennsylvania, USA) and ABTSIH 20 2 substrate as described in Section 2:10 .2. Each point is the
mean absorbance at 405 nm of duplic ate samples .
3.4.6 Recognition of C2 and CP2 by anti-peptide antibodies on western blots.
The homogeneity of the purified C2 and CP2 samples was determined in reducing Laemmli
SDS-PAGE (Figure 26). Two bands were observed for CP2 on a silver stained gel, i.e. a very
faint band at ea. 43 kDa and a prominent band at ea. 30 kDa (Figure 26). The ~ 43 kDa band is
thought to be the dimeric form of congopain while the ~ 30 kDa band could be the monomeric
form of congopain. The formation of monomeric and dimeric forms of congopain will be
discussed in more detail in Section 3.5. For C2, only a single band was observed . The band






Figure 26. Reducing Laemmli SDS-PAGE evaluation of recombinant CP2 and C2. Molecular mass markers
[BSA, 67 kDa; ovalbumin, 43 kDa; carbonic anhydrase, 30 kDa (2 ul, lane a)], CP2 (8 ug, lane b) and C2 (5 ug,
lane c) were electrophoresed on a 12.5% reducing SDS-PAGE gel (Section 2.5.2). Protein bands were visualised
by silver staining (Section 2.6.2.2).
To detect C2 in a western blot, anti-CP2 catalytic domain peptide antibodies were used. Since
C2 was not recognised by antibodies against C-terminal extension peptide in ELISA (as
expected), these antibodies were not used in western blots to conserve the small amount of C2
available. All the antibodies detected the Mr ~ 30 kDa band, except antibodies from the non-
immunised chicken (Figure 27). In western blots of CP2 separated by reducing SDS-PAGE,
both CPl and CP2 anti-peptide antibodies detected both a 43 kDa band and a 30 kDa band
(Figure 28). As can be seen in Figure 28, the ~ 43 kDa band (dimeric form) was recognised
less well than the ~ 30 kDa band (monomeric form). Antibodies from the non-immunised
chicken did not detect any of the bands , and neither did antibodies against the C-terminal









Figure 27. Recognition of C2 by the anti-CP2 peptide antibodies on western blots. C2 (5 ug) was
electrophoresed on a 12.5% reducing SDS-PAGE gel (Section 2.5 .2), electroblotted onto nitrocellulose and
probed with non-immune IgY (lane a), anti-N-terminal peptide #1 (lane b), anti-catalytic domain peptide #2 (lane
c) and anti-active site-associated peptide #3 (lane d). Immune reactions were detected using rabbit anti-chicken













Figure 28. Recognition of CP2 by the anti-CPl peptide and anti-CP2 peptide antibodies on western blots.
CP2 (8 ug) was electrophoresed on a 12.5% reducing SDS-PAGE (Section 2.5.2), electroblotted onto
nitrocellulose and probed with: anti-CPI peptide antibodies (panel A): non-immune IgY (a), anti-N-tenninal
peptide D (b), anti-catalytic domain peptide E (c), anti-active site-associated peptide F (d) and anti-CP2 peptide
antibodies (panel B): non-immune IgY (a), anti-N-tenninal peptide #1 (b), anti-catalytic domain peptide #2 (c),
anti-active site-associated peptide #3 (d) and anti-C-tenninal extension peptide #4 (e). Immune reactions were
detected using rabbit anti-chicken-HRPO conjugate (Jackson ImmunoResearch Laboratories inc, Pennsylvania,
USA) and the substrate used was 4-chloro-l-naphthollH202as described in Section 2.7.2.
3.4.7 Inhibition of catalytic activity using antibodies.
Generally, anti-peptide antibodies had an activity enhancing effect compared to non-immune
antibody (Figures 29 and 30). Antibodies produced in weeks 15 and 16 post immunisation
usually had the highest activity enhancing effect.
Figure 29 shows the enhancement of CP2 activity by the anti-peptide antibodies. Low
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concentrations (between 31.25 and 62.5 ug/ml) of anti-N-terminal peptide (#1) antibodies
stimulated CP2 activity (up to 36.7%) but at higher concentrations, there was slight inhibition
of CP2 activity (up to 1.3%). With an increase in antibody concentration their effect on
enzyme activity diminished (Figure 29A). Lower concentrations of anti-catalytic domain
peptide (#2) antibodies (between 31.25 and 250 ug/ml) enhanced CP2 activity (up to 12.7%)
but at 500 ug/ml concentration there was inhibition of CP2 activity (up to 15.7%) (Figure
29B). Anti-active site peptide (#3) antibodies had a slight inhibiting effect (up to 2.6%) on
CP2 activity at lower concentrations (between 31.25 and 62.5 ug/ml) but at higher
. concentrations they seemed to have no effect on CP2 activity, except for those produced in
weeks 15 and 16 post immunisation. These antibodies had an activity enhancing effect (up to
23.9%) (Figure 29C). Anti-CPl active site peptide (F) antibodies enhanced CP2 (up to 17.1%)
and as the antibody concentration increased from 62.5 ug/ml to 259 ug/ml, activity was
inhibited (up to 11.1%) (Figure 29D).
Most anti-peptide antibodies seemed to have a stimulating effect on C2 activity. The
stimulation apparently increased with an increase in antibody concentration. Anti-N-terminal
peptide (#1) antibodies stimulated C2 activity up to 27.6% (Figure 30A), anti-active site
peptide (#3) antibodies up to 42.1% (Figure 30C) and anti-CPl active site peptide (F)
antibodies up to 29% (Figure 30D). Only anti-catalytic domain peptide (#2) antibodies seemed
to give a biphasic response. For most antibodies, a biphasic response is obtained at different
antibody concentrations whereby small amounts of sera stimulate activity, whereas higher
antibody concentrations inhibit activity (Richmond, 1977). The enzyme activity was
stimulated (up to 35.4%) at lower antibody concentrations (between 31.25 and 250 ug/ml) ,
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Figure 29. Effect of anti-peptide antibodies on Z-Phe-Arg-AMC hydrolysing activity of CP2. Serial two fold dilutions of anti-peptide antibodies raised
against N-term inal peptide #1 (panel A), catalytic domain peptide #2 (panel B), active site-associated peptide #3 (panel C) and active site-assoc iated peptide F
(panel D) from weeks 2-6 (0), weeks 7-10 (_), weeks 11-12 (<», weeks 13-14 (X) and weeks 15-16 (e) were pre-incubated (37 C, 15 min .) with CP2 (20 ng)







Antibody concentration (u g/ml)
100










Cl) . -... > 15c: .::;























50 100 150 200 250
0




































Figure 30. Effect of anti-peptide antibodies on Z-Phc-Arg-AMC hydrolysing activity of C2. Seria l two fold dilutions ofanti-peptide antibodies raised against
N-terminal peptide #1 (panel A), catalytic domain peptide #2 (panel B), active site-associated peptide #3 (panel C) and active site-associated peptide F (panel D)
from weeks 2-6 (0), weeks 7-10 (_), weeks 11-12 (0), weeks 13-14 (X) and weeks 15-16 (e) were pre-incub ated (37°C, IS min.) with C2 (20 ng) before
addition of the substrate (Section 2.12;2). Enhanc ement was expressed as a percentage ofCP2 hydrolys is ofZ-Phe-Arg-AMC relative to non-immune IgY.
91
3.5 Discussion
In this study, antibodies against congopain peptides were raised , based on the hypothesis that
congopain may contribute to pathogenesis and that an immune response to congopain may
contribute to trypanotolerance (Authie et al., 2001). T. congo/ense possesses at least two
families of closely related cysteine proteinases, named CP1 (Fish et al., 1995) and CP2 (Jaye
et al., EMBL accession number L25130). The deduced amino acid sequences of the two
cysteine proteinases are 90% identical but they differ in their N-terminal sequences (Boulange
et al., 2001). For this reason, peptides from both CP1 and CP2 were selected for the
immunisation trials.
Peptides were chosen using a computer programme for epitope prediction, Predict 7
(Carmenes et al., 1989). The epitope prediction plots of the peptides selected showed
overlapping peaks of hydrophilicity, flexibility, antigenicity and surface probability. The
results also showed that the peptides selected should occur on the surface of the CP2 molecule.
Sequences from the active site clefts of CP1 and CP2 were also selected, even though they did
not appear to be on the surface of the enzyme molecule, because peptides from active site
clefts are likely to elicit anti-catalytic antibodies (Troeberg et al., 1997). C-terminal extensions
of trypanosomal cysteine proteinases are known to be antigenic (Lalmanach et al., 2002); for
this reason peptides in the C-terminal extensions of congopain and vivapain were chosen.
Also, when this study was undertaken only the sequence of the C-terminal extension of
vivapain was known. Following the recent elucidation of the complete sequence of vivapain
(Prof. Theo Baltz, University of Bordeaux, France, personal communication) a parallel study
of the immunogenic epitopes in the catalytic domain of vivapain could be undertaken.
Mariani et a1. (1987) showed that coupling of peptides to carrier proteins may result in
increased immunogenicity of the peptide by up to 100 fold. Peptides were therefore
conjugated to rabbit albumin via MBS or glutaraldehyde before immunisation into chickens,
resulting in a molecular mass much higher than 5 kDa, which is regarded as the minimum
molecular weight necessary to obtain an efficient immune response (Schwarzkopf et al.,
2001). Additionally, adjuvants are known to enhance the immune response to antigen (Roitt,
1997), so Freund's adjuvant was used in this study. Chickens were ideal for immunisation
because of their many advantages, mainly the high yield of antibodies obtained from egg yolk
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(Schwarzkopf et al., 2001).
All the resulting anti-peptide antibodies were able to recognise their respective peptides in an
ELISA compared to antibodies isolated from the eggs laid by non-immunised chickens. The
antibody production peaked between weeks 6 and 12 post immunisation. Free peptides were
used as antigens instead of conjugated peptides in ELISAs for .monitoring antibody
production. This is to ensure that only antibodies produced against peptides, and not those
produced against the carrier protein, are detected in the ELISA. This obviates the need to
prepare a second peptide-carrier conjugate with a different carrier protein for use as coating
antigen.
It was essential to affinity purify the anti-peptide antibodies because non-affinity purified
antibodies are only partially purified during PEG isolation. Unpurified preparations have
antibodies against carrier protein, against epitopes created by coupling chemistry, termed
carrier modified residues (CAMOR) regions (Briand et al., 1985), and against unrelated
proteins. Therefore, not all the antibodies will react with the antigen of interest when using
non-affinity purified antibodies. In the present study, most affinity purified anti-peptide
antibodies showed an increased reactivity with the peptide compared to non-affinity purified
antibodies. However, for some anti-peptide antibodies, the reactivity of-the affinity purified
antibodies and non-affinity purified anti-peptide antibodies was almost similar. This may be
due to poor efficiency of the peptide affinity matrices, as a result of which not all the anti-
peptide antibodies were bound to the column, even after repeating the purification procedure
several times.
To measure the subpopulation of antibodies in each affinity purified anti-peptide antibody
preparation able to cross-react with the whole enzyme, microtitre plates were coated with
either the CP2 catalytic domain (C2) or the whole CP2 instead of peptide. This' type of assay
does not necessarily measure antibodies able to cross-react with native enzyme since proteins
become partially denatured when they are adsorbed to a solid phase (Van Regenmortel,
1990b). A positive cross-reaction, however, is usually interpreted as an indication that the
peptide has the potential of being an epitope of a protein. Both anti-CP 1 and anti-CP2 peptide
antibodies recognised the whole CP2 enzyme and C2 in ELISAs. This means that in solution
peptides adopted a variety of interchangeable conformations, some of which mimicked those
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found in the partially denatured protein adsorbed to the ELISA plate. The amino acid
sequences of CP I and CP2 are 90% identical (Boulange et aI., 200 I). The cross-reactivity of
anti-CP 1 peptide antibodies with CP2 is not surprising but anti -CP 1 peptide antibodies did not
recognise CP2 as strongly as did the anti-CP2 peptide antibodies.
Anti-congopain peptide antibodies not only recognised whole CP2 and its catalytic domain,
C2, in an ELISA, but were also shown to recognise their target sequences in fully denatured
CP2 on a western blot. In CP2 blots two bands were observed, one slightly larger than 30 kDa
and the other slightly smaller than 43 kDa. These are thought to be the monomeric and dimeric
forms of congopain, respectively. These two forms of congopain occur as a result of a change
of charge of side chains within the peptide (residues 38-45), resulting in either alpha helix
(monomeric) or beta-turn (dimeric) forms (Dr Edith Authie, ILRl, Nairobi, Kenya, personal
communication). The formation of such charges is pH dependent. Using short peptides it is
possible to assess the susceptibility of the individual amino acid residues to form an alpha-
helix or a beta-turn (Darby and Creighton, 1993). The group of amino acid residues which
play a role in the formation of a dimeric form (beta turn) or a monomeric form (alpha-helix) is
made up of the homologous pairs K-E in congopain, corresponding to R-D in cathepsin W
(Figure 31). Depending on the relative charges of each amino acid within a pair, the sequence
would either adopt an alpha-helix or beta-turn structure (Dr Johan Hoebeke, IBMC,
Strasbourg, France, personal communication).
Congopain (aa 38-45) WKVAGHE L dimer/monomer
Cruzipain (aa 38-45) W-F-L-A-G-H-P-L monomer
Cathepsin W (aa 38-45) W-R-I-S-F-W-D-F dimer
Figure 31. Peptide sequences of congopain, cruzipain and cathepsin W, used in determining their
propensity to form monomers and dimers (Dr Johan Hoebeke, IBMC, Strasbourg , France, personal
communication). The amino acid residues shown in bold are responsible for the formation of intramolecular
bridges.
The alpha-helical structure is destabilised when oppositely charged residues are located at
intervals of three to four residues, because this results in these residues occurrinz on the same
1::1
face of the helix and thus forming salt bridges (Darby and Creighton, 1993). At pH 5.0, the
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charges of the side chains of both lysine (K) and histidine (H) in congopain will be positive
because the pH will be lower than their side chain pKa values ( 10.0 for K and 6.0 for H, Table
9) and the charge of the side chain of glutamic acid (E) will be negative because the pH will be
higher than the side chain pKa value of E (pKa is 4.2, Table 9). It is therefore likely that at this
pH, K will interact with the adjacent H+ rather than with K+. Since Hand E are consecutive
residues , there would be no salt bridge, and the alpha-helical structure (monomeric form)
would remain stable. At pH 7.0, histidine will not be charged because the pH will be higher
than the side chain pKa value, lysine will remain positive and glutamic acid will remain
negative. K+ is likely to interact with K at this pH, forming a salt bridge which destabilises
alpha-helical structure, resulting in a beta turn (dimeric form). Cathepsin W remains in a
dimeric form at both pH 5.0 and pH 7.0 because the charge of the side chain of arginine (R)
remains positive at both pH 5.0 and pH 7.0 since the side chain pKa value of R is 12.5 (Table
9). Tryptophan (W) does not ionise and therefore remains neutral at any pH. The charge of the
side chain of aspartic acid (D) remains negative at both pH 5.0 and pH 7.0 because the side
chain pKa value of D is 3.9 (Table 9). The salt bridge between R+ and D- will be stable
between pH 5.0 and pH 7.0, forming a beta turn (dimeric form). For cruzipain, both
phenylalanine (F) and proline (P) do not ionise , therefore there will be no salt bridge and
cruzipain will remain in a monomeric form.
Table 9. Side chain charges determining monomer or dimer formation in congopain, cruzipain
and cathepsin W.
Protease Residue pKa Charge at Monomerl Charge at pH 7 Monomerl
(side pH 5 dimer dimer
chain)
Congopain K 10.0 + +
H 6.0 + No charge
E 4.2 Monomer Dimer
Cruzipain F No charge No charge
P No charge Monomer No charge Monomer
Cathepsin W R 12.5 + +
W No charge No charge
D 3.9 Dimer Dimer
In initial experiments anti-peptide antibodies recognised the monomer better than the dimer,
consequently a relatively large amount of CP2 was loaded on the gel in order to increase the
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visibility of the dimer band for scanning purposes. This resulted in broad monomer bands on
western blots. Poor recognition of the dimer may be due to the fact that it has a compact
structure and the epitopes recognised by the anti-peptide antibodies may have been less
accessible or even 'hidden' in the dimer (Dr Edith Authie, ILRI, Nairobi, Kenya, personal
communication). The dimeric form of C2 was also not recognised by anti-peptide antibodies.
This may be due to the fact that the truncated dimer and the full length dimer do not share the
same conformational characteristics. The C-terminal domain (present in CP2), may account
for the different accessibilities of the anti-peptide antibodies (Dr Edith Authie, ILRI, Nairobi,
Kenya, personal communication). This result still needs to be investigated further.
Various enzymes such as cathepsin L (Coetzer et al., 1991), trypanopain-Tb (Troeberg et al.,
v~- 'o~ )~~( \......J ',a""
1997) and P450 enzyme (Schulz-Utermoehl et al., 2000) are inhibited by their anti-peptide
antibodies. The use of anti-peptide antibodies that bind specifically to an enzyme and inhibit
its activity is a useful approach in identifying regions that are involved in the catalytic function
of the enzyme. IgG from T. congolense infected N'Dama cattle recognised the catalytic
domain of CP2 and inhibited its Z-Phe-Arg-AMC hydrolysing activity (Authie et al., 2001).
This suggests that critical CP2 epitopes are likely to be located in the catalytic cleft of CP2. In
the present study antibodies against CP2 peptides were tested for their ability to inhibit the
hydrolysis of Z-Phe-Arg-AMC by CP2 and C2. This investigation was not done for antibodies
against CP1 peptides (except for antibodies against the peptide corresponding to a region of
the CPl active site) because of the limited amount of enzyme available. Furthermore, in a
previous study, antibodies against the CPl catalytic domain did not inhibit the activity of CP2
(Authie et al., 2001). Antibodies raised against the peptide in the C-terminal extension of CP2
were unlikely to have any effect on CP2 activity because the enzyme can remain active in the
absence of the C-terminal extension. These antibodies were therefore not tested.
?
/ prCVious studies have shown that antihodies may have complex effects on eozymes
(Richmond, 1977; Dennison and Pike, 1991; Troeberg et al., 1997). Specific antibodies can
inhibit, enhance or in certain cases, small amounts of antibodies stimulate enzyme activity,
whereas higher antibody concentrations can neutralise enzyme activity (Pollock, 1964). In this
study the effect of anti-peptide antibodies on C2/CP2 hydrolysis of Z-Phe-Arg-AMC was
stimulatory at lower antibody concentrations and inhibitory at higher antibody concentrations
but sometimes purely stimulatory. Stimulatory responses may be due to a conformational
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change induced by antibodies. This may indicate that the conformation of an antigen is more
important than its primary sequence in determining its reaction with an antiserum (Richmond,
1977). The effects of anti-peptide antibodies varied at different stages of the immune response.
Generally, antibodies produced in weeks 7-10 and weeks 15 and 16 post immunisation
enhanced enzyme activity more than the other antibodies. This shows that various batches of
antibodies may vary in their properties, even when the same antigen preparation is used to
raise antibodies and the same immunisation course is followed (Richmond, 1963).
Congopain was inhibited by IgG from cattle immunised with C2 (Authie et al., 2001).
Congopain is active in a broad pH range, from pH 4.0 to 8.5, with an optimum at pH 6.0
(Boulange et al., 2001). In the current study, the pH of the antibody diluting buffer was 8.0.
This pH was also used by Troeberg et al. (1997) for trypanopain. Even though pH 8.0 falls
within the.active congopain pH range, it is realised that using the optimum pH of 6.0, or the
physiologic pH might improve the results obtained in this study. Authie et al. (2001) used an
antibody diluting buffer of pH 7.2 and the IgG used displayed an inhibitory effect over
congopain. It is appreciated that the conditions used in this part of the experiment were not
optimal for both the antibodies and congopain, but because of the time constraints and the
limited amount of the CP2 and C2 enzyme available the experiment was not repeated. In
future investigations, the effect of anti-peptide antibodies on congopain hydrolysis of Z-Phe-
Arg-AMC will need to be investigated under the conditions used by Authie et al (2001). /
.>
The response of an enzyme to antibodies may vary depending on which substrate is present
(Pollock, 1964). When Pollock (1964) tested the effects of the same sera on penicillinase
activity using different substrates, they found that with some substrates antisera inhibited
penicillinase, while with other substrates the response was biphasic and with a further group of
substrates, antibodies enhanced enzyme activity. The results reported here only show the
effect of anti-peptide antibodies when using the substrate, Z-Phe-Arg-AMC. One cannot
assume that for every substrate, these anti-peptide antibodies would have an enzyme
enhancing effect. Antibodies may have recognised their epitopes in congopain (in cases where
the anti-peptide antibodies were not targeting the active site cleft) but since the Z-Phe-Arg-
AMC substrate is small, it was easy for it to gain access to the active site where it was cleaved.
The effect of anti-trypanopain peptide antibodies on digestion of protein substrates by
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trypanopain was investigated (Troeberg, 1997). It was expected that binding of anti-peptide
antibodies to trypanopain would block the active site and thus inhibit the digestion of protein
substrates. However, it was found that all anti-peptide antibodies tested enhanced the
hydrolysis of 14C-gelatin, while all antibodies inhibited hydrolysis of FITC-albumin. The
possible explanation given for this result is that 14C-gelatin and FITC-albumin might have
different affinity constants for trypanopain. 14C-gelatin might have a higher affinity for
trypanopain than do the anti-peptide antibodies, and it is possible that the antibodies were
displaced from the trypanopain active site upon addition of 14C-gelatin, and the enhanced
activity observed might be due to increased stabilising ability of specific antibodies compared
to non-immune antibodies. On the other hand, FITC-albumin might have a higher affinity for
trypanopain than do the anti-peptide antibodies, and as a result antibodies were not displaced
from the trypanopain active site upon addition of FITC-albumin and trypanopain activity was
therefore inhibited (Troeberg, 1997). This hypothesis was, however, not tested. It is apparent
from these results that the substrate can largely determine the effects of anti-peptide antibodies
on enzyme activity.
If the antibodies enhance enzyme activity, against protein substrates one would consider
raising monoc1onal antibodies against conformational epitopes. Monoclonal antibodies often
recognise conformational rather than linear epitopes (Van Regenmortel et al., 1990a). A
monoclonal antibody producing clone would be selected using an enzyme inhibition test.
It would be interesting to study the effect of a cocktail of anti-peptide antibodies produced in
this study on C2/CP2 activity. Using antibodies raised against peptides corresponding to
several different regions of the protein would be helpful because a single anti-peptide antibody
may not recognise certain conformations of the peptide in the constrained regions of the
protein molecule in its native state. When doing this test, it would be essential not to use
antibody concentrations that are too high so as to avoid steric hindrance which may give false
results. The concentration of the negative control antibody would have to be equal to the total
concentration of the cocktail of anti-peptide antibodies. The effect of the anti-peptide
antibodies on C2/CP2 activity using different substrates should be determined in future studies
because congopain's in vivo substrate may be proteins which are much larger than the Z-Phe-
Arg-AMC substrate. The antibodies might hinder access of protein to the active site and they
would not be cleaved. Testing the effect of anti-peptide antibodies using different protein
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substrates would help in coming to a conclusion as to whether these antibodies stimulate or
inhibit enzyme activity.
This study has shown that the anti-peptide antibodies prepared were specific for the enzyme
whether it is fully denatured (western blots), partially denatured (ELlSA) or in its native form
(enzyme fluorometric assay with the Z-Phe-Arg-AMC substrate). This means that antibodies
were produced against various conformations which the peptides adopted in solution, some of
which mimicked those found in the native protein and some of which mimicked those found in
the denatured protein. This study proved that most of the peptides selected might be possible
epitopes of congopain. Noticeably, antibodies recognised peptides around the active site best.
However, antibodies produced against these peptides were not able to inhibit congopain
activity. The possible explanation for this result might be that the peptides selected are partial
epitopes of congopain. The epitope prediction program used by Carmenes et al. (1989) was
useful in the analysis of both CPl and CP2 amino acid sequences but this method may not be
sufficient in determining the exact residues which make up optimum epitopes. Pepscan
technology may be useful in determiningresidues which make up an optimum epitope because
in this method, overlapping and progressively shorter, truncated versions of the peptides are
synthesised and tested for recognition by antisera against the whole molecule (Sumar, 2001).
The Pepscan method will be discussed more fully in Chapter 6.
The specificity of the anti-peptide antibodies raised in the present study, makes them useful
reagents . Specific antibodies that bind to denatured protein in western blots are best suited for
immunoscreening of expression libraries (Patrie, 1994). These antibodies can also be used in
the immuno-affinity purification of the CP2 enzyme. The peptides representing the epitopes




Natural immunogenicity of congopain and vivapain peptides and
their possible use as diagnostic tools for trypanosomosis
4.1 Introduction
Diagnosis of parasitic diseases is usually based on clinical signs and symptoms or by detecting
either antibodies or parasite antigens . However, in trypanosomosis, early clinical signs are not
specific (Rebeski et al., 1999a) and are not easy to use as a means of diagnosis . A diagnostic
method which is sensitive, specific, simple and inexpensive is required.
Parasite detection depends on demonstrating the parasite in chancre fluid, lymph fluid, blood,
bone marrow or cerebrospinal fluid. In wet blood film preparations, parasites can be detected
but not identified by the disturbance they cause among red blood cells by their flagellar
movement (Van Meirvenne and Le Ray, 1985). Examination of Giemsa-stained thick blood
films is more sensitive . Parasites can also be localised using the dark ground buffy coat
technique which involves the centrifugation of blood in a specialised tube, resulting in
concentration of parasitised red blood cells in a layer because of their lower density. The
centrifuged tube is observed directly using a fluorescence microscope. Since the contrast
between stain and background is high, parasitised red blood cells are easily seen (Oaks et al.,
1999). Parasites can also be localised by DEAE cellulose anion-exchange chromatography.
Infected blood samples are subjected to anion exchange chromatography, where trypanosomes
are selectively eluted and can be recovered by centrifugation or membrane filtration (Van
Meirvenne and Le Ray, 1985). However, the diagnosis of trypanosomosis in animals with low
parasitaemia is hampered by low sensitivity of traditional detection methods (Rebeski et al.,
1999a). The diagnosis of trypanosomosis by direct parasitological techniques is feasible only
in the acute state of the illness, when the blood is colonized by a large number of parasites . In
the chronic state of the illness, when the level of parasiteamia is low, definitive diagnosis is
difficult (Reyna-Bello et al., 1998).
The limitations of parasitological diagnosis have been the driving force for research into
alternative techniques that give indirect evidence of infection. Serological techniques , such as
indirect immunofluorescence and ELISA, detect antibodies directed at parasite components or
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parasite antigens circulating in host blood (Masake et aI., 2002). The availability of the ELISA
technique has led to its use in veterinary diagnostic laboratories in at least 15 countries
affected by trypanosomosis (Masake et aI., 2002). There are various ELISA systems that have
been developed for the detection of bovine trypanosomal antibodies (Rebeski et aI., 2000) but
there is still a need for better ELISA technologies for trypanosomosis detection. Serological
assays can detect parasite antibodies but cannot determine whether the antibodies result from
current or past infection. Comparison of sensitivities and specificities of the assay is difficult
since protocols and antigen extracts have not been standardised (Oaks et aI., 1999). One way
of improving the ELISA technique could be by the use of epitopes, rather than whole antigen,
since success of the latter greatly depends on the antigen being used (Sanchez et aI., 2001).
The antigen should be trypanosome specific and the immune response of the host against that
particular antigen should be good. One of the advantages of using synthetic peptide epitopes as
antigens in antibody detection ELISAs, is that the sensitivity of the assay improves because,
when the infected host recognises the foreign protein molecule, antibodies against the epitopes
are produced are specific for the epitopes. Peptide antigens provided a more sensitive and
specific alternative to trypanosome lysates for detection of anti-Tocruzi antibodies as required
for blood screening assays (Haughton et aI., 2000).
In addition to serologic methods, molecular assays based on the polymerase chain reaction
(PCR) have been proposed as alternative tools for parasite detection during the chronic stage
of trypanosomosis (Gomes et aI., 1999). This is a promising techniqu e for the specific
detection of different species of trypanosomes which is based on amplifying certain repetitive
DNA sequences coding for trypanosome proteins (Masake et aI., 2002). Among the few
candidate proteins available is a 69 kDa invariant protein , present in T. congolense, T. brucei
and T. vivax. The cloning of the gene of this protein revealed that it is a member of 70 kDa
heat shock proteins (Boulange et aI., 2002). Kinetoplast DNA has been amplified by PCR for
the detection of T. cruzi in human blood (Gomes et aI., 1999). Sensitivity reported ranged from
96 to 100% compared with serologic diagnosis (Gomes et aI., 1999). PCR takes about three to
four hours , electric power is needed to run a thermal cycler and the reagents are relatively
expensive. The PCR assay requires facilities that many laboratories do not have and it is not
suitable for a large number of samples. A cheaper assay is thus required, but it would be
difficult to get better sensitivity than that repoited for the PCR technique .
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There is a report of an ELISA type assay for PCR products which is under evaluation (Masake
et aI., 2002). In this method, DNA isolated from blood samples of infected cattle, is first
amplified by PCR using oligonucleotide primers specific for T. brucei or T. vivax. The PCR
products, which are exclusive to either T. brucei or T. vivax, are biotinylated. None of these
primers are evident in the DNA from the blood samples of the cattle exposed to non-infected
tsetse. The biotinylated PCR-products are applied to the wells of microtitre plates pre-coated
with streptavidin. The unbound PCR-products are removed by washing. The bound PCR-
products are incubated with a fluorescein-labelled oligonucleotide probe specific for the
trypanosome species tested. Following the washing step, the fluorescein-labelled probe is
revealed by incubation with anti-fluorescein antibody conjugated to alkaline phosphatase
(Masake et aI., 2002).
An objective of the present study was to investigate the use of congopain epitopes as
diagnostic tools. This is based on the observation that congopain is the major antigen in
T. congolense infected cattle (Authie, et aI., 1992). Under natural tsetse challenge both
trypanotolerant and trypanosusceptible cattle have high levels of anti-congopain IgG (Authie,
1994). These antibodies from infected cattle may be directed against discrete epitopes in
congopain. In a previous study, chicken anti-sheep cathepsin L IgY recognised an active site
associated cathepsin L peptide, suggesting that this peptide is a natural immunogenic epitope
in chickens (Coetzer et aI., 1992). Such a peptide could be used as a diagnostic tool in an
ELISA rather than the whole cathepsin L enzyme.
In this study, peptides selected as described in Chapter 3 (Section 3.4.1, Tables 6 and 7) were
immobilised on ELISA plates and indirect ELISAs were done to detect anti-congopain peptide
antibodies in serum samples from cattle experimentally infected with T. congolense or
immunised with C2, in comparison with non-immunised control cattle. The aim was to
investigate whether the congopain peptides are naturally immunogenic in cattle, which could
suggest that these sequences are partial or complete epitopes of congopain. The naturally
immunogenic epitopes could be used as diagnostic tools by screening for the presence of
antibodies that target the congopain epitopes in T. congolense infected sera using ELISAs. The
ability of sera from T. congolense and T. vivax infected cattle to bind to peptides
corresponding to sequences in the C-terminal extension of congopain and vivapain (Section
3.4.1, Table 7) was also tested in ELISAs. The aim was to find out whether these two peptides
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could be used as tools to differentiate between T. congolense and T. vivax infections.
4.2 Detection of anti-congopain antibodies with indirect ELISAs using CP1 and CP2
peptides as antigens
In these assays levels of antibodies against congopain peptides were measured. This is based
on the observation that T. congolense infected sera have high levels of anti-congopain
antibodies (Authie et al., 1993a). These antibodies may be able to recognise specific
congopain peptides if they are naturally immunogenic epitopes of congopain. Sera from cattle
immunised with C2 were also tested since it has been hypothesised that epitopes of congopain
are likely to be in the catalytic domain (Authie et al., 2001). An antigen may be immunogenic
to one species and not immunogenic in another species (Harlow and Lane, 1988). Sera from
rabbits immunised with native congopain or C2 were therefore tested to check whether
peptides would be naturally more/less immunogenic in rabbits compared to cattle.
4.2.1 Reagents
ELISA reagents prepared as per Section 2.10.1
0.5% (w/v) gelatin-PBS. Gelatin (0.5 g) was dissolved in PBS (lOO ml).
T. congolense infected sera. Sera from adult N'Oama and Boran cattle experimentally infected
with T. congolense were a gift from Or Edith Authie [ILRI, Nairobi , Kenya]. Sera were
collected between 70 and 100 days post infection.
Sera from C2 immunised cattle, uninfected cattle. Sera from uninfected Boran cattle,
immunised with Pichia pastoris expressed C2 were provided by Or Edith Authie (ILRI,
Nairobi , Kenya). Cattle were around 1 year old. Sera were collected 3 weeks after the second
booster.
Sera from rabbits immunised with native congopain or C2. Serum from a rabbit immunised
with monoclonal antibody affinity purified congopain from lysates of T. congolense
bloodstream forms was used. Serum from a rabbit immunised with C2 was also used. Both
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sera were a gift from Dr Edith Authie (ILRI, Nairobi, Kenya).
4.2.2 Procedure
Peptides (Section 3.4.1, Tables 6 and 7, 10 ug/ml) were coated to the wells of ELISA plates
(16 h, 4°C). Non-specific binding of antibody to the wells was prevented by blocking with
0.5% gelatin-PBS (1 h, 37°C). Sera were diluted in serial two-fold dilutions using 0.5%
gelatin-PBS from 1/100 to 1/1600 and incubated (2 h, 37°C). Goat anti-bovine IgG-HRPO
(Jackson ImmunoResearch Laboratories inc, Pennsylvania, USA) was used as detection
antibody. Where sera from rabbits were used, goat anti-rabbit IgG-HRPO (Jackson
ImmunoResearch Laboratories inc, Pennsylvania, USA) was used as detection antibody. The
remainder of the procedure was as described in Section 2.10.2.
4.3 Differentiation between T. congolense and T. vivax infection with indirect ELISA
using C-terminal extension peptides.
Generally, methods for the detection of trypanosomal antigens in serum samples have proved
to be unsatisfactory with respect to diagnostic sensitivity (Rebeski et aI., 1999b). Therefore,
more sensitive diagnostic methods , including the detection of Trypanosoma specific antibodies
have been developed (Greiner et aI., 1997). Peptides from C-terrninal extension sequences of
congopain and vivapain were coated as antigens in ELISA plates to investigate whether they
would be useful in distinguishing between infections by T congolense and T. vivax. A
criterion for the selection of peptides was to choose a CP2 peptide sequence that does not
match with the aligned sequence of vivapain and visa versa. This was done in order to avoid
chances of cross-reactivity. Alignment of C-terrninal extension sequences of vivapain and
congopain, and the peptides selected, is shown in Figure 32.
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25
C term vivapain G P G P T P T P T P T T T T T T T T T
C tennCP2 G P P P P P P T P T F T - - - - - - - - - - - -
50
C term vivapain A D N C S A T V Y N TNT C
C tennCP2 - - Q E L C E G A E C Q s K C T KAT F P T G K C
25
75
C term vivapain I R L G A L G S M V A T C G A G V L E L K A Y M Q
C tenn CP2 v Q L S G A G S V I A S C G S N N L T Q I V Y P L
50
100
C term vivapain N E Q C T G T PER L S L P L D K C L A S L S V S
C tennCP2 S S S C S G F S V P L T V P L D K C L P I V I G S
75
C term vivapain ATYHCN
C term CP2 V M Y E C
100
Figure 32. Alignment of the C-terminal extension sequences of vivapain and CP2. Identical residues are
indicated in bold. The selected peptide from vivapain (amino acid sequence deduced by Prof. Theo Baltz,
University of Bordeaux, France, personal communication) is highlighted in red, and the selected CP2 peptide
(amino acid sequence deduced by Jaye et aI., EMBL accession number L25130) is highlighted in green.
4.3.1 Reagents
ELISA reagents as per Section 2.10.1.
Sera from six crossbred Zebu x Baoles heifers, experimentally infected with T. congolense and
T. vivax were a gift from Dr Marc Desquesnes [Centre International de Recherche-
Developpement sur l'Elevage en Zone Sub-humide (CIRDES), Bobo Dioulasso, Burkina
Faso]. Cattle were around 2-3 years old. Sera from T. congolense infected cattle were collected
between day 26 and day 58 post infection. Sera from T. vivax infected cattle were collected
between day 55 and day 219 post infection.
105
4.3.2 Procedure
As per Section 2.10.2 and the modifications as per Section 4.2.2.
4.4 Results
4.4.1 Recognition of CP2 and CPl peptides by sera from cattle experimentally infected
with T. congolense.
Both N'Dama and Boran cattle experimentally infected with T. congolense elicited antibodies
that recognised CP2 and CP1 peptides better in comparison to the recognition of peptides by
the non-immune sera used as negative controls. On average, for CP2 peptides, the C-terminal
extension peptide (# 4) was best recognised followed by the N-terminal peptide (# 1), the
active site peptide (# 3) and the catalytic domain peptide (# 2). On average, for CP1 peptides,
the N-terminal peptide (D) was best recognised followed by the active site peptide (F) and the
catalytic domain peptide (E). Recognition of the peptides by the sera from trypanosusceptible
Boran cattle, was not significantly different from the recognition of peptides by the sera from
trypanotolerant N'Dama cattle. However, the poor recognition of peptides by the sera from the
trypanosusceptible Boran heifer #407, is quite remarkable. This result suggests differences in
the humoral responses to congopain between trypanosusceptible cattle and trypanotolerant
cattle. The results are summarised in Table 10.
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Table 10. Recognition of CP peptides by sera from cattle experimentally infected with T.
congolense.
Sera Peptides coated down in ELISA plates
0 E F # I #2 #3 # 4
ND 122a,d + + ++++ + + + + + + + ++ + +++ + +++
NO 139 +++ + + + ++++ ++ ++ +++ + ++ ++
N04 ++++++ + + + + + +++++ ++++ + + +++ ++ + ++++
BR 340 b +++++ + +++ +++++ +++++ + + + + +++ +++ ++ +++ +
BR 723 +++ + + + ++++ + ++++++ + + + + +++ + ++ + + + + +++
BR 407 c ++ + + + ++ + +
Average 97.2 ± 87.5± 93.9± 87.5 ± 64.3 ± 80.2± 91.4 ±
percentage 60.1 55.8 72.1 44.1 43.1 41.6 53.4
recognition
aND, N'Dama cattle .
b BR, Boran cattle.
cAminus sign indicates less than 0% recognition when compared to recognition by non-immune sera.
dThe number of plus signs indicate % recognition when compared to recognition by non-immune sera (one plus
sign, 1-30%; two plus signs, 31-59%; three plus signs, 60-79%; four plus signs, 80-120%; five plus signs, 121-
160% and six plus signs, 160-200%).
4.4.2 Recognition of CP2 and CPI peptides by sera from C2 immunised, uninfected
cattle.
All peptides (except the C-terminal extension peptide, # 4) were recognised by C2 immunised
Boran cattle compared to the non-immune sera. This was expected because C2 does not have a
C-terminal extension. This result is also an indication of the specificity of the response to the
C2 immunogen. A representative result of recognition of peptides by C2 immunised sera is
shown in Figure 33. The N-terminal extension peptide (# 1) and the catalytic domain peptide
(# 2) were the main CP2 peptides that were targeted by antibodies in the sera . On the other
hand, the active site peptide (F) was the main CP 1 peptide targeted by the antibodies.
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Figure 33. Recognition of CP2 and CPI peptides by sera from C2 immunised, uninfected cattle. CP2 (Panel
A) and CPI (Panel B) peptides (10 ug/ml) were coated to the wel1s ofELISA plates. Sera ofC2 immunised cattle
(shaded bars) and non-immunised cattle (unshaded bars) were titrated between 1/100 and 1/1600 dilutions.
Binding was detected using goat anti-bovine IgG-HRPO-linked detection antibody (Jackson ImmunoResearch
Laboratories inc, Pennsylvania, USA) and ABTS/HzOz substrate. Representative data for the 1/1 00 dilution is
shown. Bars represent SEM (n = 5).
4.4.3 Recognition of CP2 and CPI peptides by sera from C2 and native congopain
immunised rabbits
Antibodies in the sera produced against C2 in rabbits recognised mainly the active site peptide
(# 3) and the N-terrninal peptide (# 1) from CP2 and the active site peptide (F) from CPl when
compared to recognition by non-immune rabbit sera. All peptides were poorly recognised by
antibodies in the sera produced against native congopain compared to recognition by non-
immune rabbit sera (Table 11).
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Table 11. Recognition of CP peptides by sera from C2 and native congopam immunised
rabbits.
Immu nogen Peptides coated down in ELISA plates
D E F # I # 2 # 3 # 4




"Representative data for the 1/100 dilut ion is shown .
bA minus sign indicates less than 0% recognition when compared to recognition by non-immune sera.
cThe number of plus signs indicate % recogn ition when compared to .recognition by non-immune sera (one plus
sign, 1-30%; two plus signs, 31-59 %; three plus signs, 60-79 %)
4.4.4 Distinction between T. congolense and T. vivax infection in an ELlSA by using C-
terminal extension peptides as coating antigens.
The recognition of peptides by antibodies present in all the sera from the different crossbred '
Zebu x Baoules cattle was consistently slightly higher for CP2 peptide (# 4) compared to
vivapain peptide (# 5), when using T. congolense infected sera, and slightly higher for
vivapain peptide compared to CP2 peptide when testing T. vivax infected sera (Figure 34). The











vivapain vivapa in CP2
peptide CP2 peptide peptide peptide
Figure 34 . Recognition of CP2 and vivapain C-terminal extension peptides by T. congolense and T. vivax
infected sera. CP2 and vivapain peptides (10 ug/rnl) were coated to the wells of ELISA plates. T. congolense
infected sera (Panel A, shaded bars), T. vivax infected sera (Panel B, shaded bars) and uninfected sera (unshaded
bars) were titrated between 1/100 and 1/1600 dilutions. Binding was detected using goat anti-bovine IgG-HRPO-
linked detection antibody (Jackson ImmunoResearch Laboratories inc, Pennsylvania, USA) and ABTS/HzOz
substrate. Representative data for the 1/1.00 dilution is shown. Bars represent SEM (n = 4).
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4.5 Discussion
The work described in this Chapter determines whether cysteine proteinase peptides selected
from the catalytic domain (T. congolens e) and the C-tenninal extension (T. congolense and T.
vivax) described in Chapter 3 are natural immunogenic epitopes. This study took advantage of
the fact that congopain is naturally immunogenic and in the course of an immune response to
natural T. congolense infection, congopain elicits antibodies (Authie et al., 1993a). Paratopes
on antibodies produced by the infected host against congopain interact with certain regions
(epitopes) in the congopain molecule. These regions have not yet been identified, therefore the
peptides selected were used to determine whether they are targeted by the antibodies in the
infected sera or not. Should the main targets be identified, they could be used as diagnostic
tools.
All congopain peptides, except the catalytic domain peptide (#2), were recognised by T.
congolense infected sera compared to recognition by sera from uninfected cattle. This could
either mean that the conformation adopted by peptide #2 coated in an ELISA plate did not
mimic the conformation that occurs in the corresponding region of native congopain which is
recognised by the antibodies or it could mean that peptide #2 is not an immunogenic epitope
of congopain. On the other hand, sera from C2 immunised, uninfected cattle targeted mainly
the N-tenninal peptide #1, peptide #2 and the active site associated peptide F. Apparently
peptide #2 becomes immunogenic when the truncated form of the enzyme is used as an
immunogen. The region corresponding to peptide #2 possibly becomes more exposed and
accessible for antibody binding in the truncated form of the enzyme. The poor recognition of
the C-tenninal extension peptide (#4) by the sera from C2 immunised cattle is not surprising
because C2 is a truncated CP2 enzyme which does not include the C-tenninal extension of
congopain. Interestingly, the longer CPl active site peptide (F) is recognised much better by
sera (T. congolense infected and C2 immunised) compared to recognition of the shorter CP2
active site peptide (# 3). Longer peptides are better able to adopt the conformation in the
mature, whole protein, thereby inducing protein reactive antibodies (Dr Stuart Rodda,
Mimotopes, Clayton, Australia, personal communication). Peptide sequences may need to be
modified to identify optimal peptide sequences which can result in a more optimal targeting of
the peptide by antibody. However, C2 immunised rabbit sera targeted the shorter active site
associated peptide #3. This suggests that the region corresponding to peptide #3 in C2 was
more immunogenic in rabbits than in cattle . This result is in agreement with the suggestion by
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Harlow and Lane (1988), that different species may respond differently to an immunogen.
This is supported by the finding that antibodies raised in rabbits against cathepsin L did not
recognise the cathepsin L active site His-containing peptide, whereas those produced in
chickens against cathepsin L did recognise this peptide (Coetzer et al., 1992). Contrary to
these findings, the epitopes identified in this study and shown to be immunogenic in chickens,
were also immunogenic in cattle. The latter was evidenced by the recognition of all the
peptides by the sera of T. congolense and/or T. vivax infected cattle.
None of the peptides were recognised by antibodies from the native CP2 immunised rabbit. It
may be argued that antibodies made against native congopain may not have recognised the
conformation adopted by the peptides coated in ELISA plates, which may not mimic the
conformation that occurs in the corresponding regions of native congopain. Another possible
explanation is that the immune response against native congopain was poor. These antibodies
may be tested by determining whether they recognise native congopain coated on an ELISA
plate. This control test could be done once native congopain is available from our
collaborators.
Another objective of this study was to differentiate between T. congolense and T. vivax
infection. There is a need for trypanosome antigens that would be species specific because
diagnostic ELISAs for trypanosomes lack the desired specificity and sensitivity (Gomes et al.,
1999). Although antibodies raised in chickens against the congopain and vivapain C-terminal
extension peptides showed no cross-reactivity in an ELISA with the respective peptides
coated, there was very high cross-reactivity by the T. congolense and T. vivax infected sera.
However, T. congolense infected sera consistently recognised the congopain peptide slightly
better than the vivapain peptide, while T. vivax infected sera recognised the vivapain peptide
slightly better than the congopain peptide. Cross-reactivity may be due to polyreactive
antibodies in T. congolense infected sera, as suggested by Buzaand Naessens (1999). Another
possibility is that the cattle tested had mixed infections of T. congolense, T. brucei and T.
vivax. This was confirmed by indirect ELISA results from another laboratory provided by Dr
Marc Desquesnes [CIRDES, Bobo Dioulasso, Burkina Faso] which showed that there was
cross-reactivity by the sera. The antigens used (trypanosome lysates) were different from the
peptides which were used in this study but the same sera were used. T. congolense infected
sera and T. vivax infected sera recognised antigens specific for T. congolense, T. brucei and T.
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vivax. T. vivax infected sera recognised the antigen specific for T. congolense by up to 16%,
while the recognition of the antigen specific for T. vivax was 76%. On the other hand, T.
congolense infected sera recognised the antigen specific for T. vivax by up to 32%, while the
recognition of the antigen specific for T. congolense was 47%. The possibility of mixed
infections in the sera provided was not expected since the cattle were bought seronegative.
However, there are many reports of mixed infections in field investigations both in wildlife
and domestic livestock (Mattioli et al., 1999), and mixed infections could occur between the
time of testing prior to acquiring the cattle and the time of experimental infection. Further
evidence for possible mixed infection is given by the results of parallel experiments conducted
with the peptides selected in this study in a collaborator's laboratory in Belgium. Experimental
infection of cattle and goats with T. congolense or T. vivax in a completely trypanosome free
area (Belgium vs Burkina Faso), showed that the congopain C-terminal extension peptide is
specific for T congolense infection and is not recognised by sera from T. vivax infected cattle
(Dr Phillippe Buscher, Institute of Tropical Medicine, Antwerp, Belgium). Optimal antibody
binding sequences of these two peptides need to be identified by testing modified sequences of
these two peptides and hopefully the sensitivity of this assay would improve.
This study has shown that most of the peptides, particularly the N-terminal peptide (# 1), the
active site associated peptide (# 3), the C-terminal extension peptide (# 4) and the active site
associated peptide from CPl (F), are naturally immunogenic and possible epitopes of
congopain because an immune response was induced against these regions (peptides) of CP2
during immunisation with CP2. These peptides seem to form a part of the essential regions of
the enzyme since they were targeted partially by the tested sera. However, from each of these
peptides, one would have to identify optimal peptide sequences corresponding to the regions
of the enzyme by analysing a series of overlapping peptides. Identification of optimal antibody
binding peptide can be done by window net analysis and replacement net analysis (Sumar,
2001). Window net analysis allows further optimisation of binding of antibodies by
synthesising different lengths of overlapping peptides. Replacement net analysis allows the
study of the effects of changes in amino acids within the predicted epitope to binding of
antibodies (Sumar, 2001). These analysis methods will be discussed in more detail in Chapter
6.
After identifying optimal binding epitopes one would have to develop a standardised
112
diagnostic assay. Serum samples tend to give higher backgrounds compared to monoclonal
and anti-peptide antibodies and the interpretation of data can be difficult in terms of what
comprises an epitope and where the background cut off should lie (Sumar, 2001). For optimal
interpretation of serodiagnostic results one would have to consider biological influencing
factors, including sex, breed, age, health and nutritional status of the animals to be tested since
these factors can greatly affect the immune system of the animals and hence their response to a
trypanosomal proteinase during infection. This shows that there are some limitations and
factors which can jeopardise the accuracy of the results when trying to diagnose
trypanosomosis by using serological assays which detect antibodies. Furthermore, false
positive results of antibody tests can be encountered as a result of antibodies that persist after
successful therapy or self-cure (Greiner et al., 1997; Rebeski et al., 1999b), therefore antibody
tests would be more useful when studying epidemiology of the disease rather than for
diagnostic purposes.
It has been suggested that the most effective antigens in the diagnosis of T. cruzi are those
with immunodominant, repeating B cell epitopes (Bums et al., 1992). In this study, synthetic
peptides representing a single epitope of congopain were used as coating antigens to detect
anti-congopain antibodies in T. congolense infected cattle. In contrast to this, a multiepitope
synthetic peptide has been used successfully by Haughton et al. (2000) as an antigen. A
tetrapeptide representing four immunodominant epitopes from several core antigens of T. cruzi
was used to detect serum antibodies in an ELISA. Higher sensitivity and specificity were
observed for the tetrapeptide/recombinant protein assay than for a lysate-based ELISA
(Haughton et aI., 2000). Multiepi tope peptides could constitute reproducible, easily
manufactured reagents that can give more sensitive and specific alternatives to trypanosome
lysates in immunoassay development (Haughton et al., 2000). In future studies it would be
interesting to apply the multiepitope synthetic peptide approach of Haughton et al. (2000) for
the diagnosis of T. congolense when the optimal epitopes of congopain have been identified.
In conclusion, most congopain peptides identified and tested in this study seem to be essential
regions of the enzyme. Further characterisation and modifications of these peptide sequences
need to be done to identify optimal epitopes of congopain. The use of peptides as antigens in
serum screening assays could provide a better alternative to trypanosome lysates, bearing in
mind that there are some shortcomings when using this assay such as those mentioned above.
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More tests need to be done before these potential diagnostic tools are used in detecting T.




Interaction of CP2 with o'z-macroglobulin
5.1 Introduction
The implication of congopain in pathogenesis suggests that this enzyme interacts with host
proteins. CP2 hydrolyses substrates over a wide pH range from pH 4.0 to 8.5 (Authie et al.,
2001) and is therefore likely to be active at physiological pH. There are several endogenous
host cysteine protease inhibitors which control cysteine proteinase activity. These include
cystatins which are divided into three families: family one members which have no disulfide
bonds, family two members which have two disulfide bonds and family three members
(kininogens) which have nine disulfide bonds (Salvesen and Nagase, 1989). u2-Macroglobulin
(U2M) is a natural inhibitor that fails to discriminate between proteinase classes and binds to
and inhibits most proteinases (Salvesen and Nagase , 1989). CP2 interacts with natural
inhibitors, for example, with cystatins (cystatin families 2 and 3) and kininogens (Lalmanach
et al., 2002). The aim of this part of the present study was to determine whether CP2 interacts
with a natural bovine protease inhibitor, u2-macroglobulin. Other trypanosomal proteinases
from T. cruzi (Ramos et al., 1997) and from T. b. brucei (Troeberg et al., 1996) interact with
u2M. This interaction could possibly be exploited to increase the immunogenicity of CP2 as
was done previously for hen egg lysozyme (Chu and Pizzo, 1993; Chu et al., 1994), prostate-
specific antigen (Otto et al., 1998), and hepatitis B virus surface antigen (Cianciolo et al.,
2002).
U2M is a member of a group of high molecular weight proteins collectively known as the u-
macroglobulins (Salvesen and Nagase 1989). The o-macroglobulins are the only natural
inhibitors that do not differentiate proteinase classes and are thought to play an important role
in physiological control of extracellular proteolytic activity (Barrett et aI., 1979). The U2M
molecule is a tetramer of four identical subunits that form two disulfide-bonded dimers which,
in turn, are associated through non-covalent forces (van Jaarsveld et al., 1994) (Figure 35).
The molecular weight of bovine U2M is ~ 800 000 kDa and each subunit has a molecular
weight of~ 180 000 kDa (Nagasowa et al., 1970). In the middle ofeach subunit is a stretch of
amino acid residues that are vulnerable to proteolysis. This region is called the 'bait region'.
Cleavage of any peptide bonds in the 'bait region' triggers a conformational change in U2M
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resulting in the entrapment of the proteinase (Ramos et al., 2002) (Figure 36). The
conformationally changed uzM becomes more compact and migrates faster through native gels
and is referred to as the fast form (F-uzM), whereas the original form is known as the slow
form (S-uzM) (Chu and Pizzo, 1994).
Covalent linkage of a proteinase to uzM does not occlude the enzyme's active site, so the
sterically entrapped enzyme retains activity towards low molecular weight substrates but not
substrates with a molecular mass higher than 30 kDa (van Jaarsveld et al., 1994). Inactive
proteinases and zymogens are not bound by uzM (Salvesen and Nagase, 1989). Since CP2 is
likely to be active at physiological pH, it is possible that this enzyme is bound by uzM.
Figure 35. Diagrammatic representation of the uzM molecule (Barrett et al., 1979). uzM is a tetramer of four
identical subunits formed by the noncovalent association (at the sites marked 'r') of two disulfide-bonded pairs of
subunits.
The fact that uzM bound proteinases retain activity against small substrates, suggests that the
function of uzM extends beyond simple proteinase inhibition (Chu and Pizzo, 1993). uzM does
not only bind proteolytic enzymes but other non-proteolytic proteins can be bound by uzM
(Chu and Pizzo, 1993). Non-proteolytic proteins such as insulin (Chu et al., 1991), cytokines
(James, 1990), growth factors and hormones (Kratzsch et al., 1995) were shown to be bound
by uzM. The binding mechanisms of these molecules may vary and binding may be either
covalent or non-covalent. In most cases covalent binding occurs via disulfide interchange
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when hormones are present during proteolytic activation of uzM and in some cases non-
covalent entrapment may occur as in uzM-protease interaction. The covalent-binding that
occurs between these molecules and uzM may be different from that accompanying protease
binding (lames, 1990).
A B c
"Recep torrecogn itio nsites
Figure 36. Schematic representation of the conformational change that uzM undergoes upon proteolytic
activation (Chu and Pizzo, 1994). A: Native uzMwhich is able to inhibit proteinases but which is not receptor-
recognised. B: Proteinase(s) (indicated by broken circles) enter the trap to get to the 'bait' region and when the
proteinase cleaves the bait region, a conformational change of uzM is initiated. C: uzM with an entrapped
proteinase(s) (indicated by shaded circles) looks more compact and the receptor recognition sites are exposed.
Studies have shown that conformational changes of uzM-protein in complexes lead to the
exposure of receptor recognition sites that result in clearance of uzM-protein complexes from
the circulation (van Jaarsveld et al., 1994). uzM "senses" situations involving increased
proteolysis, such as during inflammation or tissue destruction, where it inhibits potentially
harmful proteinases, microbial or otherwise, and captures proteins for delivery to cells which
have uzM receptors, such as macrophages, hepatocytes and other cells involved in biological
and chemical detoxification (Chu and Pizzo, 1994). The use of uzM as an adjuvant takes
advantage of its natural function. As in the natural mechanisim, antigens entrapped by uzM
with exposed receptor recognition sites are quickly delivered to macrophages, potentially
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resulting in enhanced immunogenicity.
The possible enhancement of the immunogenicity of CP2 could be determined by complexing
with U2M and immunising a suitable animal with the complex, thereby enhancing delivery of
CP2 to macrophages possessing U2M receptors. However, this was beyond the scope of the
present study. In this study U2M was isolated from bovine plasma and characterised by western
blotting (Section 5.2). The interaction between CP2 and U2M was investigated as a preliminary
study to the future use of U2M to potentially increase CP2 immunogenicity.
5.2 Isolation and characterisation of U2M from bovine plasma
The method used for the isolation of U2M was that of Barrett et al. (1979) in conjunction with
the modified method of Kurecki et aI. (1979). The u2M-containing fraction of bovine plasma
was first precipitated with PEG 6000 (Barrett et al., 1979), followed by chromatography on a
zinc chelate column (Kurecki et al., 1979). The isolation of the thiol-containing U2M on a zinc-
containing gel is based on the suggestion that imadozole and thiol groups on protein molecules
are the most important binding sites for zinc- and copper- containing adsorbents (Porath and
Olin, 1983). An additional molecular exclusion chromatography (MEC) step on Sephacryl-S- .
300 HR was done to further purify U2M from other contaminating serum proteins which were
also bound by the zinc chelate.
5.2.1. Reagents
Acid-citrate-dextrose. Citric acid.Hjt) (4 g), Na3C6Hs07.2H20 (11 g) and glucose.H20 (12.21
g) were dissolved in distilled H20 and made up to 500 ml.
Bovine plasma. Blood was harvested from cattle at slaughter (Abakor abbatoir, Cato Ridge).
Bovine blood (1 litre) was collected into two litre glass bottles containing acid-citrate-dextrose
(140 ml). The collected blood was stored for 48 h at 4°C before the plasma was separated from
the red blood cells by centrifugation (8000 x g, 30 min, 4°C). The plasma was re-centrifuged
(8000 x g, 30 min, 4°C) and stored for 24 h at 4°C.
25% (w/v) PEG 6000. PEG 6000 (50 g) was dissolved in 200 ml of distilled H20.
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50 mM Na2EDTA buffer, 500 mM NaCl, pH 7.0. Na2EDTA.2H20 (4.653 g) and NaCl (7.305
g) were dissolved in 200 ml of distilled H20, titrated to pH 7.0 with NaOH and made up to
250 ml with distilled H20.
3 mg/ml ZnCl2J?H 6.0. ZnCh (0.3 g) was dissolved in 90 ml of distilled H20, titrated to pH
6.0 with HCl and made up to 100 ml with distilled H20.
2 M Na2C03. Na2C03 (26.5 g) was dissolved in 125 ml of distilled H20 .
250 mM Na-acetate buffer, 150 mM NaCl, pH 5.0. CH3COOH (3.75 g) and NaCl (2.19 g)
were dissolved in 200 ml of distilled H20, titrated to pH 5.0 with NaOH and made up to 250
ml with distilled H20.
20 mM Na-phosphate buffer, 150 mM NaCl, pH 6.0. NaH2P04.2H20 (3.12 g) and NaCl
(8.76 g) were dissolved in 950 ml of distilled H20, titrated to pH 6.0 with NaOH and made up
to 1 litre with distilled H20.
20 mM Na-cacodylate buffer, 150 mM NaCl, pH 5.0. Na-cacodylate (1.07 g) and NaCl (8.76
g) were dissolved in 950 ml of distilled H20, titrated to pH 5.0 with NaOH and made up to
1 litre with distilled H20.
100 mM Na-phosphate buffer, 0.02% (w/v) NaN3, pH 7.0. NaH2P0 4.2H20 (31.202 g) and
NaN3 (0.4 g) were dissolved in 1.9 litres of distilled H20, titrated to pH 7.0 with NaOH and
made up to 2 litres with distilled H20.
5.2.2 Procedure
Step I. PEG precipitation. Plasma (250 ml) was mixed with 25% (w/v) PEG solution (70 ml).
The mixture was stirred for 10 min, left for 20 min at RT and centrifuged (10 000 x g, 20 min,
RT). 25% (w/v) PEG solution (180 ml) was added to the supematant. The mixture was stirred .
for 10 min, left for 20 min at RT and centrifuged (10 000 x g, 20 min, RT). The precipitate
was collected and dissolved in 20 mM Na-phosphate buffer, 150 mM NaCl, pH 6.0 (42 ml)
119
and dialysed against the same buffer overnight (2 x changes).
Step 2. Zinc chelate chromatography. Imidodiacetic acid-epoxy-activated Sepharose 4B was
used. The gel was washed with 50 mM EDTA, 500 mM NaCI solution, pH 7.0 (1 column
volume) before thoroughly washing with distilled H20. The gel bound chelate of zinc was
obtained by passing a ZnCh solution (3 mg/ml) through a column containing imidodiacetic
acid-Sepharose 4B (0.75 x 9 cm, 0.67 ml/min, 4°C). Fractions (2 ml) were collected into tubes
containing 2 M Na2C03 (2 ml) and the presence of Zn2+ was assessed by the formation of an
insoluble ZnC03 precipitate. The gel was washed with 250 mM Na-acetate buffer, 150 mM
NaCI , pH 6.0 (1 column volume, 1.67 ml/min, 4°C). The gel was equilibrated with 20 mM Na-
phosphate buffer, 150 mM NaCI, pH 6.0 (2 column volumes, 1.67 ml/min, 4°C). The dialysed
u2M-containing material was applied to the zinc chelate column. The column was washed with
20 mM Na-phosphate buffer, 150 mM NaCI, pH 6.0 and fractions were collected (5 ml
fractions, 0.83 ml/min, 4°C) . When the A280nm was less than 0.02, elution of U2M was effected
with 20 mM Na-cacodylate buffer, 150 mM NaCI, pH 5.0 (2 ml fractions, 0.83 ml/min, 4°C) .
Fractions which had high absorbance values were assumed to contain U2M material because by
lowering the pH from 6.0 to 5.0 the interaction between U2M and zinc chelate matrix is
destabilised (Kurecki et al., 1979). These fractions were therefore pooled.
Step 3. Chromatography on Sephacryl S-300 HR. The column (1.25 x 90 cm, 0.42 ml/min)
was pre-calibrated with blue dextran (M, 2000 000), bovine thyroglobulin (M, 670 000),
ferritin (M, 440 000) , ovalbumin (M, 44 000) and horse myoglobin (M, 17 000). Fractions
from step 2 containing U2M material were concentrated by dialysis against PEG 20 000
(Section 2.4.1.1) and applied to the Sephacryl S-300 HR column (0.42 m1/min, 4°C) pre-
equilibrated with 100 mM Na-phosphate buffer, 0.02% NaN3, pH 7.0. Protein was eluted with
the same buffer and absorbance monitored at 280 nm. u2M-containing fractions were
evaluated by Laemmli SDS-PAGE (Section 2.5.2) ·and characterised by western blotting
(Section 2.7.2) using rabbit anti-c-M antibodies (a gift from Dr Edith Authie, ILRI, Nairobi,
Kenya). U2M fractions were stored at 4°C.
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5.3 Inhibition of CP2 by U2M
5.3.1 Azocasein assay
5.3.1.1 Reagents
As per Section 2.13.1
5.3.1.2 Procedure
Enzyme activity was assayed as described in Section 2.13.2, except that CP2 (0.068 nmo1es in
100 III Brij 35) was pre-incubated with U2M (0.068 nmo1es or 0.136 nmo1es to give a 1:1 or a
1:2 molar ratio of CP2:U2M in assay buffer, 1 h, 37°C) before adding azocasein/urea substrate.
The experiment was repeated three times . Proteolytic activity was determined by measuring
the hydrolysis of substrate at 366 nm and comparing to that of CP2 without U2M (100% of
activity) and expressed as % inhib ition.
5.3.2. Bz-Pro-Phe-Arg-pNA assay
The procedure followed was according to Ramos et al. (2002).
5.3.2.1 Reagent
Substrate [30 mM Bz-Pro-Phe-Arg-pNA]. Bz-Pro-Phe-Arg-pNA (0.1 g) was dissolved In
DMSO (1 ml) and diluted to 5 ml with distilled H20 .
Phosphate buffered saline (PBS) pH 7.2. As per Section 2.10.1
5.3.2.2 Procedure
CP2 (44 pmo1es) was incubated with different concentrations of U2M at molar ratios of 1:0.25,
1:0.5, 1:1, and 1:2 for 60 min at 37°C. The enzyme activity of CP2 in the presence or absence
of u2M inhibitor was assayed with the synthetic chromogenic substrate Bz-Pro-Phe-Arg-pNA
at pH 7.2 (100 ul, to give final concentration of 3 mM) and the reaction was followed
spectrophotometrically at 405 nm. Proteolytic activity was measured and compared to that of a
CP2 control without U2M (100% activity) and expressed as percentage inhibition. To
determine the time course of inhibition of CP2 activity by U2M, CP2 was incubated with U2M
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(molar ratio 1:1) for 5, 10, 15,20,30,40, 50 and 60 min at 37°C. Proteolytic activity was
measured and expressed as above. Each of thes e experiments was repeated three times .
5.4 Results
5.4.1 Purification and characterisation of 0'2M
0'2M precipitated by PEG 6000 was resolved from other plasma proteins by zinc chelate
chromatography (Figure 37). The binding of proteins in metal chelate affinity chromatography
depends on pH (Kurecki et al. , 1979). 0'2M and other plasma proteins which bind to the zinc
chelate remained tightly bound to the zinc column at pH 6.0, allowing removal of other plasma
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Figure 37. Chromatography of 112M on a zinc chelate column. Zinc chelate column (0.75 x 9 cm, 0.83 ml/min ,
4°C) was pre-equilibrated with 20 mM Na-phosphate buffer, 150 mM NaCI , pH 6.0 . The PEG 6000 precipitate
containing u2M was loaded onto the column and 5 ml fractions collected. After elution of unbound protein with
the equilibration buffe r, bound protein was eluted with 20 mM Na-cacodylate buffer, 150 mM NaCI, pH 5.0,
applied at point -1- and 2 ml fractions collected. (-) fractions pooled.
Analysis of the zinc chelate bound 0'2M-containing fraction on SDS-PAGE revealed protein
contaminants smaller than 76 kDa (Figure 39, lane d). MEC on Sephacryl S-300 HR (Figure
38) succeeded in removing these protein contaminants from the zinc chelate bound fraction
(Figure 39, lane e). The first peak was chosen because according to the calibration with
standard proteins of known molecular weight, 0'2M (M, 720 00) would be eluted at this
volume. Non-reducing Laemmli SDS-PAGE showed that the 0'2M-containing material pooled
after MEC consisted of an 0'2M tetramer protein band at 720 kDa and an 0'2M dimer band at
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360 kDa (Figure 39, lane e). U2M was thus purified to homogeneity using a combination of
PEG precipitation, zinc chelate chromatography and Sephacryl S-300 MEe.
The purified U2M sample was further characterised by western blotting (Figure 40). Purified
U2M was recognised by rabbit anti-n-M antibodies. The U2M dimer band at 360 kDa and the
single quarter subunit band at 170 kDa were recognised in the reduced sample (Figure 40, lane
b). The U2M tetramer band at 720 kDa and dimer band at 360 kDa were recognised in the non-
reduced sample (Figure 40 lane c).
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Figure 38. Molecular exclusion chromatography of u2M on a Sephacryl S-300 HR. A Sephacryl S-300 HR
column (1.25 x 90 cm, 0.42 ml/min, 4°C) was equilibrated with 100 mM Na-phosphate buffer, 0.02% NaN3, pH
7.0. The concentrated sample (1.5 ml) from zinc chelate chromatography was loaded and protein was eluted with
the equilibration buffer. (~) pooled fractions.
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Figure 39. Non-reducing 5% Laemmli SDS-PAGE for evaluation of U2M purification steps. Samples loaded
on the gel were: molecular mass markers (myosin, 669 kDa; U2M, 170 kDa; ~-galactosidase, 116 kDa; transferrin,
76 kDa and glutamic dehydrogenase, 53 kDa; 5 Ill, lane a), bovine plasma (15 ug, lane b), dissolved PEG 6000
precipitate (15 ug, lane c), zinc chelate bound fraction (5 ug, lane d) and U2M fraction eluted from Sephacryl S-
300 HR column (10 ug, lane e). The positions of the 720 kDa U2Mtetramer and 360 kDa dimer are shown on the
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Figure 40. Recognition of purified U2M by rabbit anti-u2M antibodies on a western blot. Molecular mass
markers (thyroglobulin, 669 kDa; ferritin, 440 kDa; catalase, 232 kDa; lactate dehydrogenase, 140 kDa and BSA,
67 kDa) (5 Ill, lane a), reduced U2M (10 ug, lane b) and non-reduced U2M (10 ug, lane c) were electrophoresed on
a 5% SDS-PAGE (Section 2.5.2), electroblotted onto nitrocellulose and probed with rabbit anti-a-M antibodies.
Immune reactions were detected using goat anti-rabbit alkaline phosphatase conjugate and the substrate used was
NBT/BCIP (Section 2.7.2).
5.4.2 Inhibition of CP2 by a2M.
CP2 activity was inhibited by U2M. Inhibition tests using azocasein as substrate gave 26.6%
inhibition and 59% inhibition at 1:1 and 1:2 molar ratios of CP2:U2M, respectively (Table 12).
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On the other hand, inhibition tests using Bz-Pro-Phe-Arg-pNA as substrate gave 40%
inhibition at 1:0.25 molar ratio and at 1:0.5 molar ratio there was a slight decrease of
inhibition and then the level of inhibition plateaued at higher molar concentrations of U2M
(Figure 41, panel A). Hydrolysis of Bz-Pro-Phe-Arg-pNA substrate by CP2 in the absence of
U2M expressed as a percentage was slightly higher after incubation for longer than 20 min than
hydrolysis of the substrate in the presence of U2M (1: 1 molar ratio) (Figure 41, panel B). These
results show that there is an interaction between CP2 and U2M and the decreased hydrolytic
activity of the active enzyme upon the Bz-Pro-Phe-Arg-pNA substrate can be attributed to its
trapping by U2M.
Table 12. Inhibition of CP2 by U2M using azocaseinas substrate.
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Figure 41. Inhibition of CP2 by uzM using Bz-Pro-Phe-Arg-pNA as substrate. CP2 (44 pmoles) was
incubated (60 min, 37°C) with various concentrations of uzM (Panel A). Hydrolysis of the substrate by CP2 in the
presence and absence (100% activity) of uzM was measured. CP2 (44 pmoles) was incubated with uzM at 1:1
molar concentration (e) and without uzM (x) for different durations (Panel B). Hydrolytic activity was determined
by taking absorbances at 405 nm. Bars represent SEM (n = 3).
5.5 Discussion
Long, complex purification procedures tend to result in the inactivat ion of U2M (van Jaarsveld
et al., 1994). An ideal purification method for U2M is therefore one that balances obtaining
pure U2M with one that retains most of the U2M in the active form (van Jaarsveld et al., 1994).
In this study U2M was purified in three major steps, namely, PEG precipitation, zinc chelate
chromatography and MEe on Sephacryl S-300 HR. The method of Kurecki et al. (1979) was
modified by employing PEG 6000 as precipitating agent instead of ammoniumsulfate because
fractionation with PEG is a mild procedure that removes the P-lipoprotein more effic iently
than does preparative ultracentrifugation, and without convers ion of the U2M S-form into the
F-form risked by the use of ammonium sulfate (Barrett et aI., 1979). However, there has been
some difficulty reported with the PEG precipitation procedure due to losses in u2M inhibitory
activity, consequently the precipitation step has been omitted and more milder techniques such
as anion exchange chromatography have been used instead (van Jaarsveld et aI., 1994).
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In the present study, the precipitation of U2M was complete at 12.5% (w/v) PEG but U2M eo-
precipitated with other plasma proteins as revealed by SDS-PAGE. The affinity of U2M for
Zn2+ was used as a basis for its second purification step. Large amounts of U2M remain tightly
bound to the zinc column at pH 6.0 allowing removal of other plasma proteins (Kurecki et al.,
1979). After this step, SDS-PAGE revealed that there were still contaminating small molecular
weight proteins revealing the limited efficiency of the zinc chelate column. Porath and Olin
(1983) reported that both imidazole and thiol groups on protein molecules are important zinc
binding sites, therefore it is highly likely that there were other plasma protein molecules with
these functional groups , resulting in their inevitable binding to the zinc chelate matrix. The
MEC step on Sephacryl S-300 HR took advantage of the high molecular weight of U2M and
resulted in its successful resolution from other contaminating plasma proteins as shown by
SDS-PAGE. Under non-reducing SDS-PAGE conditions, a 720 kDa and a 360 kDa band were
observed. The expected molecular masses of U2M under non-reducing conditions on SDS-
PAGE is between 720 and 725 kDa for the tetrameric form of U2M and at 360 kDa for the
dimeric form of U2M. This is because the minimal"covalent subunit without reduction is the
half molecule of U2M of 360 kDa (Barrett et al., 1979). The result obtained in this study agrees
favourably with the literature. The method used in this study for the purification of U2M was
successful in giving the purity of U2M required for the purposes of this study and for further
use as an adjuvant. The isolated U2M was characterised immunologically by western blotting.
Isolated U2M was recognised specifically by anti-c-M antibodies showing bands corresponding
to the expected molecular mass of U2M. This result confirmed that the protein isolated from
bovine plasma was indeed U2M.
This study has shown that U2M interacts with CP2 and inhibits its activity. However, the
activity of complexed CP2 enzyme remained when using azocasein and Bz-Pro-Phe-Arg-pNA
as substrates. The proteolytic activity of complexed CP2 was higher when using Bz-Pro-Phe-
Arg-pNA as substrate compared to azocasein. Salvesen and Nagase (1989), suggested that
smaller substrates are more likely to be hydrolysed by u2M-complexed proteinases. This is
because proteinases entrapped within the large U2M molecule are sterically hindered and only
small substrates are able to access the entrapped proteinase.
Other trypanosomal cysteine proteinases which are thought to be pathogenic have been found
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to be inhibited by host proteinase inhibitors. Examples include the inhibition of trypanopain-
Tb from T. b brucei by U2M, kininogens and various cystatins (Troeberg et al., 1996),
cruzipain from T. cruzi by U2M (Ramos et al., 1997; 2002) and congopain from T. congolense
by kininogens (Lalmanach et al., 2002). However, these proteinases still remain pathogenic to
the host in vivo. This suggests that the interaction of U2M and other host inhibitors does not
completely inhibit these trypanosomal proteinases. Studies of CP2 interaction with bovine
kininogens indicated that there was not complete inhibition of CP2; moreover, the interaction
triggered the release of kinins which may be harmful to the host (Lalmanach et al., 2002). This
suggests that the interaction between trypanosomal proteinases and host proteinase inhibitors
may increase rather than decrease the disease (Lalmanach et al., 2002). It has been
demonstrated in this study that comp1exed enzyme retains activity against a small peptide
substrate. u2M-trypsin complexes retains activity against small substrates such as peptide
hormones and cytokines (Borth and Teodorescu, 1986), thereby interfering with the normal
regulatory system of the host animal. In a previous study by Ramos et al. (2002), U2M-
cruzipain complexes retained activity against a protein substrate since faint activity bands were
visualised in gelatin SDS-PAGE. Their study indicated decreased proteolytic activity but not
complete inhibition. These results show that the role of U2M in inhibiting parasite cysteine
proteinases may riot be sufficient in hindering the pathogenic effects of these proteinases.
U2M can also be used to "convert" a poorly immunogenic protein into a strongly immunogenic
protein because the complexed U2M becomes receptor recognised and can be efficiently
internalised by macrophages and other cells that express U2M receptors (Cianciolo et al.,
2002). It has been suggested that immune responses to pathogenic CP2 may play an essential
role in the mechanism of trypanotolerance (Authie et al., 2001). Therefore a more efficient
immune response to this antigen may enhance disease resistance. The proof of interaction
between CP2 and U2M would help in studying the immunogenicity of CP2 complexed with
U2M in future studies.
In addition to studying the possible enhancement of the immunogenicity of CP2 by
complexing with U2M, one could also use the same approach to study the possibility of the
enhancement of the immunogenicity of the epitopes of CP2 incorporated into U2M.
Incorporation of non-proteinase antigens into U2M has been achieved (Cianciolo et aI., 2002).
U2M is converted to receptor-recognised U2M by incubation with ammonia, resulting in the
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cleaving of the bait region of uzM without any proteolysis step. uzM-NH3 is heated to
approximately 50°C in the presence of a non-proteinase antigen. When cooling to RT the
antigen gets incorporated (Cianciolo et al., 2002). uzM also binds peptides in vitro by
coincubation of peptides, proteins and uzM at 50°C (Binder et al., 2001). It would be
interesting for future studies to raise antibodies against critical epitopes of CP2 complexed
with uzM. Enhancement of the immunogenicity of CP2 or CP2 epitopes by complexing with





Trypanosomosis is a complex and often fatal disease caused by infection with one or more of
the pathogenic tsetse-transmitted protozoan parasites of the genus Trypanosoma. The disease
is known as nagana in livestock and is of major economic importance. T. congolense, T. brucei
and T. vivax species are the major pathogenic trypanosomes in sub-Saharan Africa (Anene et
al., 2001). The therapeutic and preventitive use of trypanocides has limitations which include
toxicity and the development of resistance by the parasites (Aksoy et al., 2001). The effects on
the environment, of insecticides used for vector control has been a subject of controversy
(Grant, 2001).
An alternative approach to the control of the disease has been suggested. Several studies have
confirmed the importance of parasite proteinases for parasite viability and as major pathogenic
factors (for example, Mbawa et al., ·1992; McKerrow et al., 1999; Troeberg et al., 1999;
Cazzulo et al., 2001). In this and other studies (reviewed in Robertson et al., 1996; McKerrow
et al., 1999; Klemba and Goldberg, 2002), the focus has been on the proteinases as targets for
the development of therapeutic agents and vaccines, hence focusing on an anti-disease
approach rather than an anti-parasite approach. One way of inhibiting proteinases is by
specific antibodies. Trypanoresistant/tolerant cattle develop high IgG responses to congopain,
a trypanosome cysteine proteinase, during primary infection with T. congolense, whereas
susceptible cattle have only limited immune responses to congopain (Authie, 1994).
Immunisation trials with congopain, aiming at enzyme inhibition through specific antibodies,
have been carried out in cattle (Authie et al., 2001). Immunised trypanosusceptible cattle,
unlike non-immunised cattle, maintained or gained weight during infection with T. congolense
(Authie et al., 2001), suggesting that antibodies against congopain contribute to
trypanotolerance. 'Protective' epitopes of congopain, which elicit antibodies with inhibitory
effect over congopain activity, have not previously been identified, thus the main focus of this
study was to map the immunogenic epitopes of congopain.
T. congolense possesses at least two families of closely related congopain enzymes named
CPl (Fish et al., 1995) and CP2 (Jaye et al., unpublished, EMBL accession no. L25130). CPl
and CP2 differ in their functional characteristics, suggesting two separate roles in host-parasite
130
interactions (Boulange et al., 2001). Consequently peptides which have the potential of being
immunogenic for the production of anti-catalytic antibodies were identified in the primary
structures of both CPl and CP2. The epitope prediction program, Predict 7 (Carmenes et al.,
1989), was used to select the peptides. Using this program, numerical values which reflect
hydrophilicity, flexibility, surface probability and antigenicity for overlapping sequences of
amino acid residues in each enzyme were plotted. The features mentioned above are essential
for predicting whether the sequence will be immunogenic or not, for example, hydrophilic
residues are more likely to be located on the surface of the enzyme and would therefore be
easily accessible to antibodies. Sequences which gave plots with local peaks of hydrophilicity,
flexibility, surface probability and antigenicity were selected.
Peptides selected from the catalytic domain of CP2 include a peptide located at the N-
terminus, a central catalytic domain peptide and an active site-associated peptide. Peptides
were also selected from similar regions of the catalytic domain of CPI. CP2 peptides were
longer than CP1 peptides (except for the active site associated peptide) but there was high
sequence homology between the CP2 peptides and the CP1 peptides. The immunogenicity of
the selected peptides, conjugated to rabbit albumin as a carrier protein, was determined by
immunisation into chickens. Antibodies were produced against all peptides, as evidenced by
their binding to the corresponding peptides in ELISAs. More importantly, the anti-peptide
antibodies were able to recognise whole CP2 in ELISA and western blot tests. This suggests
that there was similarity between the conformations adopted by peptides when exposed to the
experimental animals' immune systems and the corresponding regions in the CP2 molecule.
Even anti-CPl peptide antibodies recognised sequences in the CP2 enzyme, reflecting the high
degree of homology (90%) between CPl and CP2 sequences. Recombinantly expressed,
whole CP2 enzyme and the catalytic domain of CP2 (C2) were used in the tests because CP2
from T. congolense has been extensively studied and no native CP1 enzyme has been
characterised from T. congolense bloodstream form lysates (Lalmanach et al., 2002).
Once it was established that the anti-catalytic domain peptide antibodies recognise the whole
enzyme, their effects on the catalytic activity of CP2 was investigated. Studies have shown
that anti-enzyme antibodies can have varying effects on enzymes, depending on the enzyme
used, the region targeted and the substrate used (Richmond, 1977; Dennison and Pike, 1991;
Coetzer et al., 1992; Troeberg et al., 1997). The epitopes which are able to produce inhibitory
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antibodies are likely to be located in the catalytic domain of CP2, since IgG from C2
immunised cattle inhibited congopain (Authie et al., 2001). Anti-pept ide antibodies produced
in this study had either enzyme stimulating effects at lower antibody concentrations and
enzyme inhibitin g effects at higher antibody concentrations (biphasic) or they had an
enhancing effect at all antibody concentrations used. The latter result suggests that some anti-
peptide antibodies induced a more active CP2 conformation. Similar results were described by
Richmond (1977) for p-Iactamase and Troeberg et al. (1997) for trypanopain-Tb. Even though
most of the anti-peptide antibodies did not have an inhibiting effect on the enzyme activity,
they did recognise and bind to native CP2 but had a biphasic or stimulatory effect.
This study has been able to identify congopain peptides , using an epitope prediction program,
which appear to be partial epitopes of congopain. This was deduced from the observation that
antibodies against these peptides were able to recognise the whole CP2 enzyme in partially
denatured (ELISA) and denatured (western blot) forms. However, the antibodies against these
peptides did not have an enzyme activity inhibiting effect, but rather an enzyme activity
enhancing effect or biphasic effect. Antibodies from cattle immunised with C2 inhibited
congopain, suggesting that the essential epitopes of CP2 are located in the catalytic domain of
CP2 (Authie et al., 2001). Inhibition tests in the latter study involved incubation of antibodies
for 12 h on ice (to prevent hydrolysis of the antibodies by congopain). This was regarded as
excessive since 15 min incubation at 37°C with the antibody before activation of the enzyme
and assay against peptide substrate was found optimal for inhibition of cathepsin Land
trypanosomal oligopeptidase B, respectively (Coetzer et al., 1991; Morty et al., 2000). Either
the conformation adopted by the peptides presented to the immune system is not similar to that
adopted by the corresponding regions in C2, or the peptides selected do not induce the
production of neutralising antibodies. In addition to this, most epitopes are discontinuous,
rather than continuous (Van Regenmortel, 1986), and the peptides selected may be integral
parts of an epitopes . Binding of antibodies raised against these parts of the protease may have
resulted in a more active enzyme conformation. The anti-peptide antibodies may have
recognised the corresponding regions of the native CP2 enzyme, but because the Z-Phe-Arg-
AMC substrate used in this study is small, the substrate might have gained access to the active
site (especially in cases where the antibodies were not against active site associated sequences)
where it was cleaved.
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It would be interesting in future studies to look at the effect of a cocktail of the anti-peptide
antibodies produced in this study on CP2 activity. It should also be taken into consideration
that these antibodies may have different effects in the in vivo situation since the natural
substrates are large protein molecules. Enzyme assays using different protein substrates in the
presence of anti-congopain peptide antibodies need to be done. This will require more enzyme
than was available in this study, since enzyme assays using protein substrates are less sensitive
than those using synthetic peptide substrates. Nevertheless, the anti-peptide antibodies
produced in this study react with full-length CP2 and can thus be useful in basic research.
These antibodies would be useful in identifying the CP2 product of an open reading frame,
localising the gene product to particular cells or subcellular organelles, identifying enzymatic
functions, following the role of particular regions of enzyme through the enzyme maturation
processes, analysing the expression of exons following DNA rearrangements and RNA
splicing and purifying the enzyme by immunoaffinity chromatography techniques (Shinnick et
al., 1983; Morty et al., 2000).
Another objective was to examine the natural antigenicity of the congopain peptides described
above. This was done by testing the recognition of the peptides in an ELISA by sera from
infected or immunised cattle. Sera from both trypanosusceptible Boran and trypanotolerant
N'Dama cattle infected with T. congolense targeted all peptides compared to non-immune
sera, but the CP2 catalytic domain peptide was the most weakly recognised peptide. Sera from
uninfected cattle immunised with C2 were tested in an ELISA for their ability to target CP2
and CPI peptides. CP2 peptides located at the N-terminus and in the catalytic domain were the
primary targets of antibodies in these sera and the active site-associated peptide from CPI was
also the primary target. This suggests that these peptides form part of immunogenic epitopes
of CP2. However, some peptides (especially the N-terminus peptide from CPI and the active
site associated peptide from CP2) cross-reacted only weakly with cattle IgG. It can be assumed
that this weak cross-reactivity is due to the fact that the respective peptides represent only a
portions of more complex epitopes and not able to adopt the correct conformation present in
the folded enzyme that can be recognised fully by these antibodies. All peptides were poorly
recognised by rabbit anti-native congopain antibodies. Apparently these peptides are naturally
immunogenic in cattle but not in rabbits. A similar result was reported by Coetzer et al. (1992)
where a peptide associated with the active -site of cathepsin L was recognised by chicken anti-
cathepsin L antibodies and not by rabbit anti-cathepsin L antibodies.
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Only the C-tenninal extension sequence for a T. vivax cysteine proteinase, called vivapain, had
been determined when this study was undertaken (Prof. Theo Baltz, University of Bordeaux,
France, personal communication). Therefore a peptide was selected from the C-tenninal
extension of vivapain using the same epitope prediction program that was used for selecting
congopain peptides. The C-tenninal extension sequences of congopain and vivapain were
aligned and a peptide which has very little sequence homology between the two sequences
was selected without compromising immunogenicity. The aim was to identify a peptide that
could be used to distinguish between T. vivax and T. congolense infections. Sera from T.
congolense infected cattle consistently targeted the congopain peptide slightly more than the
vivapain peptide, while sera from T. vivax infected cattle consistently targeted the vivapain
peptide slightly more than the congopain peptide. This result was not expected, since this
assay failed to distinguish very clearly between T. congolense and T. vivax infections. Cross-
reactivity might be due to trypanosome non-specific (polyreactive) antibodies. Trypanosome
non-specific antibodies have been observed in cattle infected by T. congolense and T. vivax
(Buza and Naessens, 1999). It is also possible that the sera used in this study had mixed
infections of both T. congolense and T. vivax. This is supported by the results of the parallel
experiments that were conducted by the collaborator in Beligium using peptides selected in
this study and sera from experimentally infected cattle and goats in a trypanosome free area
(Belgium). The congopain C-tenninal extension peptide was specific for T. congolense
infection and was not recognised by sera from T. vivax infected cattle (Dr Philippe Buscher,
Institute of Tropical Medicine, Antwerp, Belgium). On the other hand, modification of the
peptide sequences might improve the sensitivity of the assay, hence improving their potential
use as diagnostic tools.
The congopain peptides selected cross-reacted with T. congolense infected sera but the assays
were not very sensitive. This suggests that the peptides selected are effective but not optimal
peptides. Optimal peptides can be identified by analysing a series of overlapping peptides. One
way in which this can be done is by multiple pin peptide scanning ('Pepscan') technology
(Sumar, 2001). In this method , a large number of peptides are synthesised and subsequently
tested against a large number of antibody containing samples. Overlapping peptides, spanning
the entire amino acid sequence of the enzyme, are built on polyethylene pins by the sequential
addition of amino acids. The size of the peptides is usually between five to eight residues long.
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The pins are mounted on a plastic holder with an 8 x 12 format similar to ELISA plates.
The epitopes of antibodies of interest are localised by ELISA using the pin bound peptides . In
these tests, appropriate controls are included, for example, by including non-immune sera and
by testing the binding of detection antibody-enzyme conjugates to pin bound peptides. Briefly,
the peptide pins are blocked with blocking buffer to reduce non-specific binding to the pins.
The pins are taken out of the blocking solution and placed in serum sample solutions in the
plate. Following washing of the pins, the pins are incubated in enzyme-linked detection
antibody. The pins are washed, incubated in the substrate after which the absorbance of the
coloured product is read at the appropriare wavelength.
The ELISA is followed by further analysis of epitopes, which were recognised by the test sera,
by window net analysis and replacement net analysis (Sumar, 2001). In window net analysis,
peptides of different lengths representing one epitope are synthesised and tested with sera to
identify the minimal antibody binding peptide . The replacement net analysis is done to
identify residues which are essential for binding. This is done by replacing each amino acid
residue of the epitope by the nineteen remaining amino acid residues and then testing each
peptide with antisera of interest (Sumar, 2001).
The Pepscan technology provides an alternative approach for the synthesis, analysis and
selection of candidate epitopes. Epitopes on the glycoprotein E of Varicella zoster virus that
causes chicken pox have been identified by the Pepscan technology (Garcia-Valcarcel, 1997).
These epitopes may be potentially viable candidates for a peptide -based vaccine. In
conjunction with replacement net analysis, Pepscan can give well-defined epitopes, identifying
the exact residues that are important for the binding of antibody to the epitope. Antigen
antibody interactions for myoglobin were studied using Pepscan (Rodda et al., 1986). An
epitope containing six residues was identified, followed by analysis of the peptide which
showed that the N-terminal leucine was important to the binding of antibody to the epitope.
For future studies one could use the Pepscan technology to identify optimal congopain
peptides which could be used as diagnostic tools and possibly to raise CP2-inhibitory anti-
peptide antibodies. The refined epitopes would probably include some of the peptides selected
in this study, as they seem to have the potential of being partial CP2 epitopes.
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In addition to attempting to define the epitopes of congopain, preliminary studies to increase
the immunogenicity of congopain were also undertaken. It has been hypothesised that
increasing the immunogenicity of congopain to elicit high titre anti-congopain antibodies
would contribute to the modulation of the disease since trypanotolerant cattle have high titres
of anti-congopain antibodies. u2-Macroglobulin (U2M) is a natural host inhibitor of
proteinases. Inhibition occurs by entrapment of an active proteinase within the U2M cage. In
addition, it has been demonstrated that antigen complexed with U2M becomes more
immunogenic, resulting in an enhanced antigenic presentation of an entrapped antigen
(Cianciolo et aI., 2002). No reports have been published of congopain and U2M interaction,
only cruzipain-n-M interaction has been reported (Ramos et aI., 1997; 2002). The interaction
between congopain and U2M was investigated in order to assess the possibility of increasing
the immunogenicity of congopain by immunising with CP2 complexed with U2M.
u2-Macroglobulin was isolated from bovine plasma and the inhibition of CP2 hydrolysis of
azocasein and Bz-Pro-Phe-Arg-pNA by U2M was determined. The results suggested that CP2
interacts with U2M and inhibition tests using azocasein as substrate gave 26% inhibition of the
activity of the entrapped enzyme. This means that U2M may play an important role during T.
congolense infection as a back-up inhibitor, reducing the effects of congopain. This may be
especially relevant in the light of the observation by Lalmanach et a1. (2002) that congopain
interaction with bovine kininogens does not achieve complete enzyme inhibition and triggers
release of kinins. Furthermore, Lonsdale-Ecc1es et a1. (1995) reported that a kininogen-like
molecule from rat serum enhances activity of the T. b. brucei cysteine proteinase, trypanopain-
Tb, in fibrinogen zymograms of T. b. brucei lysates. The modulation of congopain activity by
U2M is evidently not sufficient by itself, however, since congopain has been shown to be one
of the major pathogenic factors released by T. congolense. This is deduced from the
observation that anti-congopain antibodies may contribute to the mechanism of
trypanotolerance (Authie et aI., 1993a).
The result obtained in this study, showing interaction of congopain with U2M may be exploited
to enhance the immunogenicity of congopain. By taking advantage of the adjuvanticity of the
U2M molecule, CP2 can be complexed with U2M to raise antibodies against CP2, hence
enhancing the immunogenicity of CP2 enzyme as was done for hen egg lysozyme (Chu and
Pizzo, 1993), insulin (Chu et aI., 1991) and a monomeric form of hepatitis B virus surface
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antigen (Cianciolo et al., 2002). To do this, a study needs to be done to identify suitable molar
ratio concentrations of CP2 and uzM molecules, a suitable experimental animal system, the
effect of the source of uzM and the immune system challenged (for example, rabbit uzM-CP2
complexes immunised into rabbits) and also to compare the antibody titres when using uzM
and other adjuvants. Freund's complete adjuvant, aluminium salts , muramyl dipeptide analogs
and a variety of infectious agents have been used in various systems and have been shown to
be effective adjuvants, although undesirable side effects have been reported (Muller, 1990b).
These adjuvants, together with RWL (proprietary adjuvant from Smith Kline Beecham), which
has been used in the successful production of antibodies against congopain (Authie et al.,
2001), need to be tested and compared to antibody titres when using uzM as adjuvant. Once
optimal CP2 epitopes have been identified, these peptides could be complexed with uzM by
the chemistry described by Cianciolo et al. (2002) which involves incubation of uzM with
ammonia. The uzM-NH3 is heated in the presence of protein/peptide of interest resulting in
substantial incorporation of protein/peptide when cooled to RT. For the incorporation of non-
protease antigens , this approach avoids the chances of an antigen being cleaved by the
proteinase (Cianciolo et al., 2002). Where congopain is the antigen, this could be evaluated as
an alternative method for complexing congopain with uzM. Human immunodeficiency virus-I
C4-V3 peptides complexed with uzM have shown 100-1000 fold enhancement of both
antibody and cytotoxic T lymphocyte response compared to peptides formulated in complete
Freund's adjuvant (Cianciolo et al., 2002). The optimal peptides of CP2 could not only be
valuable diagnostic tools , but may also be used for the development of an anti-disease vaccine.
In conclusion, anti-congopain peptide antibodies which interact with the whole enzyme were
produced. These antibodies could be useful in basic research, such as immunoaffinity
purification of congopain. Recombinant congopain is expensive and time consuming to
generate. Purification of congopain from the parasites using these antibodies could provide a
better alternative. The congopain peptides identified in this study also provide alternative tools
that could be used in diagnostic assays rather than recombinant CP2. It was also shown in this
study that congopain interacts with uzM. This paves the way for the study of an alternative
way of enhancing immunogenicity of congopain and congopain epitopes using uzM as an
alternative adjuvant. If uzM shows superior adjuvanticity compared to other adjuvants,
congopain peptides complexed with uzM could be used to form a peptide based vaccine, once
the optimal epitopes of congopain have been identified. This study has made contributions at
137
several fronts to the development of an anti-disease vaccine for trypanosomosis and sensitive
diagnostic tools for the disease.
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